impact medicine feel well live long annual report wwwgskcommission global quest improve quality human life enable people feel well live long spirit undertake quest enthusiasm entrepreneur excite constant search innovation value performance achieve integrity attain success world class global leader people contribute passion unmatched sense urgency strategic intent want indisputable leader industry glaxosmithkline plc english public limited company share list london stock exchange new york stock exchange glaxosmithkline plc acquire glaxo wellcome plc smithkline beecham plc december way scheme arrangement merger company effective december report annual report glaxosmithkline plc year end december comprise single document annual report company accordance united kingdom requirement annual report formf securities exchange commission united states america summary report year annual review intend investor need detail annual report produce separate document annual review include joint statement chairman chief executive officer summary review operation summary financial statement summary remuneration report annual review issue shareholder annual report issue shareholder elect receive document available glaxosmithkline corporate website wwwgskcom website glaxosmithkline website wwwgskcom give additional information group information available website constitute annual reportglaxosmithkline glaxosmithkline plc annual report year end december content report director financial summary joint statement chairman chief executive officer description business corporate governance remuneration report operate financial review prospect financial statement director statement responsibility independent auditor report consolidated statement profit loss consolidate statement total recognise gain loss consolidate statement cash flow consolidated balance sheet reconciliation movement equity shareholder fund company balance sheet note financial statement financial record investor information shareholder return shareholder information share capital taxation information shareholder cross reference form glossary term annual report approve board index director march publish march contact detail glaxosmithkline financial summary restate increase statutory result cer sale trading profit profit taxation earningsnet income basic earning share dividend share merger restructure disposal subsidiary trade profit profit taxation earningsnet income business performance sale trading profit profit taxation adjust earningsnet income adjust earning share business performance primary performance measure management present exclude merger item integration restructuring cost disposal business management believe exclusion nonrecurre item provide well comparison business performance period present statutory result include nonrecurre item information provide supplement include consolidated statement profit loss page prepare accordance ukgaap group multinational business operate country earn revenue incur cost currency result group report sterling affect movement exchange rate sterle overseas currency group use average exchange rate prevail year translate result overseas company sterling currency influence translation dollar euro japanese yen average sterling exchange rate strong usdollar japanese yen cent seven cent respectively weak euro cent compare order illustrate underlie performance group practice discuss result term constant exchange rate cer growth represent growth calculate exchange rate determine result overseas company sterling remain unchanged previous year discussion report term cer state represent growth actual exchange rate cer represent growth constant exchange rate frs defer tax implement group frs require defer tax account provision basis partial provision basis early year change account prior year adjustment comparative information restate necessary cautionary statement forwardlooke statement group report file securities exchange commission sec include document write information release oral statement public future behalf group contain forwardlooke statement forwardlooke statement group current expectation forecast future event investor identify statement fact relate strictly historical current fact use word anticipate estimate expect intend project plan believe word term similar meaning connection discussion future operate financial performance particular include statement relate future action prospective product product approval future performance result current anticipate product sale effort expense outcome contingency legal proceeding financial result group undertake obligation update forwardlooke statement result new information future event forwardlooke statement involve inherent risk uncertainty group caution investor number important factor include document cause actual result differ materially contain forwardlooke statement factor include limit discuss risk factor page annual reportglaxosmithkline joint statement chairman chief executive officer new product growth drive commercial strength success new product provide fuel future growth new product represent cent total pharmaceutical sale cent sale seretideadvairfor asthma second large product continue grow impressively cent billion recently launch avandametfor type diabetes avodartfor benign prostatic hyperplasia important line extension augmentinand paxil look forward launch new compound line extension include levitra new treatment erectile dysfunction promote bayer wellbutrin new improve version successful antidepressant create productive organisation outset merger rethought way carry glaxosmithkline aim create purpose glaxosmithkline deliver productive organisation industry establish medicine positive impact quality therapeutically focus centre excellence drug discovery human life choose fundamental cedd cedd nimble entrepreneurial range challenge objective theme year skill scale resource require drive midstage annual review development project key decision point proof concept largescale phase iii clinical trial please report year significant year activity new organisation progress establish glaxosmithkline world see significant progress advance promise early stage lead pharmaceutical company achieve strong financial pipeline pharmaceutical product clinical development result despite entry generic competition glaxosmithkline project clinical development usa augmentin major product new chemical entity number therapy area progress stem group key strength broadly new vaccine number new chemical entity start phase base product portfolio strong financial capability promise clinical trial double merger early stage pipeline product build confident phase pipeline core attribute confident help development build good late stage pharmaceutical glaxosmithkline continue deliver success future pipeline industry plan provide detailed update progress end achieve business success essential demonstrate stakeholder world success partner choice conduct business integrity continue size quality global organisation positive contribution society strength sale marketing team enable glaxosmithkline partner choice industry good financial performance sign unprecedented major external collaboration deliver solid financial performance year help boost product challenge operating environment global pharmaceutical sale portfolio provide exciting new opportunity grow cent nearly billion pharmaceutical number area unmet medical need erectile sale grow cent despite generic competition augmentin dysfunction obesity hiv group demonstrate continue financial strength total sale seven cent business performance trading profit patent challenge cent strong performance key therapy year number development area include central nervous system respiratory antiviral involve patent key product vaccine july usa generic version augmentinwa business performance earning share grow cent launch follow rule federal judge deliver guidance demonstrate continue augmentinpatent invalid appeal financial strength provide group sound decision firm belief patent valid platform future offset impact generic recent glaxosmithkline good progress merger successful launch new improve version augmentin manufacturing restructuring plan remain track formulation deliver forecast total annual merger manufacturing glaxosmithkline involve litigation patent restructure saving billion wellbutrin srand zybanin usa await outcome stop continuous improvement programme appeal judgement year favour andrx operational excellence deliver additional saving corporation apply market generic version continue productsglaxosmithkline description business description business discuss activity resourcesandthe operating environment business identifie development achievement follow heading business history development company product operating environment competition regulation operating activity market distribution manufacture supply research development operating resource intellectual property information technology glaxosmithkline people property plant equipment business community corporate social responsibility responsibility environment health safety access healthcare develop world global community partnership discussion group management structure corporate governance procedure set corporate governance pagesto remuneration report give detail group policy director remuneration amount earn director senior management page discussion group operate financial performance financial resource give operate financial review andprospect page report glaxosmithkline group mean glaxosmithkline plc subsidiary undertaking thecompany mean glaxosmithkline plcglaxosmithkline share mean ordinary share ofglaxosmithkline plc american depositary share ad represent glaxosmithkline share report figure quote market size market share market growth rate relate month end september orlater available glaxosmithkline estimate base onthe recent datum independent external source value sterle relevant exchange rate figure quote product market share reflect sale glaxosmithkline licensee brand name appear italic report trade mark glaxosmithkline associate company theexception baycol levitratrade mark bayer bexxar trade mark corixa corporation inc hepseraa trademark gilead services inc natrecora trade mark scios inc navelbine trade mark pierre fabre mdicament nicoderm trade mark aventis pritor trade mark boehringer ingelheim international gmbh licence group glaxosmithklinejoint statement chairman chief executive officer seroxatpaxil continue subject threat generic positive action international programme hivaid competition particularly usa education care support establish year back international programme country federal judge chicago recently rule glaxosmithkline patent usa cover hemihydrate form paxilwa valid glaxosmithkline key partner global effort eliminate infringe generic company apotexs product lymphatic filariasis disable disfigure disease currently believe patent infringe apotexs product affect million people threaten billion appeal ruling continue pursue poor nation world date litigation infringement patent relate paxilagainst glaxosmithkline donate million tablet apotex generic company usa year commitment eradicate disease result pende matter possible time generic guardian newspaper give list recently recognise competition paxilin usa unclear consequently glaxosmithkline total global community expenditure glaxosmithkline publish earning guidance remain great british company increase previously state guidance high single digit percentage comprehensive programme social investment invest growth business performance earning share constant million support global community programme product exchange rate assume generic competition paxil donation charitable contribution usa generic launch paroxetine hydrochloride imminent glaxosmithkline reassess guidance corporate governance corporate governance continue high profile issue uptake paxil enhance form antidepressant publication higg review role effectiveness launch excellent represent nonexecutive director sir robert smiths report audit cent paxil new prescription usa committees usa sarbanesoxley act law patent challenge number product zofran july impact glaxosmithkline relation lamictal case illustrate industrywide trend certification annual report form disclosure generic company file patent challenge early process relationship external auditor internal control obviously defend intellectual property vigorously number governance issue glaxosmithkline regularly undertake thorough review group internal control contribution society system commit remain leader governance responsible behaviour type organisation include process structure multinational company government charity high public agenda year report corporate social acknowledgement responsibility set commitment reflect ethical business discover effective medicine healthcare social environmental concern business decision product people world result create second report update activity publish shareholder value great position build time annual report cover issue success year build good pipeline industry generate significant interest stakeholder launch new product extend thank corporate social responsibility report include employee commit make happen indicator progress addressing issue bob ingram chief operating officer president pharmaceutical corporate responsibility integral business operation retire end december continue inherent mission glaxosmithkline make significant work parttime vice chairman pharmaceutical special positive contribution society world advisor group like express appreciation medicine vaccine healthcare product research contribution company particular develop manufacture sell significant role make merger success product improve people life ensure profitable behalf board corporate executive team sustainable future business understand thank shareholder support hope stakeholder include employee want know share enthusiasm company look forward profit need reassure sound ethical basis continue success business focus make contribution improve healthcare alleviate suffer develop world great significant progress tackle enormous challenge hivaid end secure arrangement supply preferentiallypriced hivaids medicine world poor country shipment medicine develop world continue grow significantly year year september reduce preferential price hivaid medicine cent sir christopher hogg garni chairman chief executive officer glaxosmithkline description business business history development company glaxosmithkline plc subsidiary associated undertaking constitute major global healthcare group engage creation discovery development manufacture marketing pharmaceutical consumer healthrelated product glaxosmithkline corporate head office london area great west road brentford middlesex england tel glaxosmithkline operational headquarters philadelphia research triangle park usa operation country product sell country principal research development facility usa japan italy belgium product currently manufacture country major market group products usa japan france germany theuk italy glaxosmithkline plc public limited company incorporate thdecember english law december company acquire glaxo wellcome plc smithkline beecham plc english public limited company way scheme arrangement merger company glaxo wellcome smithkline beecham major global healthcare business october glaxo wellcome plc change glaxosmithkline services plc march glaxosmithkline service unlimited historical reference glaxo wellcome plc document change business segment glaxosmithkline operate principally industry segment pharmaceutical prescription pharmaceutical vaccine consumer healthcare overthecounter medicine oral care nutritional healthcaredescription businessglaxosmithkline product pharmaceutical therapeutic area trade mark compound mechanism indication vary country central nervous seroxatpaxil paroxetine selective serotonin reuptake depression panic anxiety system inhibitor wellbutrin bupropion noradrenaline reuptake inhibitor depression imigranimitrex sumatriptan agonist migraine cluster headache naramigamerge naratriptan agonist migraine lamictal lamotrigine sodium channel modulator epilepsy requip ropinirole dopamine agonist parkinson disease zyban bupropion noradrenaline reuptake inhibitor smoking addiction respiratory flixotideflovent fluticasone propionate inhale antiinflammatory asthma bronchial condition serevent salmeterol xinafoate bronchodilator bronchial asthma bronchitis seretideadvair salmeterol fluticasone bronchodilatorantiinflammatory asthma propionate flixonaseflonase fluticasone propionate intranasal antiinflammatory hayfever perennial rhinitis ventolin salbutamolalbuterol bronchodilator bronchial asthma bronchitis becotidebeclovent beclomethasone dipropionate inhale antiinflammatory bronchial asthma bronchitis beconase beclomethasone dipropionate intranasal antiinflammatory hayfever perennial rhinitis antiviral trizivir lamivudine zidovudine reverse transcriptase inhibitor hivaid abacavir combivirbiovir lamivudine zidovudine reverse transcriptase inhibitor hivaid epivirtc lamivudine reverse transcriptase inhibitor hivaid retrovirazt zidovudine reverse transcriptase inhibitor hivaid ziagen abacavir reverse transcriptase inhibitor hivaid agenerase amprenavir protease inhibitor hivaid valtrexzelitrex valaciclovir dna polymerase inhibitor shingle genital herpe zovirax aciclovir dna polymerase inhibitor herpe infection shingle chicken pox cold sore zeffixheptavir lamivudine reverse transcriptase inhibitor chronic hepatitis infection heptodinepivir hbv antibacterials augmentin amoxicillin broad spectrum oralinjectable common infection antimalarial clavulanate potassium antibiotic zinnatceftin cefuroxime axetil oral antibiotic common infection fortumfortaz ceftazidime injectable antibiotic severe life threaten infection bactroban mupirocin topical antibiotic skin infection amoxil amoxicillin broad spectrum oralinjectable common infection antibiotic malarone atovaquoneproguanil electron transport system treatment prophylaxis malaria metabolic avandia rosiglitazone ppargamma agonist type diabete gastrointestinal avandamet rosiglitazone metformin ppargamma agonist type diabetes hydrochloride antihyperglycemic agent metformin zantac ranitidine hydrochloride antisecretory duodenal ulcer stomach ulcer reflux dyspepsia avodart dutasteride selective inhibitor type benign prostatic hyperplasia isoform vaccine havrix hepatitis engerixb hepatitis twinrix hepatitis infanrix diphtheria tetanus acellular pertussis oncology zofran ondansetron receptor antagonist nausea vomit cancer emesis therapy hycamtin topotecan topoisomerase inhibitor ovarian cancer small cell lung cancer navelbine vinorelbine cytotoxic nonsmall cell lung cancer breast cancer cardiovascular coreg carvedilol alphabeta blocker congestive heart failure lanoxin digoxin cardiac antiarrhythmic congestive heart failure cardiac arrhythmia flolan epoprostenol inhibitor blood clot primary pulmonary hypertension lacipil lacidipine calcium channel blocker hypertension pritor telmisartan angiotensin antagonist hypertension arthritis relafen nabumetone non steroidal antiinflammatory osteoarthritis rheumatoid arthritis glaxosmithkline description business product pharmaceutical therapeutic area antiviral combivir combination retrovirand epivir consolidated glaxosmithkline principal pharmaceutical product presently position reverse transcriptase inhibitor direct therapeutic area analysis salesby cornerstone multiple antihiv product regimen physician therapeutic area description principal product acceptance clearly demonstrate value place setout minimise pill burden face patient sale therapeutic area ziageni reverse transcriptase inhibitor product potency central nervous system ease use resistance profile allow play significant role respiratory variety highly active tolerate andsimplified hiv antiviral treatment regimen antibacterialsantimalarial triziviris combination combivirand ziagen combine metabolic gastrointestinal antihiv therapie tablet twice daily administration vaccine oncology emesis ageneraseis protease inhibitor treatment hiv cardiovascular medicine class bring market arthritis glaxosmithkline ageneraseha twice daily dose regimen significant food drink restriction divest product zeffixhas approve marketing usa europe china markets treatment chronic hepatitis valtrexis treatment chicken pox zoster shingle cold sore central nervous system cns episodic genital herpe long term suppression seroxatpaxilis selective serotonin reuptake inhibitor ssri genital herpe valtrex supersede zovirax widely approve depression panic obsessive compulsive disorder treat herpe infection post traumatic stress disorder social anxiety disorder general anxiety disorder paxil control release version antibacterial antimalarial launch usa augmentinis broadspectrum antibiotic suitable treatment wide range common bacterial infection wellbutrini antidepressant available usa normal particularly effective respiratory tract infection augmentin orsustaine release tablet formulation esis extra strength suspension specifically design treat imigranimitrexis receptor agonist treatment child recurrent persistent middle ear infection ofsevere frequent migraine cluster headache augmentin xris extra strength tablet form adult combat reference product sector naramigamergeis grow problem bacterial resistance community new migraine product zinnatis oral antibiotic primarily communityacquire lamictalis treatment epilepsy combination infection lower respiratory tract fortumis product achieve penetration mature hospitalbase injectable antibiotic market market successful treatment severe case malaroneis oral antimalarial treatment requipis specific dopamine dlike receptor agonist prophylaxis malaria cause plasmodium falciparum treatment ofparkinson disease metabolic gastrointestinal zybanis nicotinefree prescription medicine available avandiais potent insulin sensitise agent act asasustainedrelease tablet treating problem underlie pathophysiology type diabete avandametis smokingaddiction combination avandiaand metformin hci medicine target insulin resistance decrease glucose production respiratory convenient pill seretideadvair combination sereventand flixotide offer alongacte bronchodilator antiinflammatory single zantac treatment peptic ulcer disease range inhaler ofgastric acid relate disorder continue play major role number market patent protection lose sereventis longacting bronchodilator ventolinis selective shortacting bronchodilator vaccine flixotidefloventand becotidebecloventare inhale steroid glaxosmithkline market range hepatitis vaccine havrix treatment inflammation associate bronchial asthma protect hepatitis engerixbagainst hepatitis chronic bronchitis twinrixis combine hepatitis vaccine protect disease vaccine available adult flixonaseflonaseand beconaseare intranasal preparation paediatric strength treatment perennial seasonal rhinitis infanrixis range paediatric vaccine combination infanrix provide protection diphtheria tetanus pertussis whoop cough infanrix pentapediarix provide additional protection hepatitis polio andinfanrix hexafurther add protection haemophilus influenzae type causesmeningitisdescription businessglaxosmithkline additionally glaxosmithkline market priorixa measle major product mump rubella vaccine typherix vaccine protection category product typhoid fever varilrix vaccine varicella chicken pox overthecounter medicine analgesic panadol oncology emesis dermatological oxy zofrani prevent nausea vomiting associate zovirax chemotherapy radiotherapy cancer available abreva bothoral injectable form approve use gastrointestinal tum prevention treatment postoperative nausea vomit citrucel respiratory tract contac hycamtinis second line treatment ovarian cancer beecham forsmall cell lung cancer smoking control commit navelbine approve line treatment nonsmall cell lung nicorette cancer combination cisplatin single agent nicoderm niquitin cardiovascular nicabate coregis alphabeta blocker prove natural wellness support abtei effective intreate mild moderate severe heart failure oral care aquafresh glaxosmithkline sole marketing right usa corega drbest arthritis macleans relafenis nonsteroidal antiinflammatory drug treatment odol arthritis polident poligrip sensodyne category include group principal dermatological nutritional healthcare horlick product betnovate thehigher potency dermovateand new lucozade cutivateare antiinflammatory steroid product treat skin ribena disease sucha eczema psoriasis divest product overthecounter medicine accordance agreement regulatory approval lead product panadol widely available merger glaxo wellcome smithkline beecham paracetamolacetominophen analgesic nicorettegum product kytril treatment chemotherapy nicodermniquitincqand nicabaterange smoking control radiotherapyinduce nausea vomit famvir patch tum calcium base antacid citrucellaxative contac antiviral treatment shingle herpe divest treatment cold influenza abtei natural indecember medicine vitamin range oxyacne treatment zovirax abreva treatment cold sore product consumer healthcare glaxosmithkline consumer healthcare introduce glaxosmithkline principal consumer healthcare product new prescription overthecounter switch presently directedto major area analysis sale area isset eumovate cream clearing skin flareup dermatitis eczema beconase allergy hoursfor hayfever australia overthecounter medicine oral care oral care lead oral care product toothpaste mouthwashe nutritional healthcare aquafresh sensodyne macleansand odolbrand divest product name range toothbrush sell aquafresh sensodyneand bestnames addition denture care product available principally polident poligripand corega constant exchange rate sale cent high brand name nutritional healthcare lead product category lucozadeglucose energy sport drink ribenablackcurrantbase juice drink rich vitamin horlick range milkbase malt food chocolate drink glaxosmithkline description business operating environment competition pharmaceutical respiratory glaxosmithkline respiratory franchise drive growth pharmaceutical industry highly competitive seretideadvair gain patient competitor product glaxosmithkline principal competitor large international cannibalisation sereventand flixotide ventolinand becotide pharmaceutical company substantial resource face generic competition year company major product mention maintain significant sale pharmaceutical subject competition major respiratory competitor singulair merck especially product period patent protection usa symbicort astrazeneca primarily european patent generic version manufacturers generic union spiriva pfizerboehringer ingelheim primarily product typically donot bear significant research development europe cost consequently areable offer product considerably low price thebrande competitor research antiviral development base pharmaceutical company normally major competitor hiv market bristol myers squibb seek achieve sufficiently high profit margin sale volume merck pfizer period patent protection repay original investment fund research forthe future competition glaxosmithkline pioneer role hiv market generic product generally occur patent major market retrovirand epiviracte cornerstone combination expire increasingly patent challenge prior patent therapy available combivirin single tablet launch expiry ziagen ageneraseand trizivirhave broaden thegroup glaxosmithkline undertake range activity maximise portfolio hiv product valtrexha helped strengthen value intellectual property include introduce innovative group position antiherpe area zoviraxface product market possible accelerate process competition generic aciclovir valtrexand zovirax bring new product tomarket increase brand recognition compete novartis famvir zeffixwa antiviral customer market treat hepatitis gileads hepsera second approve usfood drug administration fda glaxosmithkline believe competitive position dependent september discovery development new product effective marketing exist product antibacterial antimalarial pharmaceutical industry introduction new product generic version augmentinand ceftinzinnat process competitor affect pricing level result introduce usa follow successful legal challenge product replacement assurance product generic manufacturer note financial statement outmoded notwithstanding patent trade mark legal proceeding augmentinha lose patent protection protection addition increase government pressure country europe recently launch augmentin physician patient use generic pharmaceutical augmentin escompete broad range brandname medicine increase competition brand generic antibiotic malarone safety profile product long protect patent convenient dose regiman helped product strong position versus mefloquine follow recent launch cns disorder malaria prophylaxis major competitor paxilin usa selective serotonin reuptake inhibitor ssri market fluoxetine generic form eli lillys metabolic gastrointestinal prozac zoloft pfizer forest laboratory celexa lexapro major competitor avandiais takeda chemical acto principal competitor usa wellbutrinare ssris copromote eli lilly usa effexor wyeth product success seroxatpaxiland wellbutrin target generic manufacturer vaccine glaxosmithkline continues respond appropriately glaxosmithkline major competitor vaccine market include note financial statement legal proceeding aventis pasteur merck wyeth engerixband havrix imigranhas grow glaxosmithkline lead product compete vaccine produce merck comvax address previously unmet need migraine recombivax hepatitis vaqta avaxim hepatitis sufferer company launch compete infanrixsmajor competitor aps range dtpabase product new formulation imigransuch nasal spray combination vaccine introduction naramighave help group retain lead competitor migraine market maintain growthdescription businessglaxosmithkline competition consumer healthcare grant marketing authorisation afford group protection period competitor rely confidential datum main competitor group consumer healthcare market regulatory file basis marketing authorisation include major international company colgatepalmolive datum protection period begin thedate authorisation johnson johnson pfizer procter gamble unilever wyeth grant european union andexpire year addition company compete authorisation grant centralised procedure glaxosmithkline select market year authorisation grantedvia mutual recognition major competitor product overthecounter otc procedure depend onthecountry concern medicine usa drug price competition patent term usametamucil laxative clearasil acne treatment restoration act hatchwaxman establish current pepcid indigestion private label smoking control framework approval generic drug include related patent product datum protection provision hatchwaxman sponsor lemsip cold remedy nurofen anadin abbreviate new drug application anda receive analgesic nicorette nicotinell smoking control marketing approval submit safety efficacy datum remedy rely pioneer company extensive preclinical clinical development datum provide propose generic drug nutritional healthcare major competitor horlicksare demonstrate bioequivalent pioneer product ovaltine milo malt food chocolate drink generic drug approval subject datum protection competitor ribenaare primarily local fruit juice product period year new chemical entity year lucozadecompete energy drink modification support new clinical study glaxosmithkline hold lead global position key provision hatchwaxman file andacan consumer product area worldwide second large oral trigger procedure allow patent holder initiate patent care large otc medicine nutritional infringement litigation significant procedural advantage healthcare hold lead position india assure fdas approval propose generic ireland product stay month pende resolution litigation procedure generate litigation regulation pharmaceutical controversy particularly currently apply resulted multiple nonconcurrent month stay international pharmaceutical industry highly regulate propose generic product fdahas propose change national regulatory authority administer panoply law regulation address certain aspect procedure andregulation govern testing approval manufacturing generate litigation controversy reform legislation label marketing drug review safety propose congress andefficacy pharmaceutical product regulatory requirement major factor determine usa second reauthorisation prescription drug substance develop marketable product user fee act come effect october pdufa iii time expense associate development recent general accounting office report senate particular importance requirement country committee health education labor pension note product authorise register prior marketing gradual increase median time gain approval drug authorisation registration maintain subsequently standard review designation approval time priority review drug judge fda represent national regulatory authority jurisdiction include significant therapeutic advance remain constant usa european union japan australia high median time approval month standard technical appraisal consequently introduction new pharmaceutical product generally entail lengthy increase gap approval time approvalprocess priority standard application approval time drug designate standard review reach low european union procedure obtain month rise month marketing authorisation medicinal product centralise procedure application direct remain see substantial additional resource fund theeuropean medicine evaluation agency lead pdufa iii result reduction overall approval times authorisation valid member state compulsory drug biologic review times certain biologic product derive biotechnology optional new vaccine substantially impact recently activesubstance innovative medicinal product announce consolidation review activity center mutual recognition procedure applicable drug evaluation research activity previously majority conventional medicinal product operate mutual carry center biologic evaluation research recognition national marketing authorisation agreement reach resolve procedure bind arbitration glaxosmithkline description business decade regulatory authority focus value money significant attention measure manage risk associate increasingly necessary demonstrate value use prescription product particularly noticeable money new product particular impact drug usa fda pharmaceutical industry budget expenditure burden disease subject intense public scrutiny adequacy treat measure take protect public health substantial funding market need satisfy healthcare purchaser fda strengthen post market surveillance activity value money additional hurdle product include pdufa iii performance goal associate acceptance regulatory test ofsafety efficacy legislation drug manufacturer encourage submit quality delay bring effective improve voluntarily propose risk management plan application medicine market reduce effective patent marketing new drug recent development represent protection time additional challenge market registration process usa market increasingly difficult june fda announce approval supplemental significantly improve therapy obtain premium price new drug application snda allow restrict market exist medication philosophy found valuebase pricing lotronexalosetron hydrochloride treat woman severe difficult follow circumstance usa diarrhoeapredominant irritable bowel syndrome ib possible price product reflect value november reintroduction follow advisory committee review implementation fdaglaxosmithkline agree risk possible predict extent management programme intend ensure patient groupsbusiness affect future legislative physician fully inform possible risk benefit regulatory development relate specific pharmaceutical lotronex product price international market country outside usa regulation consumer healthcare europe regulatory environment continue extremely varied challenging glaxosmithkline anticipate consumer healthcare industry subject national regulation introduction new product continue require substantial testing approval manufacturing labelling marketing effort time expense comply regulatory requirement product country high standard technical appraisal entail lengthy approval process new product price control launch manycountrie price pharmaceutical product national regulatory authorisation require approve control law government influence price switch product prescription otc requirement control national healthcare organisation bear include longterm experience quality safety efficacy large cost supply product consumer oftheproduct wide patient population data confirm usa debate reform healthcare system thatthe relevant condition selflimite easily increase focus pricing currently government diagnose bythe consumer price control private sector purchase federal legislation require pharmaceutical manufacturer pay prescribe rebate certain drug order eligible reimbursement medicaid federal healthcare programmes europe historically affect government regulation pricing reimbursement pharmaceutical industry continue experience pressure price range measure include acrosstheboard cut link lowcost country price referencing delay agree reimbursement increase pressure generic substitution crossborder import fromlowprice market exert commercial pressure incountryprice japan discussion ongoing new price reimbursement control government introduce worldwide pharmaceutical market continue experience increase pressure pricing reimbursement government healthcare provider nonprice factor new product high volume principally drive growth pharmaceutical expendituredescription businessglaxosmithkline operating activity marketing distribution directtoconsumer dtc advertise major component product marketing usa dtc advertisement glaxosmithkline sell product worldwide primary source information patient request specific extensivenetwork subsidiary licensee distributor brand product physicians usa gross profit margin earn sale pharmaceutical outside usa dtc prohibit limited product generally higher earn sale rolein inform patient european union dtc consumer product reflect risk uncertaintie prescriptiononly product currently prohibit australia inherent develop marketing pharmaceutical risk government allow dtc advertising pharmacyonly product include high level research development expenditure subject certain safeguard new zealand dtc allow required discover test obtain patent protection new selfregulate industry collaboration advertising product competition new generic product standard agency market allow dtc date glaxosmithkline worldwide operation subject number impact limit risk inherent conduct business certain country include addition direct marketing product subsidiary possible nationalisation expropriation restrictive glaxosmithkline enter agreement withother government action capital regulation addition currency pharmaceutical company comarkete copromotion fluctuation change economic condition occur product market example levitra bayer favourable unfavourable effect trading income group regard factor market distribution consumer healthcare deterrent expansion international operation closely review method operation particularly principal market consumer healthcare otc medicine develop country develop strategy respond usa germany australia argentina italy mexico change economic political condition japan canada france principal market oral care product usa germany nutritional drink marketing distribution pharmaceutical business particularly strong ireland india range product available market analysis total pharmaceutical sale include divested product geographic region set otc oral care product primarily distribute pharmacy mass market outlet directly sale geographic region wholesaler nutritional healthcare product distribute similar extensive retail wholesale network usa europe international manufacture supply asia pacific glaxosmithkline large portfolio product range japan tablets toothpaste inhaler complex capsule latin america different pack size presentation middle east africa canada manufacture medicine begin development therapeutic active ingredient bulk active select formulation global manufacture supply gms develop manufacturing process scale volume production active compound glaxosmithkline sell prescription medicine primarily primary manufacturing site convert active compound wholesale drug distributor independent chain retail finish dosage formulation responsibility secondary pharmacy physician hospital clinic government entity manufacturing site institution product ordinarily dispense public pharmacy prescription write doctor gms operate single global network site hospital doctor surgery country year gms produce tonne bulk active billion pack package usa world large pharmaceutical market deliver sale country world pressureto contain healthcare cost encourage growth support approximately new product line extension manage care organisation pharmacy benefit manager launch year intermediary use range method low cost include substitution generic product cheap gms focus deliver therapy brand product prescribe doctor secure source supply high quality product increase importance supplier healthcare compliance regulatory requirement customer community glaxosmithkline contract manage care expectation sector small number wholesaler good class cost market glaxosmithkline deploy salesforce lead edge practice performance site representative support medical staff promote procurement global function prescription product medical prescriber healthcare purchaser personal visit organisation gms operation structure supply chain region promotion glaxosmithkline product supplement scientific seminar advertising medical journal television advertising provision sample direct mailing information contain group website glaxosmithkline description business primary supply chain vaccine supply chain global organisation site spread vaccine production locate principally rixensart belgium country broad range active ingredient antibiotic site worldwide manage vaccine supply chain nonantibiotic product manufacture package involve anticipate market need flexible approach site locate australia india ireland singapore able meet fluctuation demand base usa majority active ingredient manufacture forecast different market firm order health primary supply chain supply secondary authority mass vaccination campaign bulk fill pharmaceutical site europe north america international packaging carefully balanced stocking vaccine help manage shortterm increase demand increase secondary supply chain prompt disease outbreak increase demand european region public owe disease awareness campaign site european region spread country european site manufacture nearly consumer healthcare supply chain major pharmaceutical product market globally consumer healthcare manufacturing site spread glaxosmithkline wide variety finish dosage form country consumer healthcare supply chain diverse include manufacture supply otc north america region medicine oral care nutritional healthcare smoking control pharmaceutical site north america region product internal facility contract supplier locate puerto rico canada usa worldwide international region research development pharmaceutical international region comprise manufacture site global biological pharmaceutical research country spread distinct area site development function glaxosmithkline responsible middle eastafrica site spread asia pacific area discover develop registering commercialise site china japan latin america support effective marketing innovative prescription medicine vaccine delivery system treatment glaxosmithkline integration prevention human disease longterm integrate change programme implement time merger call global supply network gsn fundamental goal thorough understanding structure deliver benefit major stream disease investigation involve pioneer work ingenetic activity predictive medicine traditional research discipline addition work create new medicine reduction abovesite infrastructure cost vaccine extensive effort gain clear understanding procurement initiative unmet need patientsand healthcare provider continue network rationalisation payer guide overall direction logistic improvement operational excellence lean sigma improvements glaxosmithkline invest billion pharmaceutical organisation benefit network rationalisation plan production cease insight scientist world employ site country include argentina india staff biological pharmaceutical activity japan kenya mexico south africa taiwan venezuela site worldwide include usa disposal closure site announce beckenham brentford cambridge dartford year greenford harlow stevenage tonbridge ware welwyn external suppliers usa bristol tennessee philadelphia upper merion procurement global function support function area upper providence pennsylvania research triangle glaxosmithkline business manufacture park north carolina large area billion spend external belgium rixensart supplier year include purchase active ingredient canada mississauga chemical intermediate partfinishe finished product gms france les ulis evreux take appropriate step protect supply chain italy verona disruption result interrupt external supply japan tsukuba science city takasaki appropriate stock level contract alternative register spain tre cantos madrid supplier continue deliver range product market accelerate progress early stage development extensive inlicense activity begin continue latestage early pipeline significantly enhance practical prioritisation management portfolio compound development focus ensure glaxosmithkline invest resource achieve optimum value deliver new medicine patientsdescription businessglaxosmithkline product development pipeline product development pipeline set show considerable breadth depth end glaxosmithkline pharmaceutical vaccine project development clinic key vaccine phase evaluation clinical pharmacology usually conduct pharmaccine volunteer compound shionogiglaxosmithkline pharmaceutical llc joint venture phase determination dose initial evaluation inlicense alliance relationship party efficacy conduct small number patient date submission date regulatory approval maa phase iii large comparative study compound versus placebo approval letter andor establish treatment patient approvable letter establish clinical benefit safety maa marketing authorisation application europe nda new drug application usa compound type indication phase maa nda cardiovascular urogenital metabolic antifactor monoclonal antibody stroke beta adrenergic agonist type diabete thrombin inhibitor prevention thrombotic complication cardiovascular disease peroxisome proliferatoractivator dyslipidaemia receptor pparagonist ppar agonist dyslipidaemia ppar agonist type diabete nin oral insulin analogue type diabete ccka agonist obesity indirect thrombin inhibitor prevention thrombotic complications cardiovascular disease lppla inhibitor atherosclerosis bvt htc agonist obesity piboserod antagonist atrial fibrillation avandia sulphonylurea ppar gamma agonist plus sulphonylurea type diabete iii avodart alpha reductase inhibitor prostate cancer prevention iii nesiritide recombinant betatype natriuretic peptide acute heart failure submit ssep levitravardenafil pdev inhibitor erectile dysfunction submit sjan aljul avandia ppar gamma agonist type diabete combination insulin submit alfeb avandamet ppar gamma agonist plus metformin type diabete approve soct aoct avandia metformin combination tablet infectious disease topical pleuromutilin bacterial skin infection lapdap artesunate antifolate artemisinin treatment uncomplicated malaria phospholipid antiendotoxin emulsion sepsis augmentingranule beta lactam antibiotic respiratory tract infection incl penicillinresistant pneumoniae modify release granule formulation augmentin chewable beta lactam antibiotic acute otitis medium incl penicillinresistant iii pneumoniae highdose chewable tablet augmentinxr beta lactam antibiotic treatment acute exacerbation chronic bronchitis iii aecb include complicated aecb oxibendazole polymerase inhibitor treatment adult paediatric helminth iii intestinal infection sitamaquine unknown treatment visceral leishmaniasis iii tafenoquine aminoquinoline malaria prophylaxis adult iii lapdap antifolate treatment uncomplicated malaria submit soct antiviral aspartyl protease inhibitor hiv infection nonnucleoside reverse transcriptase inhibitor hiv infection hiv integrase inhibitor hiv infections ziagenepivir reverse transcriptase inhibitor hiv infection combination tablet iii protease inhibitor amprenavir prodrug hiv infection submit sdec sdec valtrex nucleoside analogue hsv suppression immunocompromise patient submit ssep valtrexzelitrex nucleoside analogue prevention herpe simplex virus hsv transmission submit snov soct glaxosmithkline description business compound type indication phase maa nda neurology gastrointestinal endothelin antagonist stroke antagonist alzheimer disease schizophrenia dual alpha integrin antagonist vla multiple sclerosis inflammatory bowel disease ibd asthma rheumatoid arthritis corticotropin releasing factor crfr irritable bowel syndrome ib anxiety antagonist depression cox inhibitor second generation pain adenosine agonist neuropathic pain endothelin antagonist stroke benzodiazepine inverse agonist alzheimer disease vascular dementia carabersat benzopyran migraine prophylaxis epilepsy imigranimitrex agonist migraine needlefree injection talnetant tachykinin antagonist ibs schizophrenia alvimopan adl peripheral muopioid antagonist post operative ileus iii imigranimitrex agonist migraine fast dissolve tablet iii lamictal sodium channel inhibitor neuropathic pain iii requip nonergot dopamine agonist parkinson disease control release formulation iii requip nonergot dopamine agonist restless leg syndrome iii imigranimitrex agonist adolescent migraine nasal formulation submit ssep aldec oncology musculoskeletal inflammation grot cxc chemokine prevention chemotherapyinduce cytopaenia cathepsin inhibitor osteoporosis osteoarthritis recombinant human interleukin immunologicallysensitive cancer melanoma immunomodulator renal cell thrombopoietin agonist chemoprotection alpha kinase inhibitor rheumatoid arthritis chronic obstructive pulmonary disease kinesin inhibitor breast ovarian cancer vascular epidermal growth factor tyrosine solid tumour kinase inhibitor topotecan topoisomerase inhibitor bioenhancer cancer erbb egfr dual kinase inhibitor solid tumour breast colorectal cancers ethynylcytidine selective rna polymerase inhibitor solid tumours hycamtin topoisomerase inhibitor small cell lung cancer line therapy repifermin keratinocyte growth factor mucositis wound care inflammatory bowel disease hycamtin topoisomerase inhibitor nonsmall cell lung cancer second line therapy iii hycamtin topoisomerase inhibitor small cell lung cancer second line therapy iii oral formulation hycamtin topoisomerase inhibitor ovarian cancer line therapy iii ibandronate bisphosphonate treatment prevention postmenopausal iii osteoporosis monthly oral dose ibandronate bisphosphonate treatment prevention postmenopausal iii osteoporosis quarterly dose navelbine vinca alkaloid nonsmall cell lung cancer oral therapy iii bexxar radiolabelle antib monoclonal nonhodgkin lymphoma submit ssep antibody hycamtin topoisomerase inhibitor small cell lung cancer second line therapy submit snov ibandronate bisphosphonate treatment prevention postmenopausal submit sjun sjul osteoporosis daily oral regimen psychiatry antagonist schizophrenia alzheimer disease noradrenalinedopamine reuptake inhibitor depression bipolar disorder glycine antagonist smoking cessation antagonist depression anxiety corticotropin releasing factor crfr anxiety depression ib antagonist antagonist depression anxiety talnetant tachykinin antagonist schizophrenia ib vilazodone selective serotonin reuptake inhibitor ssri depression emd hta partial agonist lamictal sodium channel inhibitor bipolar disorder acute treatment iii paxil ssri premenstrual dysphoric disorder pmdd intermittent iii treatment control release formulation lamictal sodium channel inhibitor bipolar disorder longterm prophylaxis submit saug sjun paxil ssri pmdd continuous treatment control submit sjun release formulation paxil ssri social anxiety disorder submit sdec wellbutrin noradrenalinedopamine reuptake inhibitor depression control release formulation submit saug daily dosingdescription businessglaxosmithkline compound type indication phase maa nda respiratory beta agonist asthma chronic obstructive pulmonary disease copd selective inos inhibitor asthma copd allergic rhinitis beta agonist asthma copd alpha kinase inhibitor copd dual alpha integrin antagonist vla asthma ibd chemokine receptor antagonist asthma allergic rhinitis alpha integrin antagonist asthma allergic rhinitis glucocorticoid receptor agonist asthma copd allergic rhinitis awd pde inhibitor asthma copd allergic rhinitis mepolizumab antiil monoclonal antibody asthma atopic dermatitis ariflo pde inhibitor copd submit sdec noncfc meter dose inhaler propellant serevent beta agonist asthma copd iii flixotideflovent inhale corticosteroid asthma copd approve aapr aldec seretideadvair beta agonistinhale corticosteroid asthma approve ajun aloct oct diskusaccuhaler dry powder inhaler seretideadvair beta agonistinhale corticosteroid adult paediatric asthma daily dose iii seretideadvair beta agonistinhale corticosteroid copd submit ssep almar dec serevent beta agonist copd approve amar hepatitis vaccine hepatitis recombinant hepatitis prophylaxis extra strength hepatitis recombinant extra strength hepatitis prophylaxis iii tbd twinrix dose recombinant combine hepatitis prophylaxis approve asep childadolescent paediatric vaccine rotarix live attenuate oral rotavirus prophylaxis meningitidi conjugate meningitis prophylaxis meningitis cuba subunit meningitis prophylaxis tbd pneumoniae paediatric conjugate pneumoniae disease prophylaxis child iii mmrvaricella live attenuate measle mump rubella varicella prophylaxis iii infanrixpediarixpenta recombinant diphtheria tetanus pertussis hepatitis approve aoct adec hepbipv inactivated polio prophylaxis infanrixhexahep ipvhib conjugatedrecombinant diphtheria tetanus pertussis hepatitis approve aoct tbd inactivated polio prophylaxis haemophilus influenzae type prophylaxis vaccine dengue fever attenuate tetravalent vaccine prophylactic use hiv recombinant hiv prophylaxis new influenza subunit influenza prophylaxis new delivery pneumoniae elderly conjugate pneumoniae disease prophylaxis staphylococcal antibody monoclonal antibody prevention staphylococcal infection epsteinbarr virus ebv recombinant ebv prophylaxis human papillomavirus hpv recombinant prophylaxis hpv infection malaria recombinant malaria prophylaxis boostrix subunit adolescentadult booster diphtheria tetanus approve aoct pertussis boostrix ipv subunit adolescentadult booster diphtheria tetanus iii pertussis inactivated polio simplirix recombinant genital herpe prophylaxis iii pharmaccine gskpowderject recombinant hepatitis treatment recombinant treatment lung cancermelanoma content portfolio change time new compound progress research development development market owe nature drug development process unusual compound especially early stage investigation terminate progress development competitive reason new project preclinical development disclose project type identify glaxosmithkline description business compound progress phase clinical development discovery project list table progress nonclinical safety testing early phase clinical development compound continue rigorous nonclinical clinical commercial assessment lead proof concept decision month compound mechanism indication topotecan multidrug resistance inhibitor topoisomerase inhibitor cancer endothelin antagonist stroke inos inhibitor asthma topical pleuromutilin bacterial skin infection norepinephrinedopamine reuptake inhibitor depression cathepsin inhibitor osteoporosis glycine antagonist smoking cessation interleukin cancer thrombopoietin agonist chemoprotection alphaintegrin antagonist allergic rhinitis inhale beta adrenergic receptor agonist asthma aspartyl protease inhibitor hiv ppar pan agonist diabete neurokine antagonist depression alpha kinase inhibitor rheumatoid arthritis dual alphaintegrin antagonist multiple sclerosisirritable bowel syndrome inhale corticosteroid asthmaallergic rhinitis nonnucleoside reverse transcriptase inhibitor hiv kinesin inhibitor cancer chemokine receptor antagonist asthma vegfr tyrosine kinase inhibitor solid tumour lapdap artesunate chlorproguanildapsone combination artesunate malaria hiv prophylactic vaccine hiv dengue fever vaccine vaccine dengue fever significant regulatory submission product countryregion description advair usa label corticosteroid spare effect combination salmeterol longacte betablocker fluticasone corticosteroid dry powder diskusdevice ariflo usa cilomilast pde inhibitor treatment chronic obstructive pulmonary disease avandamet europe combination rosiglitazone metformin type diabetes coreg usa carvedilol alphabetablocker inlicense roche cardiac dysfunction follow heart attack flixotide europe low age limit fluticasone inhale corticosteroid asthma flovent usa cfcfree meter dose inhaler fluticasone ibandronate europe usa bisphosphonate treatment osteoporosis inlicense roche lamictal europe usa lamotrigine sodium channel blocker longterm prophylaxisprevention bipolar disorder lamictal japan lamotrigine epilepsy levitra europe pde inhibitor treatment erectile dysfunction inlicense bayer nesiritide europe natriuretic peptide inlicense scios inc acute heart failure paxil usa controlled release paroxetine selective serotonin reuptake inhibitor treatment premenstrual dysphoric disorder paxil usa paroxetine treatment social anxiety disorder europe usa protease inhibitor hiv valtrex usa europe valaciclovir dna polymerase inhibitor suppression transmission herpe simplex virus wellbutrin usa additional sustained release strength bupropion noradrenalinedopamine reuptake inhibitor treatment depression wellbutrin usa extended release formulation bupropion treatment depressiondescription businessglaxosmithkline product approval approval receive number new product include significant new indication formulation exist product summarise table countryregion product approval date description augmentin usa october extend release formulation amoxicillin betalactam antibiotic clavulanate beta lactamase inhibitor adult respiratory tract infection avandamet usa october fix dose combination avandia metformin type diabete avodart usa october year data dutasteride alpha reductase inhibitor treatment benign prostatic hypertrophy bph avodart europe july dutasteride treatment bph epivir usa october daily dose lamivudine reverse transcriptase inhibitor hiv flixotide europe october low age limit fluticasone inhale corticosteroid asthma flonase usa intranasal fluticasone nasal symptom flutide japan october fluticasone cfcfree inhaler lotronex usa june reintroduction alosetron irritable bowel syndrome ibs paxil usa february paroxetine selective serotonin reuptake inhibitor panic disorder pediarix usa december combine diphtheria tetanus pertussis hepatitis polio vaccine child serevent diskus usa march dry powder formulation salmeterol longacte beta blocker copd serevent mdi diskus japan april salmeterol meter dose dry powder inhaler asthma sultanol diskus japan march shortacte beta blocker salbutamol dry powder device asthma twinrix dose europe september combine vaccine hepatitis valtrex usa september valaciclovir dna polymerase inhibitor treatment cold sore wellbutrin usa june additional strength bupropion depression zovirax cream usadecember aciclovir dna polymerase inhibitor treatment cold sore zylorictablet japan march allopurinol xanthineoxidase inhibitor treatment gout process discovery commercialisation delivery measure productivity number innovation product create commercial value product ability address unmet need healthcare customer include patient healthcare professional budget holder regulator centre perspective constitute valuable new product genetic preclinical research excellence development new position ensure generate right medicine safety efficacy quality information respond drug discovery prove different perspective datum demonstrate overall discovery new product value research development social benefit new medicine increase length quality cedd life increase workplace productivity historical contradiction pharmaceutical industry need lever advantage large organisation lose creative spirit research environment glaxosmithkline structure balance area benefit large scale advantage small enhance productivity intellectual property key area benefit large validate target drug product lead capital intensive high throughput activity compound screening require scarce skill process highly regulate mainly later end line glaxosmithkline strategic intent development chain area flourish good indisputable leader industry set goal advantage structural unit remain small unit industry productive organisation step respond quickly change environment opportunity achieve include initiative reduce time scientist interact optimise need return take phase discovery development chain investment focusse foster gain early understand candidate molecule entrepreneurial accountable culture increase probability make new medicine available treat patient soon possible glaxosmithkline description business power small unit manifest centre discovery research excellence drug discovery cedd ensure purpose discovery research identify lead efficient rapid validation lead candidate preclinical compound form basis drug discovery effort test proof concept criterion hand cedd investment focus improve productivity compound new product development organisation large quality quantity complete construction scale clinical trial new automation facility tre canto spain continue work facility upper providence harlow new product development function integrate clinical regulatory commercial activity necessary bring new parallel development ability generate medicine marketplace similarly new product supply efficiently large number high quality new compound organisation bridge traditional divide development substantial progress implement method evaluate manufacturing ensure robust manufacturing process high throughput biology discipline develop integration knowledge animal human biology starting deliver highly predictive model forecast efficacy significant progress integration compound extend understand human disease group japan global development commercialisation process order eliminate duplication centre excellence drug discovery speed regulatory filing discovery crucial step convert lead compound drug development portfolio japan review prioritise candidate optimise lead potency efficacy safety context global pipeline intrinsic characteristics molecule crucial success capacity embrace demonstrate validity therapeutic hypothesis develop new technology streamline drug discovery process early clinical trial result candidate cedd technology development organisation keep abreast focus specific disease area design nimble emerge technology advance creation new entrepreneurial range skill resource require medicine evaluate provide investment drive midstage development project lead optimisation knowledge require develop select technology appropriately key decisionpoint demonstration proof generate modifie technology focus concept major investment fund largescale group internal goal maximise return clinical trial asset sale spinout outlicense cedd base usa europe early research role genetic cardiovascular urogenital disease centre upper early stage find new medicine require essentially merion component target show affect mechanism metabolic viral disease centre research triangle park important pathological process human disease microbial musculoskeletal proliferative disease include compound typically small molecule include cancer centre upper providence macromolecule protein therapeutic vaccine able neurology centre harlow modulate behaviour specific target psychiatry centre verona italy respiratory inflammation centre stevenage target validation process glaxosmithkline aim identify gene relevant common disease large cedd responsible identify optimal drug unmet medical need asthma noninsulin dependent candidate desire biological effect assess diabete osteoarthritis chronic obstructive pulmonary disease safety development characteristic preclinical screen early onset heart disease alzheimer disease disease achieve cedd responsible proving arise complex interaction number gene compound safe efficacious patient smallscale variant environmental factor challenge involve clinical trial proof concept decision point significant identify gene predispose patient decision information available particular disease understand role progression date justifie compound progression latestage drug lead find new way intervene disease development necessary largescale clinical trial programme identify tractable target conduct register commercialise product genetically associate human disease interest cedd progress significantly compound initiate enable validation target associate dose human initial evaluation disease prior extensive investigation efficacy patient table compound practical application genetic move forward progress phase order progress highly year opportunity identify promise medicine rapidly compromise safety knowledge specific marker efficacy susceptibility select project currently pilot process involve adverse event enhance ability focus development running activity parallel sequentially new medicine patient likely benefit ultimately provide reassurance prescriber patientdescription businessglaxosmithkline glaxosmithkline major response challenge matrix team responsible maximise worldwide disease affect develop world microbial development opportunity product remit musculoskeletal proliferative disease cedd responsibility ensure early stage regional marketing need drug discovery unit base tre canto dedicate fully integrate development plan information find new medicine disease research project need support registration safety programme price tre canto focus malaria work formulary negotiation available careful prioritisation group hivaid vaccine address phase development ensure high potential prevention treatment world health integrate portfolio achieve organization priority disease group work team collaborate early stage cedd define numerous external partner worldwide search new target product profile new molecule integrate treatment disease develop world ddw technical development manufacturing function ensure rapid effective launch delivery product innovative preclinical development clinical programme lead molecule cedds preclinical development pcdparticipate wide range develop crossfunctional project team activity drug development process optimise selection compound potential development launch new group translational medicine technology marketplace enhancement exist product establish npd optimise use variety devise convenient formulation early development technology reduce risk cost development process metabolic fate safety compound evaluate crossfunctional input extend focus lifecycle management laboratory animal prior test human test product deliver new indication new presentation require animal human mandate highly initial regulatory approval commercial launch example regulate governmental agency lifecycle management include extend release formulation pcd researcher investigate dosage form tablet inhale augmentin development programme design deliver develop formulation enhance drug effectiveness pcd new indication use seretideadvairfor chronic responsible development drug formulation obstructive pulmonary disease copd clinical trial process support analytical method new initiative gold pass implement drug synthesis product formulation delivery scale designation agree regional market meet increase supply requirement ultimately lead manufacture key component portfolio resource technical transfer process method manufacture prioritisation management process ensure new product supply process partnership resource place key emerge asset yield optimum global manufacturing supply ensure robust product commercial benefit maximum medical benefit develop large scale commercial manufacturing launch patient gold pass asset high value strategic pcd pursue novel technology enhance productivity importance glaxosmithkline require specific organisational lower rate project failure reduce cycle time visibility urgency meet patient needs consequently enhance product value predictive toxicology integrate multi small number asset receive gold passstatus time disciplinary collaboration pcd genetics research enable focus organisation align establish improve quality candidate selection reduce latestage attrition toxicity inlicense research collaboration glaxosmithkline continue identify compound key technology area provide way improve rd enhance portfolio create innovative collaboration productivity include drug delivery system predictive technology ensure group regard partner choice particle engineering process innovation use particle large small company compound subject engineering process innovation enhance ability inlicense copromotion deal january manufacture efficiently consistently highquality product new product development alvimopan adl oral muopoid antagonist provide focus development commercialisation phase iii postoperative ileus codevelope process proceed unison major functional copromoted adolor component clinical medical biomedical datum regulatory safety bvt htc receptor agonist compound commercial strategy integrate single advanced phase obesity inlicense management organisation new product development npd biovitrum biovitrum retain exclusive crossfunctional therapeutic area strategy team commercialisation right nordic country cover follow group disease glaxosmithkline exclusive right awd backup compound cardiovascular urogenital metabolic disease advanced phase intranasal delivery infectious disease include ddw allergic rhinitis phase inhale asthma copd neurology gastrointestinal disease inlicense elbion oncology musculoskeletal disease inflammation preclinical development programme ppargamma psychiatry modulator advance bay respiratory development osteoporosis inlicense bayer bayer retain right claim certain compound use field cardiovascular disease oncology glaxosmithkline description business novel selective inhibitor sodiumdependent renal latestage project terminate glucose transporter type sglt compound preclinical development cardiac arrhythmia development oral antidiabetic agent inlicense hypertension phase oncedaily formulation exclude japan china korea taiwan kissei augmentin oral formulation analogue parathyroid hormone preclinical development treatment osteoporosis vaccine inlicense unigene laboratory inc pharmaceutical sector worldwide vaccine novel medicine contain longacte beta agonist conduct glaxosmithkline centre rixensart belgium laba treatment respiratory disease licence activity relate vaccine include clinical theravance inc phase clinical study development regulatory scaling production packaging start support function research scientist employ cellular chemokine receptor ccr antagonist currently devoted discover new vaccine develop development treatment hiv infection costeffective convenient combination product prevent backup followup compound licence ono infection cause medical problem worldwide glaxosmithkline plan initiate phase clinical study discovery work new vaccine perform potential usa half candidate vaccine express yeast bacteria mammalian cell purify high level follow strategic alliance form nobex corporation formulation vaccine involve mix antigen development commercialisation orally administer insulin select adjuvant stimulate good immune response product product develop collaboratively human step evaluate safety efficacy nin novel modify oral insulin phase candidate vaccine invivo model preclinical proof type diabete concept establish stage test alliance form exelixis inc development candidate vaccine clinical trial healthy individual evaluate exelixis small molecule compound genetodrug safety effective vaccine induce immune discovery technology platform deliver phase response protect body disease encounter later development exclusive global commercialisation natural set largescale field trial healthy individual follow manufacturing right exelixis retain copromotion right north establish safety efficacy cross section population america result obtain clinical trial development quality production process facility combine exist collaborative agreement tanabe seiyaku ltd regulatory file submit authority extend facilitate acceleration candidate selection country group intend launch vaccine tanabe glaxosmithkline hit screen addition glaxosmithkline enter number animal research agreement party codevelop comarket ethical regulatory scientific reason research animal certain compound arrangement range milestone remain vital research development new payment party acquire right intellectual medicine vaccine animal property joint venture develop commercialise specify alternative available glaxosmithkline constantly aim compound agreement group reduce number group strive exceed industry obligation payment future specify milestone standard care welfare animal use laboratory achieve financial commitment summarise animal usually breed specifically research cared note financial statement commitment life qualified train staff animal research unnecessary pain suffer discontinuation isscrupulously avoid glaxosmithkline actively engage research development carry risk failure research develop validate experimental method commensurate extension scientific knowledge provide well alternative use animal compound effect lead compound research identify possess positive activity validate target prove safe introduce human feasible glaxosmithkline acknowledge use animal research manufacture commercial scale glaxosmithkline purpose subject rightly command high level public endeavour ensure far possible risk interest glaxosmithkline public policyposition care ameliorate extensive predictive testing early possible ethical use animal research isavailable website development process despite effort ultimate test wwwgskcom secretariat product remain point administer large number patient disease research development consumer healthcare glaxosmithkline korean company chem principal centre consumer healthcare investment lgci review status joint development usa focus identification programme quinolone antibiotic factive gemifloxacin rapid development novel product bring benefit result company agree factive value consumer otc oral care nutritional healthcare well realise lgcis portfolio lgci take market consumer healthcare liaise closely pharmaceutical worldwide responsibility future commercialisation maximise group asset prescription product product include regulatory activity follow transition find application otc marketplace perioddescription businessglaxosmithkline operating resource intellectual property paxilseroxat patent protect commercial form paxilseroxatis expire major market glaxosmithkline regard intellectual property key business glaxosmithkline initiate patent infringement litigation asset effective legal protection intellectual property usa europe market number critical ensure effective return investment generic manufacturer attempt launch intellectual property protect patent trade mark version product prior patent expiry register design copyright domain registration patent trade mark right regard particularly valuable retrovirthere patent active ingredient zidovudine patent cover pharmaceutical formulation contain patent zidovudine medical use expire glaxosmithkline policy obtain patent protection usa europe significant product discover develop seretideadvairthe patent specific combination active activity patent protection new active ingredient available ingredient salmeterol fluticasone propionate significant market protection obtain new expire usa bin europe patent pharmaceutical formulation manufacturing process challenge combination patent new medical use special device administer product serevent patent active ingredient salmeterol xinafoate patent position respect significant product expire bin europe france follow italy usa augmentinin usa patents key active ingredient valtrex patent active ingredient valaciclovir potassium clavulanate extend hold invalid expire usa bin europe decision federal court decision appeal market patent potassium wellbutrin andzybanpatent basic active ingredient clavulanate expire italy expire formulation patent protect currently market srsustaine release formulation late avandia avandametthe basic patent active ingredient expire usa patents rosiglitazone product expire legal challenge uscourt europe regulatory data usa europe patent commercial form exclusivity provide protection active ingredient rosiglitazone maleate expire country usa bin europe ziagen patents active ingredient abacavir avodart patent active ingredient dutasteride expire usa bin europe normal expiry usa europe request extension term patent pende expect zofran patent active ingredient ondansetron extend term patent usa expire usa bin europe bin europe italy patent use treat emesis expire glaxosmithkline initiate legal action patent combivirthe patent specific combination lamivudine generic manufacturers usa zidovudine expire usa bin europe trade marks coreg glaxosmithkline exclusive licensee patent glaxosmithkline pharmaceutical product protect active ingredient carvedilol expire register trade mark major market general mark product market world epivirthe patent active ingredient lamivudine local variation example usa trade mark expire usa bin europe paxili instead seroxatand advairis instead seretide flixotidefloventand flixonaseflonasein usa patent active ingredient fluticasone propionate expire trade mark protection generally extend long protection expect extend virtue paediatric trade mark renew necessary exclusivity european country protection glaxosmithkline trade mark pharmaceutical product expire generally assume increase importance patent product expire particular country generic imigranimitrex patents active ingredient sumatriptan version product available expire usa bin europe italy consumer healthcare business trade mark particularly important business brand orientate lamictal patent active ingredient lamotrigine product patent protection expire usa virtue paediatric exclusivity bin europe glaxosmithkline initiate glaxosmithkline routinely engage legal dispute defence legal action usa generic manufacturer intellectual property right product note attempt launch version product prior financial statement legal proceeding patent expiry levitrad glaxosmithkline copromotion right include extension term patent active ingredient vardenafil include extension term supplementary protection certificate expire usa include extension term national supplementary protection certificate notify follow recent change italian law subject legal challenge register trademark bayer glaxosmithkline description business information technology access information regulatory agency clinical opinion leader healthcare professional patient public information technology play strategic role enhance number market step take glaxosmithkline reduce reliance paper base process clinical trial support key business process local regional registration new medicine use wireless handheld functional global level technology internet enable transformation extension key business activity collaborate assess information facilitate collaboration access information importance glaxosmithkline internet internal global basis intranet continue grow internal website allow information share group global basis support addition computer infrastructure hardware software search engine analogous externally internet organisation responsible voice video technology ability provide share access information enable monitor business technology trend grow use virtual team work collaboratively span impact glaxosmithkline prepare group risk multiple geography time zone glaxosmithkline associate modern information technology adopt strategy enable employee choose integrate business system legacy company receive information need remain priority achieve glaxosmithkline project team department avoid significant disruption critical business system computer collaborate effectively standard collaboration group function strong focus improve business product suite deploy group include process adopt new rapid cost effective method new specialist tool permit information share external colleague securely quickly enhance business performance overall internet technology initiative significant virtually glaxosmithkline major business process rely heavily saving achieve example global learning use information technology major programme management information exchange electronically broad capture source key information electronic form array supplier customer partner protection available require unauthorised access information asset grow risk improve quality potential value molecule pose computer virus major issue address discovery development key aim rigorous security management process develop web base tool provide scientist telephone video conference familiar aspect information need candidate medicine way early business life complement computerbase phase team draw shortlist molecule collaborative work screensharing tool help team consideration possible treatment specific disease fast respond practical challenge pose operate global confidence quality organisation enable glaxosmithkline knowledge worker shortlist area play important role productive key goal standard desktop highthroughput biology laboratory automation imaging adopt globally assist support employee use electronic datum capture document knowledge clinical datum software efficiently management work continue extend manufacturing enterprise glaxosmithkline people resource planning solution ensure compliant glaxosmithkline people fundamental success system common process place standard transaction business skill intellect key component middleware enable efficient movement successful implementation sound business strategy supply chain whilst time allow human capital maximise potential group independent optimisation commercial unit regional scientific commercial financial asset outcome effective functional level manufacture human resource policy glaxosmithklinessolid reputation ability consolidate critical operation reflect grow international employer choice availability reliability global datum network employee achieve group initiate candidate care sale representative benefit ability commitment seek acquire good employment connect system virtual private network away candidate reflect diversity background experience office perspective contribute success glaxosmithkline transform extend business activity insight gain genomic proteomic transform performance reward way disease target identify validate importance people translate employment information obtain variety external source need practice demonstrate value individual integrate internally generate information rapid compensation benefit package glaxosmithkline total flexible manner rely heavily information technology reward aim competitive innovative global support analysis database require significant local orientation depend good drive business amount processing power take advantage advance performance reward individual contribution computer technology new technological approach grid computing computer link use processing power fully investigateddescription businessglaxosmithkline compensation philosophy programme development comprehensive leadership development opportunity available underscore glaxosmithkline commitment performance manager level opportunity target help culture performance base pay base variable share leader meet challenge face global organisation award share option performance development planning ensure leadership motivate enable team evaluation contribute retention key talent superior individual good work development opportunity performance accomplishment business target innovative base peer interaction idea exchange contribute strategy deployment commitment flexible working flexitime teleconferencing remote working flexible work schedule human resource service information system recognise employee work good environment help glaxosmithkline human resource delivery strategy design integrate work personal life technology human resource service information deliver low cost highly effective communication involvement channel easy job candidate employee extensive programme open twoway communication retiree access information employment compensation stimulate employee engagement glaxosmithkline strategy benefit policy programme include intuitive daytoday operation include publication regular personalise webbase tool available employee summary report corporate executive team meeting location chief executive officer home feature presentation area groupwide magazine town hall meeting video property plant equipment conference satellite broadcast involve site country watch employee audience glaxosmithkline operating establishment live video stream video demand option country geographical spread group activity develop additional mean ensure employee indicate note financial statement principal group access senior level management company glaxosmithkline conduct research development powerful tool build culture driving alignment site manufacture product common goal site country refer research development pharmaceutical manufacture supply share ownership scheme encourage participation owner business increase awareness short long term business objective global local employee opinion survey allow glaxosmithkline invest billion property employee opportunity express view perspective acarrye value financial statement billion important group issue billion carrying value invest plant equipment asset construction glaxosmithkline diversity invest billion new andrenewal property plant glaxosmithkline diversity strategy focus create equipment mainly relate large number project inclusive work environment approach aim enhance improvement expansion facility worldwide employee innovation productivity valuing draw site property mainly heldfreehold new investment finance differ knowledge perspective experience style group liquid resources december group resident global community corporate executive team capital contractual commitment future expenditure lead diversity initiative key objective create million operating lease commitment implement diversity strategy measurably improve employee million attraction development retention tailor initiative glaxosmithkline business sciencebase technologyintensive progress embe inclusive behaviour glaxosmithkline highly regulate governmental authority allocate culture practice significant financial resource renewal maintenance glaxosmithkline commit employment policy free property plant equipment minimise risk interruption discrimination potential exist staff ground production achieve compliance regulatory age race ethnic national origin gender sexual orientation standard research development manufacture faith disability active pharmaceutical ingredient require use ofchemical hazardous material glaxosmithkline observe stringent particular glaxosmithkline commit offer people procedure use specialist skill manage environmental risk disability access range recruitment career activity environmental issue date opportunity effort retain support staff operation modify discontinue reference disabled working group responsibility environment health safety note financial statement legal proceeding talent management leadership development glaxosmithkline believe facility adequate development planning key element performance plan current need integration glaxo wellcome smithkline employee year review conduct beecham operation involve series announcement business function ensure diverse talent pool fully rationalisation potential disposal number site develop meet future business need successor property consider change identify key position glaxosmithkline description business business community corporate social responsibility objective target objective focus progressing year glaxosmithkline produce separate report implementation eh management system system social environmental issue cover issue mean ensure ongoing compliance legislation primary concern stakeholder include medicine regulation internal standard site analyse develop world community investment environment programme meet requirement ehs standard health safety metric environmental develop plan achieve requirement performance report year currently meet assistance corporate ehsgroup group develop indicator issue enable provide form information material intranet system progress address report available support ehs programme awards programme secretariat website wwwgskcom encourage innovative solution responsibility environment health safety target ehs improvement set accomplished year health safety target environment health safety ehsis key issue group reduction lose time injury illness rate cent year high priority responsibility ehs high environmental target include reduction energy usage level corporate group report general counsel associate greenhouse gas emission reduction waste overall responsibility provide governance service wastewater dispose increase waste recycle ehs issue operation line manager responsible ehs support ehs medical performance improvement measure professional glaxosmithkline measure impact health safety people work site impact environment environment health safety management measure impact people lose time injury illness glaxosmithkline take systematic approach manage ehs rate number injury illnesse risk impact framework information programme result lose time hour work impact air base set universal ehsstandard guide management water land measure metric tonne material emit issue organisation waste dispose impact natural resource measure cubic metre water gigajoule energy consume environment health safety audits governance responsibility glaxosmithkline conduct glaxosmithkline select measure performance improvement ehs audits site contract manufacturer key supplier base risk risk determine evaluation audit protocol develop introduce impact impact consider potential derive ehs standard new scoring system test adverse impact people environment business year fully implement continuity business reputation measure select similar report company pilot process begin global manufacturing supply recommend global reporting initiative longterm investigate obtain group wide certification multistakeholder international undertaking develop international standard ehs involve review disseminate globally applicable sustainability report guideline party registrar glaxosmithkline ehs standard auditing procedure completion number certification audits product stewardship group site aim registrar gain confidence glaxosmithkline global standard product stewardship corporate auditing process performance establishe requirement responsible ethical representative site international standard proceed management ehs aspect product certification base sample site remain lifecycle product stewardship provide systematic way site subject audits party registrar identify product process risk early obtain certification mitigate manage integrate product stewardship site audit seven followup review business activity protect people environment enhance perform continuous improvement process compliance local regulatory requirement avoid progress monitor action arise issue raise interruption product supply audits web base tool assist process develop launch environmental sustainability concept sustainable development central group commitment corporate social responsibility environmental programme work start eventual proactive management glaxosmithkline manufacture environmental sustainability mitigate environmental impact supply base key contract manufacturer look way improve production efficiency use supplier assess process evaluate renewable raw material overall balance management ehs risk impact base group eh consumption resource generation waste requirement contract manufacturer good performance investigate future group standard sustainable identify recommendation improvement development define approach discovery need manufacturing sale environmental sustainability start support toolkit develop assist selection green chemistries processesdescription businessglaxosmithkline access healthcare develop world evidence uncover company arvs sell africa notforprofit price access healthcare develop country present unique illegally reimporte european union sale challenge global community problem root high price victim trade hivaid patient poverty demand significant mobilisation resource africa beneficiarie illegal importer unprecedented sense urgency new spirit partnership diversion threaten glaxosmithkline ability provide preferential tackle share responsibility sector global price develop world offer notforprofit price society group mandate expertise require sustainable framework combine group resource address underlie problem exist commitment preferential pricing commitment glaxosmithkline play vital role key area place way prevent product diversion avoid make innovative responsible sustainable price referencing preferentially price medicine contribution improve healthcare develop world glaxosmithkline take step address problem regulatory perspective able supply country invest target disease particularly affect combivirin special trilingual access pack provide barrier develop world diversion fully deter illegal trader preferential pricing antiretroviral arvs antimalarial expert repackage medicine strict vaccine regulations enforcement counter illegal trade community investment activity partnership require foster effective health care success partnership disease develop world glaxosmithkline continue engage continued investment new drug vaccine stakeholder work improve access healthcare disease affect develop world essential longterm develop world group long history support improvement health people region community investment programme wide range challenge development resistance partnership support delivery well health education current treatment poor patient adherence complex underserved community world group treatment regimen consult work government develop group believe glaxosmithkline industry develop world united nations ngo extensive portfolio product project disease investment community continue constructive develop world group undertake dialogue organisation share aim try improve prevention treatment world health access healthcare develop world organisation priority disease develop world glaxosmithkline make vital contribution improve hivaid tuberculosis malaria group currently healthcare develop world group continue project programme relevance develop effort improve initiative apply lesson learn world aim produce vaccine look opportunity example september medicine disease disproportionally affect develop group reduce preferential price arvs country glaxosmithkline increasingly involve publicprivate cent look stakeholder partnership enable wide range project undertake play embrace partnership addition hivaid group dedicate show political commit significant new disease develop world create ensure fund critical improvement healthcare quality focus disease project prioritise primarily life develop world achieve socioeconomic public health benefit commercial return global community partnership preferential pricing arrangement glaxosmithkline community investment total glaxosmithkline offer vaccine public health million million relate group program significant discount year group patient assistance programme usa equivalent set single sustainable preferential price arvs cent group profit tax programme antimalarial wide range customer longterm commitment help bring sustainable develop country subsaharan africa total change group community investment activity focus country glaxosmithkline commit contribute health health education include improvement sustainable manner preferential price arvs antimalarial set level patient assistance programme profit cover direct cost supply patient assistance programme provide access sustain long require notable progress glaxosmithkline medicine needy uspatient expand access preferential pricing group prescription drug insurance arrangement cover world poor patient receive medicine group patient assistance country supply arvs preferential price customer include programme value million government nongovernmental organisation ngo hospital academic institution private employer glaxosmithkline description business public health programme glaxosmithkline give unrestricted gift million imperial college london gift support biomedical global alliance eliminate lymphatic filariasis research effort identify develop new treatment glaxosmithkline active involve member global disease alliance eliminate lymphatic filariasis unique partnership group announce renew support science education include ministry health endemic invest million year inspire innovative scheme country nongovernmental organisation community base postdocs research education partnership organisation academic institution international organisation department education skill imperial college london private sector commit eliminate specialist school trust world disable disease education programme include science glaxosmithkline commit antiparasitic drug world international educational programme albendazole require eliminate anticipated encourage communication share learn different year life programme fourth year culture sponsorship royal institution christmas programme million tablet worth million wholesale lecture provide opportunity young people learn acquisition cost donate country number eminent scientist expand programme extend billion people risk country addition group give grant support international impact award recognise excellence global alliance eliminate totalling work voluntary community healthcare organisation year winner receive unrestricted award positive action hivaid donate royal national institute positive action group international programme blind support new low vision unit london hiv education care community support mark tenth group support shaw trust pain management anniversary programme glaxosmithkline work project wale donation partnership network people live hivaids group sponsor exhibition art make community group international agency ngos government underdrawing renaissance painting national gallery intensify community response hivaid london support earthwatch institutes environmental positive action support international award primary school teacher year donation programme country programme include grant year international center research woman investigate underlie factor cause europe hivaidsrelate stigma discrimination develop programme europe focus children health intervention minimise barrier limit access healthcare total funding million support range longterm project conduct ethiopia tanzania zambia programme include zippys friend programme run partnership child teach cope skill child follow consultation conference community committee denmark lithuania positive action contribute support attendance participation community representative barretstown gang ireland lenvol france resource region international aids conference hold provide therapeutic recreation seriously ill child barcelona july europe receive respectively work charity healthprom azerbaijan health african malaria partnership ministry glaxosmithkline invest april glaxosmithkline launch african malaria year programme benefit nearly refugee partnership fund behavioural development programme azerbaijan new safe childbirth initiative africa help combat disease kill million people year north america november announce programme programme north america focus improve access select share grant total million year well healthcare funding million allocate programme benefit nearly million people seven north america community partnership team country million donate regional community activity share award foster healthy ageing culture regional community initiative recognise communitybased programme meet need united kingdom old people racially ethnically culturally diverse glaxosmithkline corporate contribution million background past year glaxosmithkline grant charity project science education million support shareaward organisation medical research healthcare art environment enable improve healthcare access delivery fund addition glaxosmithkline company provide international impact awards usa acknowledge reward million community investment purpose give excellence nonprofit healthcare community great combine total million support project philadelphia area winner receive total provide medical research unrestricted award foundation study infant death multiple sclerosis society action research primary immunodeficiency association stroke associationdescription businessglaxosmithkline glaxosmithkline give unrestricted gift million product donation university pennsylvania million duke university glaxosmithkline donate essential product humanitarian relief gift support discovery research effort effort donation request government identify develop new treatment disease major charitable organisation generally manufacture specifically meet request ngo complete need science summer librarybase science education assessment order product need programme philadelphia area offer handson course international community ensure right product teach certify teachers glaxosmithkline grant reach right person right time american association advancement science support programme total value group international product donation exclude lymphatic filariasis programme north carolina duke university medical center receive million wholesale acquisition cost grant year expand adult diabete glaxosmithkline wholesale list price include discount education programme outreach minority underserved standard industry method value product donation population contribution year rescue mission employee involvement ministry set glaxosmithkline educational scholarship glaxosmithkline employee encourage contribute endowment homeless people local community employee volunteer scheme support vary world include employee university north carolina chapel hill receive time donation charity employee complete overall million grant travel science voluntary work matching gift programme technology bus help improve science teaching encourage usa group match employee gift advance science career underserve ethnic value million minority student glaxosmithkline match contribution employee international united way campaign value million glaxosmithkline international community partnership supplement glaxosmithkline year grant programme address health education mobilisation unite way southeastern pennsylvania provide provide partnership fund million programme specific capacity building grant create effective include healthcare delivery united ways member agency support phase initiative personal hygiene glaxosmithkline investment volunteer excellence sanitation education kenya uganda nicaragua provide grant qualify usnonprofit organisation peru phase target school child aim reduce base employee partner volunteer time grant diarrhoearelate disease death total reflect employee volunteer hour threeyear commitment fund hivaids clinic masoyi tribal area mpumalanga foundations south africa group operate single charitable foundation group extend rural nursing excellence programme corporate programme numberof countrybase thailand sponsor female high school graduate rural foundation include area complete fouryear nursing degree glaxosmithkline glaxosmithkline france foundation support programme donate train nurse improve hivaids prevention education training care ethiopia glaxosmithkline provide integrate primarily africa result people expect management childhood illness imci partnership access care support service end unicef goal contribute global reduction north carolina glaxosmithkline foundation endow mortality morbidity child age selffunde organisation operate separate entity pneumonia diarrhoea malaria measles malnutrition foundation publish annual report available china glaxosmithkline funding support request use asset base support math science development communitybase hivaids programme health education north carolina foundation collaboration red cross movement china british red donation total million figure include cross australian red cross group total community investment figure glaxosmithklineglaxosmithkline corporate governance section discuss glaxosmithkline management structure governance procedure board corporate executive team governance policy dialogue shareholder annual general meeting accountability audit internal control framework combine code glaxosmithkline corporate governance deh board donald mchenry age nonexecutive director mchenry non director list appoint executive director smithkline beecham plc serve date distinguish professor practice diplomacy school bdfh foreign service georgetown university president sir christopher hogg aged irc group llc nonexecutive directorship include nonexecutive chairman sir christopher cocacola company fleetboston financial corporation nonexecutive director smithkline beecham plc non international paper company att corporation executive chairman reuters group plc amember previously serve ambassador permanent supervisory board air liquide chairman royal representative united nations national theatre bdg dhj sir ian prosser age sir roger hurn age nonexecutive director sir ian nonexecutive nonexecutive deputy chairman sir roger appoint director smithkline beecham plc executive chairman nonexecutive director glaxo wellcome plc deputy continents plc world travel tourism council chairman nonexecutive director cazenove nonexecutive deputy chairman plc member group plc chairman court governor cbi presidents committee henley college ronaldo schmitz age jeanpierre garnier aged nonexecutive director schmitz nonexecutive chief executive officer garnier appoint executive director glaxo wellcome plc nonexecutive director director smithkline beecham plc chief legal general group plc member board director executive officer april nonexecutive director rohm haas company cabot corporation united technologies corporation member board trustee eisenhower exchange fellowship hold phd lucy shapiro age pharmacology university louis pasteur france nonexecutive director shapiro nonexecutive mba stanford university usa director smithkline beecham plc ludwig professor cancer research department developmental biology john coombe aged director beckman center molecular genetic chief financial officer coombe executive medicine stanford university school medicine director glaxo wellcome plc responsible hold phd molecular biology albert einstein college finance investor relation member supervisory medicine board siemens accounting standard board code committee takeover panel membership board committee indicate follow paul allaire aged symbol nonexecutive director allaire nonexecutive chairman member director smithkline beecham plc nonexecutive director audit lucent technologies inc pricelinecom inc chairman corporate administration ford foundation transaction michle barzachdfj age corporate social responsibility nonexecutive director barzach nonexecutive financial result director glaxo wellcome plc member nomination international cooperation high council chairman board remuneration equilibre population director board project hope international consultant health strategy french detail term reference board committee minister health family find bdj sir peter job aged director nonexecutive director sir peter nonexecutive director glaxo wellcome plc nonexecutive director sir richard syke nonexecutive chairman sir peter walters schroders plc shell transport trading company plc tibco nonexecutive deputy chairman john young nonexecutive software inc instinet group inc multexcom inc director retired board member supervisory board deutsche bank agand bertelsmann dhj john mcarthur aged nonexecutive director mcarthur nonexecutive director glaxo wellcome plc nonexecutive director bce inc bceemergis inc cabot corporation hcacorporation koc holdings rohm haas company telsat canada aes corporation senior advisor president world bankcorporate governanceglaxosmithkline corporate executive team cet david stout president garni pharmaceutical operation chief executive officer stout president uspharmaceutical chief executive officer garnier link board appoint current position january responsible staff oversee operational aspect include establish global pharmaceutical business global policy objective initiative direct longterm strategy vaccine business join smithkline beecham head garni chief executive officer smithkline sale marketing function beecham join group president pharmaceuticals north america rupert bondy chris viehbacher senior vice president general counsel president bondy responsible legal matter group uspharmaceutical environmental health safety issue insurance responsible european pharmaceutical operation security lawyer private practice join end viehbacher take pharmaceutical smithkline beecham senior counsel operation january join wellcome director continental europe glaxo wellcome ford calhoun chief information officer andrew witty calhoun responsible information technology global president function enable key business process part pharmaceuticals europe group doctoral postdoctoral training microbiology witty responsible group pharmaceutical genetic biomathematic computer science calhoun operations europe post take january join smith kline french appoint cet witty join glaxo glaxosmithkline senior vice president asia pacific john coombe current post chief financial officer head finance function coombe responsible tachi yamada activitie financial reporting control tax treasury chairman investor relation finance system internal audit real estate research development join glaxo group financial controller yamada lead group complex business drug discovery appoint group finance director development create new medicine research join smithkline beecham nonexecutive member dan phelan board chairman pharmaceutical senior vice president human resources phelan responsible benefit compensation recruitment jennie young organisation development leadership development succession senior vice president plan human resource information system employee corporate communication community partnership health management join smith kline french mrs young responsible group internal external appoint senior vice president director communication image partnership community human resource smithkline beecham world join glaxo wellcome director investor relation howard pien president jack ziegler pharmaceuticals international president pien lead pharmaceutical operation outside usa consumer healthcare europe cover country account ziegler head global consumer healthcare business cent world population join produce oral healthcare overthecounter medicine smithkline beecham appoint nutritional healthcare product join smithkline beecham president pharmaceuticals appoint president consumer healthcare business david pulman president member global manufacturing supply palmer tyson left group december appoint post december pulman pursue role pharmaceutical industry ingram responsible global manufacturing supply chain retire december continue work network join glaxo prior recent parttime vice chairman pharmaceutical act post responsible north american supply network special advisor group attend cet meeting manufacturing strategy logistic capacity glaxosmithkline corporate governance governance policy remuneration committee remuneration committee determine term service board executive remuneration executive director corporate executive director list board assistance external independent advisor board glaxosmithkline plc responsible group evaluate make recommendation board system corporate governance ultimately accountable remuneration nonexecutive director group activity strategy financial performance committee consist entirely nonexecutive director board comprise executive nonexecutive director meet time year necessary chairman role nonexecutive director bring independent judgement ceo attend meeting remuneration board deliberation decision board consider consider senior vice president human resource nonexecutive director independent attend meet sir christopher hogg appoint nonexecutive chairman follow retirement sir richard syke nomination committee jeanpierre garni chief executive officer sir roger hurn nominations committee review structure size nonexecutive deputy chairman senior independent director composition board appointment corporate executive new board member make recommendation board process board appropriate committee review board meet sixtime year formal schedule management succession plan ensure adequacy matter reserve decision delegate committee consist entirely nonexecutive director meet specific responsibility board committee describe year consider succession planning board work agree agenda review key necessary activity business receive paper presentation enable effectively board consider review corporate administration transaction committee work undertake committees corporate administration transaction committee review approve matter connection administration board recognise occasion group business certain corporate transaction director feel necessary independent committee consist director corporate executive team legal andor financial advice agree procedure member company secretary committee meets enable necessary company secretary responsible board available individual director respect board procedure company corporate social responsibility committee secretary simon bicknell appoint corporate social responsibility committee consist entirely barrister join group secretary nonexecutive director provide board level forum board committee regular review external issue potential impact group business reputation committee board committee responsible annual governance oversight group board establish follow committee worldwide donation community support committee write term reference meet formally twice year meeting consultation require audit committee audit committee review financial internal report corporate executive team process system internal control management risk executive management group responsibility external internal audit process committee ceo senior manager form corporate propose shareholder appointment external executive team cetwhich meet time year auditor directly responsible remuneration member responsibility list corporate oversight work committee consist entirely executive team nonexecutive director meet time year chief executive officer ceo chief financial officer cfo remuneration director general counsel head global internal audit information remuneration director give corporate compliance representative external auditor remuneration report page attendance dialogue shareholder financial result committee financial result announce quarterly financial result committee review approve behalf board annual report form annual review company report formally shareholder twice year convene annual general meeting halfyear fullyear result announce ceo cfo preliminary quarterly statement trading result presentation final year end result institutional director member committee quorum investor analyst medium london new york meeting member quorate meeting addition teleconference release include chairman chairman audit committee second quarter result institutional investor analyst ceo cfo meet necessary media presentation access wwwgskcom websitecorporate governanceglaxosmithkline annual general meeting take place london formal remuneration report notification send shareholder month advance remuneration report page set meet business presentation shareholder remuneration policy operate glaxosmithkline disclosure director able attend available formally director remuneration include require meeting informally question detail company act schedule director remuneration annual general meeting set section annual report regulation resolution propose approve general meeting remuneration report ceo cfo maintain dialogue institutional auditor shareholder plan objective programme follow transfer pricewaterhousecooper business regular meeting speak regularly external conference limited liability partnership pricewaterhousecooper llp presentation january pricewaterhousecooper resign auditor group investor relation department office london company audit committee propose board philadelphia act focal point contact investor subsequently appoint pricewaterhousecooper llp auditor year company fill casual vacancy create resignation website wwwgskcom give access current financial resolution propose reappoint pricewaterhousecooper business information group llp auditor authorise audit committee determine remuneration share buyback programme october follow completion billion share special business buyback programme announce company announce company seek renew authority plan new billion share buyback programme donation political organisation incur programme cover purchase company share political expenditure cancellation accordance authority give shareholder director authority disapply preemption right annual general meeting allot new share certain circumstance maximum cent current issue share capital total billion spend obtain authority purchase ordinary share company authorise purchase maximum million maximum cent current issue share million share million share share capital purchase cancellation detail give note financial statement share capital share accountability audit internal control framework premium account exact time future purchase determine company dependent board recognise responsibility present balanced market condition factor understandable assessment group position prospect structure accountability audit operate donation political organisation eupolitical glaxosmithkline follow expenditure annual general meeting audit committee board shareholder authorise company donation audit committee board responsibility review political organisation incur political expenditure behalf board effectiveness system internal provision political party election control management risk external internal audit referendum act year group process process monitor compliance law donation noneu political organisation total regulation ethical code practice internal control donation eupolitical framework operation year organisation review continue operate date approval report annual general meeting audit committee receive regular report area significant annual general meeting hold monday risk group relate internal control follow queen elizabeth conference centre consideration report committee report annually broad sanctuary westminster london swp board effectiveness control control mitigate eliminate risk addition area director group business necessary risk achieve sir christopher hogg garnier sir roger hurn coombe satisfactory return shareholder case sir peter job mcarthur mchenry sir ian prosser schmitz companys objective apply expertise prudent shapiro retire offer reelection management elimination risk director review board article company article relate company subsidiary extend association biographical detail give material associate undertaking joint venture board investment glaxosmithkline corporate governance consider audit committee report risk oversight compliance council rocc effectiveness control board believe system rocc council senior executive authorise board internal control provide reasonable absolute oversee risk management internal control activity assurance material misstatement loss process group ensure business unit designate accord guidance internal control issue manager manage significant risk membership comprise turnbull committee member cet head department internal control risk management audit compliance audit committee keep review scope responsibility roccs responsibility include ensure result external audit independence objectivity regular analysis carry identify gap internal external auditor committee review nature control provide report cet audit committee extent nonaudit services external auditor provide addition separate report provide individual internal ensure service significant control audit compliance department direct reporting line question auditor independence group audit committee provide mechanism bypass effect january committee preapprove executive management irregularity identify nonaudit service provide external auditor internal control framework rely rocc corporate social responsibility committee board sector business unit risk management compliance review matter external issue board rmcbs help identify risk provide guidance potential impact group business risk management compliance initiative corporate reputation form internal control business unit level rocc meets regularly review framework assess significant risk mitigation plan direct risk rocc develop corporate policy refer management structure provide business unit framework risk board overall responsibility ensure group management report risk management appropriately manage achieve strategic objective agree rocc mitigation planning identification manager board enable exercise responsibility board overall responsibility management give risk require management information concern business requirement rocc oversee risk deem include relevant information risk exposure internal control significant glaxosmithkline rmcb oversee risk important external development ceo report board business function increase number risk responsible management group assist actively manage group rocc support task ceo establish cet committee corporate ethic compliance department board key functional activity management sector represent cet corporate ethic compliance internal control framework include central direction resource corporate ethic compliance department responsible allocation risk management key activity research support development implementation practice development manufacturing marketing sale legal facilitate employee compliance law group policy human resource information system financial practice thrust group compliance effort diligence framework comprehensive planning system prevent detect misconduct noncompliance annual budget approve board result law regulation promote ethical behaviour compliance operating unit report monthly compare law regulation corporate responsibility level budget forecast prepare regularly year extensive effective compliance system compliance officer support financial control procedure selfassessment exercise risk group main operating sector manufacturing mitigation activity review group internal auditor pharmaceutical consumer healthcare corporate commercial financial responsibility clearly compliance officer chair rocc coordinate delegate local business unit support regional risk management activity compliance management structure principle design provide audit function group provide summary report environment central leadership couple local operating roccs activity group significant risk autonomy framework exercise accountability audit committee regular basis control group area potentially significant risk group attach importance clear principle area potentially significant risk subject regular procedure design achieve appropriate accountability reporting rocc include follow control corporate policy risk management legal detail risk affect group find note compliance mandate business unit establish process financial statement legal proceeding manage risk significant business group risk factor page number risk area specific standard meet exceed requirement applicable law establish human resource specialist audit compliance group example corporate legal requirement discrimination harassment environment health safety worldwide regulatory integrity workforce include preemployment screening compliance assist dissemination implementation control use contractor temporary staff carry audits standard risk inherent group employeescorporate governanceglaxosmithkline research development information technology safety market product potentially significant risk protect information technology asset increase risk matter great concern glaxosmithkline conduct business extend network system datum party laboratory clinical practice dependency internet communication increase accordance applicable law regulation ensure proper system validation electronic record corporate standard exceed requirement signature key regulatory issue matter potential risk pharmaceutical product bring benefit risk group web system accessible public comply include potential effect preclinical clinical trial legal regulatory requirement represent potential conduct development potential product risk potential risk include use personally identifiable determine safety efficacy product use human information electronic record retention outsource business follow approval regulatory body spite effort application susceptibility viruse outside incursion drug introduce marketplace unanticipate group business dependent electronic effect evident group view use mean disaster recovery pose potential risk animal human tissue testing require develop new product risk security environment safety threat security employee property marketing sale environment present significant risk appropriate group operate globally complex legal regulatory safeguard precaution continually review upgrade environment vary jurisdiction group employee injury change health occupational condition policy conduct marketing accordance applicable law plant management potential impact plant regulation corporate standard environment potential risk group address exceed requirement failure observe applicable process set target provide guidance result marketing code rule government pricing management achieve sample legal restriction sale marketing practice create significant risk commercial sector combine code group failure comply result legal proceeding company seek uphold report compliance good practice corporate governance board review legal intellectual property recommendation derek higg review role product liability intellectual property antitrust government effectiveness nonexecutive director sir robert smiths investigation relate private litigation potential risk report audit committee combine code guidance glaxosmithkline group involve legal intend ensure group continue comply administrative proceeding area outcome list rule requirement relation combine code proceeding predict level certainty principle good governance code good practice potential risk party allege combined code issue list authority marketing group product infringe combine code comprise recommendation good practice intellectual property right party term control reporting function board company combine code set principle finance heading potential risk surround group ability forecast future uncertainty ability meet financial director target set budgeting process group invest new director remuneration product venture base assumption success relation shareholder effort prove inaccurate addition accountability audit prescribe detailed potential risk group treasury operation include provision respect principle tax liability transfer pricing possibility trading loss specifically provision require director report counterparty fraud compliance evolve financial annual report disclosure legal reporting requirement constitute risk group pension liability represent area potential director remuneration risk discussion find note financial director responsibility financial statement statement employee cost go concern internal control manufacturing maintain supply key glaxosmithkline product potentially compliance significant risk group policy reasonable measure director report compliance combine code ensure uninterrupted supply product include manufacture corporate governance requirement report accordance applicable law regulation accordance provision combine code set corporate standard exceed requirement director statement responsibility group take effort minimise single source key product rationalise supply chain balancing manufacturing capacity present risk potentially disrupt supply important product glaxosmithkline corporate governance sarbanesoxley act evaluation disclosure control procedure day prior date report group follow number corporate accounting scandal carry evaluation supervision usa congress pass sarbanesoxley act sarbane participation group management include ceo oxley take effect july sarbanesoxley cfo effectiveness design operation establish new enhance standard corporate accountability group disclosure control procedure inherent usa number provision sarbanesoxley apply limitation effectiveness system disclosure control glaxosmithkline company quote new york procedure include possibility human error stock exchange form adss company circumvention override control procedure corporate governance structure believe robust accordingly effective disclosure control procedure line good practice certain change necessary ensure provide reasonable assurance achieve control compliance sarbanesoxley objective base date group recommend security exchange commission evaluation ceoand cfo conclude disclosure sec glaxosmithkline establish disclosure committee control procedure effective material respect committee report ceo cfo audit ensure information require disclose report committee chair company secretary group file submit ussecuritie exchange act member consist senior manager finance legal amend record process summarise compliance public investor relation responsibility report require consider materiality information timely basis determination disclosure treatment material relate party transaction information committee responsibility timely glaxosmithkline hold cent interest quest diagnostic filing report sec formal review inc hold reduce cent content glaxosmithkline annual report form february follow quest acquisition unilab corporation december glaxosmithkline quest ceocfo certification amend term global trial agreement sarbanesoxley introduce requirement ceo longterm contractual relationship quest cfo complete formal certification require primary provider clinical laboratory testing support confirmation group clinical trial testing requirement worldwide review annual report form contain material misstatement omission february ingram member cet financial statement financial information fairly purchase portion land residential property present material aspect financial condition result own group adjacent ingram operation cash flow period report residence total sale price base responsible establish maintain disclosure independent valuation land group subsequently control procedure ensure material information determine retention residential property long know evaluated serve business need list property sale effectiveness control procedure past independent valuation property june value day result evaluation contain property offer sale report estate agent ingram high offer disclose auditor audit committee property purchase group total significant deficiency material weakness design consideration operation internal control fraud regardless materiality involve person significant role document display internal control glaxosmithkline document refer annual report available indicate report inspection register office company significant change internal control include corrective action ceo cfo complete certification file sec usa group form fglaxosmithkline remuneration report remuneration report set remuneration policy operate glaxosmithkline disclosure director remuneration include require schedule company act director remuneration report regulation regulation accordance regulation follow section remuneration report subject audit annual remuneration nonexecutive director share arrangement share option incentive plan pension remain section subject audit remuneration introduction describe process policy programme effect director remuneration set remuneration earn director glaxosmithkline interest share option share incentive plan director senior management set interest director glaxosmithkline shares glaxosmithkline plc contract information provide aggregate remuneration interest director senior management glaxosmithkline glaxosmithkline remuneration report director remuneration report report submit shareholder board approval remuneration committee engage deloitte touche annual general meeting reference chairman conduct additional independent review glaxosmithkline letter notice annual general meeting send current remuneration policy include competitiveness shareholder advise committee shaping development future remuneration policy context glaxosmithkline corporate report describe background outline group base competitive need business remuneration policy give require information global point view earning director senior management director interest share glaxosmithkline background contract glaxosmithkline world lead researchbase reference glaxosmithkline share adss mean respectively pharmaceutical healthcare company ordinary share glaxosmithkline plc american global outlook operation group employ depositary share glaxosmithkline plc ad represent people country cent glaxosmithkline share sale generate outside usa large pharmaceutical market world remuneration committee fundamental glaxosmithkline success profitability review governance arrangement board decide cent pharmaceutical sale usa year separate role remuneration chief executive officer base nomination committee order separate individual thirteen person corporate executive team cet cet board focus function accordingly remuneration considerable global experience half group committee term reference revise account work outside home country late governance standard assume remuneration responsibility previous committee october quality motivation management matter enormously member remuneration committee previously large complex company like glaxosmithkline committee time matter considerable corporate effort require recruit develop relate director remuneration motivate talented people ensure manager consider allaire chairman barzach sir roger hurn level necessary breadth experience knowledge mcarthur mchenry young retirement leadership skill allaire succeed young chairman committee pharmaceutical industry international highly specialised sir peter job appoint member characterise handful global company compete committee february chairman chief intensely talent business industry executive officer ceo invite attend committee manager scientist demand widely know meeting remuneration consider industry internationally corporately mobile board review current term reference way manager scientist glaxosmithkline reward committee light higgs review role develop industrycompetitive crucial effectiveness nonexecutive director consequent change retention effectiveness key market datum regard combine code material change remuneration remuneration senior management science base position committee term reference report year sale provide survey cover follow group report global pharmaceutical company competitor panel remit remuneration committee market cap remuneration committee consider regularly review constituent competitor panel location group policy executive remuneration approval board determine individual remuneration package abbott laboratories usa members corporate executive team astrazeneca aventis france policy set remuneration committee shape bristolmyers squibb usa remuneration level group affect eli lilly usa arrangement management population johnson johnson usa approximately individual represent cent merck usa employee population novartis switzerland tower perrin lead firm remuneration benefit pfizer usa consultant provide strategic advice glaxosmithkline general pharmacia usa remuneration benefit planning provide market datum roche switzerland tower perrin advise remuneration committee scheringplough usa separate mandate regard remuneration senior wyeth usa executive management nonexecutive director change december market capitalisation remuneration nonexecutive director determine glaxosmithkline million compare average glaxosmithkline board advice market capitalisation group million remuneration committeeremuneration reportglaxosmithkline majority competitor panel base company relate total remuneration opportunity available operate globally company compete comparable role competitor panel committee talent perceive shortfall glaxosmithkline policy provide opportunity earn total remuneration competitive position lead loss key talent range target median percentile available comparable role glaxosmithkline remuneration policy set time opportunity crystallise individual team corporate merger endorse shareholder performance meet strategic financial relate business major contribution success merger objective provide appropriate incentive exceptional performance committee policy provide market remuneration policy reference opportunity truly outstanding glaxosmithkline remuneration policy pay industry performance competitive level heavy emphasis pay performance risk remuneration policy design committee aware current level long term incentive deliver policy independent market datum focus longterm sustain success demonstrate glaxosmithkline management focus shareholder value strong emphasis share remuneration currently uncompetitive regard longterm plan incentive result total remuneration opportunity set high level minimum achievement industry median ensure integrate performance assessment management team deliver concerted action success remuneration committee continue monitor closely provide opportunity earn globally competitive reward quantum trend competitor panel award performance deliver consider good interest company shareholder remuneration committee believe individual team performance directly link organisational success salary critical glaxosmithkline future base salary establish reference median global job evaluation management level employee monitor relevant market case competitor panel centrally ensure consistency interlink performance vary base executive experience responsibility objective management chain market value adjustment base salary follow appointment group position base performance salary typically review annual basis glaxosmithkline executive remuneration consist component performance bonus salary base formal review annual performance business performance bonus team demand financial target detailed longterm incentive assessment individual accomplishment objective benefit bonus subject upper limit derive practice competitor panel high limit cent relative importance fix variable element pay base salary target business performance bring total annual executive director illustrate table cash remuneration line competitor panel annual cash remuneration rise target performance exceed fix performancerelate fall level competitor target shortterm incentive longterm incentive achieve executive invest bonus glaxosmithkline share case bonus enhance cent base pay performance bonus share option performance plan share plan share hold minimum year measure longterm incentive operate financial eps growth tsr ftse comprise share option participation performance measure percentage point great retail ep growth share plan link reward shareholder value long performance price index rpi percentage point medium term respectively individual objective year great rpi year performance condition relevant measurement period different plan design provide competitive remuneration package focus executive director meet group business objective component subject regular review sure design plan review ensure evolve meet remuneration remain competitive challenging follow need change competitive environment term section provide great detail performance condition maintain competitive position global market ensure focus current business issue glaxosmithkline remuneration report share option benefit share option allow holder buy share future date executive director participate glaxosmithkline senior price determine reference open market price share executive pension plan detail coombe time grant share option grant participate define benefit plan garni manager glaxosmithkline include executive cash balance plan usa benefits payable age director vest option grant executive director executive director participate legacy glaxo wellcome subject performance condition business performance smithkline beecham employee share plan earning share growth exclude currency exceptional usa glaxosmithkline plan replace item percentage point retirement saving plan garnier receive increase retail price index threeyear cent basic salary form glaxosmithkline measurement period respect future grant share remuneration committee review performance condition annually light market condition currently arrangement coombe member consider performance condition achieve balance sharesave plan contribute month option expectation institutional investor guideline buy share end year saving period pressure respond market practice cent discount market price rule start competitor panel saving period coombe member sharereward plan contribute month buy share number performance share plan share buy month match company participation performance share plan grant sharesave plan sharereward plan inland revenue approve approximately executive group include plan open employee term executive director designate target number share executive director receive follow benefit cash participant vest award plan subject value show performance condition apply year measurement period provision retesting operate healthcare medical dental event performance condition satisfy personal financial advice period life assurance contribution personalfamily travel condition apply half award compare glaxosmithkline total shareholder return tsr period share ownership guideline tsr company ftse index align executive interest shareholder executive period glaxosmithkline deliver return rank require hold share company chief executive officer ftse base tsr performance require hold share value time basic salary share award vest executive director require hold share value position ftse cent share vest time basic salary member cet require glaxosmithkline rank position hold share value time basic salary share subject award vest executive participate performance share plan position vest occur slide scale time salary purpose requirement share second condition apply balance award adss hold glaxosmithkline annual investment plan require glaxosmithkline business performance earning share smithkline beecham bonus deferral plan vest growth exclude currency exceptional item defer award smithkline beecham midterm percentage point increase retail incentive plan include year end garniers total price index threeyear performance period shareholding basis adss coombe condition meet share subject performance share result director exceed share condition vest condition meet ownership guideline share subject performance condition vest extent award vest report performance graph completion performance period new regulation cover director remuneration require graph present show company total shareholder combination earning base measure base return tsr tsr performance broad equity market shareholder return compare ftse index decide index follow graph show glaxosmithkline tsr time merger follow consultation time performance ftse choose number shareholder equity mandate request principal index company share quote performance measure tie ukequity index competitor panel set performance condition meet vest indicate glaxosmithkline relative performance peer performance share plan awards cet subject final approval remuneration committee consider final vest consistent underlie financial performance groupremuneration reportglaxosmithkline performance graph remuneration committee believe current termination payment executive director contract justify represent fair reasonable compensation event contract terminate give market practice associate restriction arise need protect intellectual property garni garni service agreement smithkline beecham corporation date december agreement expire glaxosmithkline total return index ftse total return index october day month glaxosmithkline pharma peer return index garnier reach birthday garniers contract specifie note compensation pay termination employment tsr graph start begin accounting year garniers current basic salary follow formation glaxosmithkline use base share increase april price december calculation graph base spot garni terminate agreement give calendar price begin end year require director remuneration report regulation glaxosmithkline month write notice follow credit performance condition performance share plan psp use average extra year pension contribution treat price period year graph year old actual age take indication likely vest award grant psp smithkline beecham corporation terminate agreement average price method select psp smoothe volatility reduce impact particularly large temporary price giving calendar month notice termination smithkline movement begin end performance period beecham corporation cause garnier entitle receive day lump sum represent salary past performance take guide future performance bonus notice period bonus calculate basis target performance give bonus payout executive director term condition cent basic salary follow section set date unexpired term addition month notice period garni executive director contract detail provision entitle receive share entitlement stock share necessary enable shareholder estimate liability incentive plan available senior executive usa company event early termination extent period fall determine overall policy respect service contract retirement date award annual share committee aim balance cost associate early option grant performance share plan grant date termination provision need protect glaxosmithkline termination notice intellectual property right committee maintain close watch pension purpose provide pension benefit advisor trend contractual term treat way additional pension contribution company competitor panel wide market place employment end year commit ensure achieve balance actual termination date year expiry service process fair limit far possible scope agreement event garniers employment continue rewarding failure committee consider recent expiry service agreement addition garni guidance produce association british insurers spouse treat year old national association pension fund actual age termination cause account alongside market practice review expiry service agreement applicable purpose contractual term calculate annuity rate pension base executive director employ service contract receive outplacement counselling financial employing company require calendar month planning advice year follow termination notice termination executive director require shall limit year choose calendar month notice life assurance cover provide benefit time executive director service contract contain garden leave salary birthday noncompetition nonsolicitation confidentiality clause garnier continue receive benefit cash value remuneration committee currently believe year notice period garniers agreement terminate contract good interest glaxosmithkline reason disability treat employ regard offer globally competitive overall remuneration purpose pension benefit retirement date package secure maximum protection intellectual addition payment distribution benefit property right garni subject excise tax interest penalty incur garnier entitle receive additional cash payment aftertax position additional tax impose glaxosmithkline remuneration report event retirement expiry service agreement addition coombe leave employment incapacity event termination employment smithkline age pension accrue beecham corporation cause event payable date incapacity augment garni elect retain director trustee pension plan glaxosmithkline merged company result entitle employ service change control glaxosmithkline provide event notice termination give resignation occur day anniversary case redundancy coombe require mitigate loss change control share option grant vest earning result immediately remain exercisable expiry option period garni employ smithkline event coombes early retirement result beecham corporation performance time condition termination glaxosmithkline service unlimited shall deem satisfied final award cause redundancy outstanding option grant performance share plan determine end glaxosmithkline share option plan exercise performance period originally specify relevant month date grant outstanding option grant participation proportionate reduction glaxo wellcome share option plan exercise retirement termination resignation respect garnier month cessation employment end participation smithkline beecham senior executive bonus option period early option investment plan provide agreement terminate year old outstanding option year old cause defer income gain exercise month date grant loss automatically distribute soon administratively case remuneration committee use discretion practicable termination garni resign retire allow long period exercise termination cause defer case award performance share plan distribute end minimum year deferral period coombes employment contract terminate redundancy retirement employ company cease member coombe glaxosmithkline group remuneration committee coombe service agreement glaxo wellcome plc determine percentage award vest glaxosmithkline service unlimite date february plan rule end financial year agreement expire march cessation employment occur ordinarily calculate day month coombe reach birthday reference performance period elapse coombe current basic salary increase extent performance condition satisfy april period employment cease reason end award performance period awards lapse coombe terminate agreement giving calendar committee determines month write notice respect coombe participation glaxo wellcome glaxosmithkline service unlimited terminate agreement long term incentive plan ltip special rule apply calendar month write notice notice participant employment end award event coombes gross misconduct wilful neglect dishonesty coombe ltip vest completion bankruptcy conviction criminal offence affect position measurement period senior executive coombe agreement specifie compensation cash entitlement pay event redundancy follow addition contractual provision outline event garni coombe service agreement equal twice annual rate salary terminate employ company entitled account bonus equal cent special defer bonus award member annual rate salary cet respect payable february equal value year benefit terminate cause prior date detail circumstance coombes pension entitlement bonus give augment equal value pension case award glaxosmithkline annual accrue period month investment plan provide agreement terminate commencing date termination employment cause defer income period consecutive month incapacity gain loss automatically distribute soon coombe entitle disablement pension administratively practicable termination resign entitle equivalent retire termination cause defer receive work period month distribute end minimum day absence amount actually receive year deferral period periodremuneration reportglaxosmithkline nonexecutive director sir peter walters john young nonexecutive director glaxosmithkline service sir peter walters retire deputy chairman contract instead letter appointment company nonexecutive director young retire nonexecutive aim provide nonexecutive director fee director effect sir peter competitive company equivalent size complexity youngs letters appointment date june nonexecutive director entitle compensation case agree serve company appointment terminate nonexecutive director conclusion annual general meeting follow anniversary appointment enhance link director shareholder case extend term set table glaxosmithkline require nonexecutive year mutual agreement sir peter receive fee director receive significant fee form annum allocation ordinary share allocate share account offer opportunity share nonexecutive director share arrangement invest balance fee share account young receive fee annum share pay directors retirement allocation american depositary share board late date basis dividend reinveste nonexecutive director share arrangement interim chairman deputy chairman chairmen sir roger hurn paul allaire michle barzach sir peter board committee receive high fee job john mcarthur donald mchenry sir ian prosser ronaldo schmitz lucy shapiro term condition letter appointment director sir richard sykes date june case agree sir richard syke retire chairman nonexecutive serve company nonexecutive director conclusion director sir richard letter appointment annual general meeting follow anniversary board date june agree appointment case extend serve company nonexecutive director term year mutual agreement fee payable conclusion annual general meeting follow share allocation nonexecutive director share anniversary appointment extend arrangement director follow term year mutual agreement sir richard receive fee annum allocation share nonexecutive director nonexecutive annual share allocate director fee annually share arrangement sir roger hurn ordinary share follow retirement board recognition paul allaire adss service company board decide michle barzach ordinary share augmentation payment pension plan respect sir peter job ordinary share sir richard agree period year john mcarthur adss june sir richard appoint senior advisor donald mchenry adss company salary annum sir ian prosser ordinary share ronaldo schmitz ordinary share company agree procure sir richard syke pension lucy shapiro adss age calculate basis salary december remain fulltime employment birthday allaire succeed young chairman committee fee increase sir christopher hogg annum date mchenry succeed sir christopher hoggs letter appointment board sir christopher hogg chairman corporate social date june agree serve responsibility committee february fee company nonexecutive director conclusion increase annum date sir ian prosser annual general meeting follow anniversary succeed sir christopher hogg chairman nomination appointment extend term committee february fee increase year mutual agreement annum date sir christophers letter appointment amend september record appointment nonexecutive director senior management remuneration chairman effect follow table set director glaxosmithkline plc chairman sir christophers fee increase remuneration earn interest share annum plus allocation share annum glaxosmithkline plc interest share option incentive nonexecutive director share arrangement plan pension benefit member corporate annum plus allocation share annum executive team cet company secretary know senior management participate remuneration plan executive director aggregate remuneration interest director senior management provide glaxosmithkline remuneration report annual remuneration total annual total fee annual annual fee defer annual salary benefit bonus remuneration salary benefit bonus remuneration footnote executive director garnier coombe total nonexecutive director sir richard syke sir christopher hogg sir roger hurn sir peter walters allaire barzach bonham sir peter job mcarthur mchenry sir ian prosser schmitz shapiro young total total remuneration previous year garnier salary fee include glaxosmithkline match compensation defer include contribution money purchase scheme garniers salary fee restate represent glaxosmithkline match order provide consistent presentation coombes bonus include glaxosmithkline match defer bonus addition bonus show coombe receive award respect second half executive director glaxo wellcome plc bonus jpgarnier coombe include special defer bonus award member cet award equivalent salary december notionally invest glaxosmithkline share adss february bonus pay february equivalent value share adss notionally acquire february plus dividend reinveste period december value share adss notionally acquire respect jpgarni decrease cent year include dividend reinveste year share notionally acquire respect coombe value december decrease cent year include dividend reinveste year addition sir richard syke receive relate appointment senior advisor june sir richard receive bonus award respect second half executive chairman glaxo wellcome plc sir richard syke sir peter walters young retired board follow retirement receive value share adss award nonexecutive director share arrangement equivalent smithkline beecham arrangement award share adss total value date award indicate sir richard syke sir peter walters young value share adss pay sir richard syke sir peter walters young change value attributable dividend reinveste change share price date award young elect receive value share equal annual instalment accordingly receive barzach receive fee euro euro gskfrance healthcare consultancy provide include fee salary mcarthur receive fee director glaxo wellcome inc mcarthur long receive fee show emolument restate fee salary accordance requirement schedule company act director remuneration report regulation schedule bonham resign nonexecutive director stmay bonham receive respect value share allocate nonexecutive director share arrangement award share value date award share worth change value attributable dividend reinveste change share price date award shapiro member glaxosmithkline scientific advisory board receive fee addition show form adss director receive remuneration currency sterle average rate exchange year director receive expense year require separate disclosure require schedule aremuneration reportglaxosmithkline nonexecutive director share arrangement nonexecutive director require receive fee form share adss detailed value date award elect receive balance fee form share adss share allocate account transfer retirement include director interest total value holding allocate elect allocate elect share adss share adss sir richard syke sir christopher hogg sir roger hurn sir peter walters paallaire barzach dcbonham sir peter job jhmcarthur mchenry sir ian prosser schmitz shapiro young total value holding december represent value share adss award prior year value dividend reinveste retirement nonexecutive director receive share adss cash equal value share adss date retirement director interest follow beneficial interest director company show register maintain company accordance company act share adss marchst december december marchst december december footnote garnier coombe sir christopher hogg sir roger hurn allaire barzach sir peter job mcarthur mchenry sir ian prosser schmitz shapiro glaxosmithkline ad represent glaxosmithkline share include share purchase glaxosmithkline sharereward plan totalling share december share march include nonbeneficial interest trust hold share december nil share march addition interest show mchenry interest defer fee plan relate period mrmchenry director smithkline beckman priorto merger beecham group defer fee index total return glaxosmithkline share payable seven year follow mchenrys retirement nonexecutive director glaxosmithkline total accumulate value defer fee december restate reflect merger fully provide equivalent glaxosmithkline adss include share adss receive fee describe nonexecutive director share arrangement dividend receive share adss convert share adss december include director interest interest abovementione director rdmarch reflect change end financial year rdmarch glaxosmithkline remuneration report share option grant weighted average option adss grant price number garnier grant weighted average option share grant price number jdcoombe sir richard syke jpgarnier grant option adss grant december grant price jdcoombe grant option share december grant price grant option share glaxosmithkline sharesave scheme december grant price option outstanding december early late vesting lapse date market price glaxosmithkline share year end give table vest date lapse date weight average grant price number early latest early late jpgarni market price year end market price year end jdcoombe market price year end market price year end option hold sir richard syke grant price market price glaxosmithkline share year end glaxosmithkline grant share option executive director senior manager annual basis november initial grant follow completion merger march measurement period option grant march commence january measurement period option grant november commence january respectively director hold option share option plan refer note financial statement employee share scheme director interest option company share follow merger director elect exchange outstanding option legacy share option plan option glaxosmithkline share director participant legacy scheme election receive additional benefit cash sum equal cent grant price original option additional benefit give new option exercise lapse provide exercise lapse second anniversary effective date merger case sir richard syke cessation executive employment early highest low closing price year end december glaxosmithkline share respectively high low price glaxosmithkline adss year december respectively market price glaxosmithkline share december december glaxosmithkline ad december share price march glaxosmithkline share glaxosmithkline ad option exercise adss gain gain garni option exercise share gain gain jdcoombe sir richard syke remuneration reportglaxosmithkline incentive plan grant adss market adss performance share plan adss number price garnier award award award grant share market share performance share plan share number price coombe award award award performance share plan psp mediumterm incentive scheme introduce psp replace longterm incentive plan midterm incentive plan operate respectively glaxo wellcome smithkline beecham term psp number share actually vest determined follow end relevant year measurement period dependent glaxosmithkline performance period describe share award grant annually november december measurement period commence follow january end year december follow completion merger initial grant march measurement period awards commence january end december share exercise market average money price market price value share award exercise exercise longterm incentive plan share number coombe longterm incentive plan ltip share award scheme operate glaxo wellcome plan close new entrant completion merger grant award coombe march february vested march february respectively completion measurement period connection merger performance condition respect grant march february waive award ltip lapse exercise month vest share ltip award atnominal cost recipient vest vest unvested participation unvested deferred participation dividend defer participation vest participation participation vest reinveste participation midterm incentive plan adss garni midterm incentive plan mtip share award scheme operate smithkline beecham plan close new entrant completion merger participation grant connection merger performance condition respect grant waive measurement period end december participation vest award garnier october thead price ad price time vest final award ad receipt award defer director garnier defer receipt award deferred award additional adss subsequently receive dividend reinvestment arenot include director interest table technically retain mtip pay average stock appreciation right sar adss grant price shapiro sar hold shapiro grant price market price glaxosmithkline ad year end shapiro member glaxosmithkline scientific advisory board sab shapiro member smithkline beecham sab completion merger glaxo wellcome member sab receive annual grant smithkline beecham sars general vest year date grant expire year date grant grant sars sab member cease sar entitle holder cash sum future date base share price growth date grant date exercise provision financial statement accrue gain sar date grant connection merger previously grant sar immediately exercisable glaxosmithkline remuneration report pension pension benefit accrue follow director define benefit scheme accrue annual benefit transfer value individual director retirement set schedule require disclosure accrue benefit end year change accrue benefit year transfer value beginning end year change transfer value year listing rule require additional disclosure change accrue benefit net inflation transfer value change change change change accrue transfer value accrue accrue transfer transfer year benefit change benefit benefit value value transfer year net accrue year value inflation benefit garnier coombe sir richard syke change transfer value show net contribution individual garnier member money purchase scheme contribution pay scheme followingsir richard syke retirement board recognition services company board decide augmentation payment pension plan sir richard director year change accrue benefit revalue effect inflation transfer value change accrue benefit calculate date leave sir richard transfer value december calculate basis pension payment include additional benefit grant retirement transfer value calculate basis actuarial advice accordance actuarial guidance note transfer value represent present value future payment plan remuneration currently individual meaningfully aggregate annual remuneration director senior management report purpose necessary provide information compensation interest director senior management asagroup group purpose disclosure group define director members cet company secretary respect financial year total compensation pay member group period serve capacity aggregate increase accrue pension benefit aggregate payment define contribution scheme member group grant option share adss award share adss performance share plan rdmarch thencurrent member group comprise person own share adss constitute cent issue share capital company group hold date option purchase share adss share adss award performance share plan share legacy glaxo wellcome longterm incentive plan share adss legacy smithkline beecham midterm incentive plan include share adss vest defer adss award legacy smithkline beecham stock appreciation right holding issue pursuant executive share option plan describe note financial statement employee share scheme director interest contract describe relate party transaction end financial year director connect person material interest contract significance relation group business group company note financial statement relate party transaction director remuneration report approve board director agree behalf paul allaire chairman remuneration committee march glaxosmithkline operate financial review prospect operate financial review prospect discusses operate financial performance group financial outlook financial resource group follow heading financial trend ratio year result year december compare year december financial position resource december outlook risk factor additionally accordance requirement year result year december compare year december select financial datum ukus gaap result accounting principle result year compare primarily result precede year reference quarterly halfyearly trend result exchange group multinational business operate countriesand earn revenue incur cost currency result group report sterling affect bymovement exchange rate sterling overseascurrencie group use average exchange rate prevail period translate result cash flow overseas group subsidiary associate undertaking joint venture sterling period end rate translate net asset undertaking currency influence translation usdollar euro japanese yen average sterling exchange rate strong dollar japanese yen cent seven cent respectively weak euro cent compare business performance constant exchange rate business performance primary performance measure management present exclude merger item integration restructuring cost disposal business management believe exclusion nonrecurre item provide well comparison business performance period present statutoryresult include nonrecurre item order illustrate underlying performance group practice discuss result term constant exchange rate cer growth represent growth calculate exchange rate todetermine result overseas company sterling remain unchanged previous year discussion review term cer state glaxosmithkline operate financial review prospect financial trend ratio statutory result restate restate cer cer sale pharmaceutical consumer healthcare total cost sale sell general administration research development trading profit profit taxation earning basic earning share penny merger restructure disposal subsidiary cost sale sell general administration research development trading profit profit taxation earning business performance result sale cost sale sell general administration research development trading profit profit taxation adjust earning adjust earning share penny research development business performance pharmaceutical consumer healthcare total business performance primary performance measure management present exclude merger item integration restructuring cost disposal business management believe exclusion nonrecurre item provide well comparison business performance period present accordingly information provide supplement include consolidated statement profit loss page prepare accordance ukgaap statutory result include nonrecurre item frs defer tax implement group frs require defer tax account provision basis partial provision basis early year change basis account prior year adjustment comparative information restate necessary interest net interest payable interest cover time time time interest cover calculate statutory profit interest divide net interest payable tax rate business performance statutory result borrowing net debt gearing gearing ratio calculate net debt percentage shareholder fund net debt minority interestsoperate financial review prospect glaxosmithkline year world economy world market pharmaceutical world economy begin upbeat fashion global pharmaceutical sale increase cent expectation recent interest rate cut side billion atlantic revive consumer confidence provide relief corporate sector feel effect september world market value growth geographic region total tragedy usa general optimism prove misplaced combination europe weaker anticipate economic growth corporate scandal germany bankruptcie profit warning dividend cut force sell france equity soar stock market volatility fear deflation conflict middle east take toll share price italy develop world plunge year run japan strong start economy cool stimulus asia pacific interest rate cut fail counterbalance negative factor latin america november federal reserve cut interest rate middle east africa cent reach low level year canada total european economy fare well country experience little growth germany particularly badly affect suffer stagnant economy rise market remain buoyant represent cent unemployment cent european central bank global prescription pharmaceutical market compare respond cent cut interest rate cent cent decade ago december glaxosmithkline hold second position world pharmaceutical japanese stock market outperform major stock market market share cent pfizer market half fall end market share cent year low glaxosmithkline product world product outlook summarise uncertain whilst augmentin avandia flixotideimigran seretideadvair consecutive year decline majority seroxatpaxil wellbutrinand zofran western stock market market commentator anticipate reasonable level economic growth world market value growth therapeutic class total likely occur second half year sluggish cardiovascular start billion economic package design boost central nervous system economy announce president bush january alimentary tract metabolic hopefully accelerate number risk antiinfective bacterial timing economic recovery viral fungal exclude vaccine respiratory exchange currency influence group result note datum base month september dollar euro japanese yen pharmaceutical sale euro jpy jun total pharmaceutical sale million compare million increase cent cent overall growth come price increase growth sterling term cent significantly impact weakness dollar currency group portfolio sale new product launch major market year account cent total sale grow cent million sale establish franchise product amount million represent cent total sale grow cent compare year sale old product actively promote million decline cent represent cent total sale pound hit high level dollar twoandahalf year climb euro gain global pharmaceutical sale fourth quarter grow cent dollar year sevenper cent twoper cent sterling term reflect sale dollar fall value euro investor weigh growth cent million europe sale impact possible war iraq tension north korea growth weak cent sale million fear economy international sale flat million nuj ced nuj ced nuj ced nuj ced nuj ced nuj ced nuj ced glaxosmithkline operate financial review prospect sale growth benefit quarter increase antiviral wholesaler stock product normal operate hiv medicine grow region total billion level year end review customer discount rebate sale cent sale trizivir glaxosmithkline new triple provision result underlie growth quarter exclude combination therapy grow cent million item estimate management high single valtrexfor herpe continue benefit convenient digit range spite generic competition augmentin oncedaily dose suppressive therapy achieve strong sale growth cent worldwide cent pharmaceutical sale therapeutic area usa october glaxosmithkline file sndafor valtrex group portfolio product major therapeutic area seek firstever indication reduce risk transmission experience doubledigit percentage growth year include genital herpe december glaxosmithkline file fast grow franchise cns billion cent ndafor protease inhibitor treatment hiv respiratory billion cent antiviral billion decline zoviraxsale reflect transfer new valtrex cent vaccine billion cent generic competition central nervous system antibacterial sale seroxatpaxil glaxosmithkline lead product antibacterial sale decline cent worldwide cent depression anxiety disorder driver growth usa augmentinsussale cent cns therapy area sale billion cent globally year result generic competition begin cent usa international sale paxilgrew quarter generic version augmentinhave introduce cent million lead continue strong growth usa follow decision usdistrict court japan product launch year ago eastern virginia hold invalid glaxosmithkline patent launch april paxil crcontinue gain acceptance augmentinexpiring hearing strong tolerability profile represent glaxosmithkline appeal court decision cent new prescription paxilin month schedule march sale ceftindecline cent generic competition begin sale wellbutrin depression grow cent quarter million reflect increase physician awareness product outstanding efficacy favourable effect profile usa glaxosmithkline new antibiotic augmentin application approval oncedaily formulation child augmentin xrfor adult perform wellbutrin submit fda esformulation launch fourth quarter represent cent brand generic augmentin glaxosmithkline medicine epilepsy lamictal continue paediatric prescription base recent weekly datum grow region achieve sale million formulation launch october represent cent cent group file sndafor lamictalseeke brand generic augmentinadult prescription firstever indication longterm management depressive episode bipolar disorder january fda approve metabolic gastrointestinal use lamictalfor treatment partial seizure worldwide sale metabolic gastrointestinal category paediatric patient age year billion cent avandiafranchise avandiaand avandamet grow cent year respiratory sale cent million glaxosmithkline continue global leader respiratory pharmaceutical sale key product avandamet combination avandiaand metformin hci seretideadvair flixotideflovent serevent amount expand avandiametabolic franchise launch nearly billion cent fourth quarter avandametfor treatment type diabetes medicine target insulin resistance sale seretideadvair glaxosmithkline second large product decrease glucose production convenient pill grow cent billion contribute approval fda avandiaha decline sereventand flixotide constituent product advair million patient worldwide asthma market leader new prescription year market seretidealso continue perform zantacsale million cent decline strongly europe cent international market market cent january glaxosmithkline receive positive opinion european committee proprietary vaccine medicinal product cpmp use seretidea new sale vaccine grow cent billion support treatment chronic obstructive pulmonary disease copd hepatitis franchise cent million group expect european marketing authorisation total sale europe grow cent sale grow month follow launch europe cent launch twinrixand continue growth half december glaxosmithkline file nda havrix drive new state mandate require hepatitis ariflofor copd vaccination school age child infanrixglaxosmithkline dtpa range combination vaccine grow cent old respiratory product ventolinand becotidecontinue million priorix tritanrixgrew cent cent decline patient convert new product respectively usa glaxosmithklines new pediarixvaccine launch january pediarixadd protection hepatitis poliomyelitis infanrixcombination result few injection infantsoperate financial review prospect glaxosmithkline pharmaceutical sale therapeutic area total usa europe international therapeutic area cer cer cer cer major product total growth growth growth growth cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretideadvair seretideadvair flixotideflovent serevent flixonaseflonase ventolin becotide antiviral hiv trizivir combivir epivir retrovir ziagen agenerase herpe valtrex zovirax zeffix antibacterials augmentin zinnatceftin fortum amoxil metabolic gastrointestinal avandia zantac vaccine hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total sale cer represent sale growth constant exchange rate analysis sale quarter give financial record page glaxosmithkline operate financial review prospect cardiovascular urogenital europe coregsale grow cent million benefit europe region contribute cent pharmaceutical sale year new indication treatment overall sale growth region cent severe heart failure good growth record market include spain central eastern europe government healthcare reform november levitravardenafil new agent include price reimbursement restriction adversely affect treatment erectile dysfunction receive positive opinion sale italy seretide glaxosmithkline large selling product european cpmp launch europe plan europe report notable growth france germany spain march fda issue approvable letter levitrain partly offset expect decline launch expect usa levitrawa sereventand flixotide trizivir show strong growth research develop bayer agand copromote major market region decline sale herpe glaxosmithkline franchise mainly result generic competition forzovirax january glaxosmithkline launch avodartdutasteride patient switch new valtrexproduct dhtinhibitor treatment symptomatic benign prostatic hyperplasia bph usa glaxosmithkline plan market international avodartin major european country launch cent sale growth international region reflect half january cardiovascular renal mixture good growth middle east africa canada drugs advisory committee fda unanimously support asia pacific decline seven cent sale latin use coregin patient heart attack america principally poor economic condition leave ventricular dysfunction recommendation base mexico brazil addition mexico suffer datum show early longterm treatment patient realignment wholesaler stock level coregcould reduce risk death cent overall international growth drive seretide seroxatpaxil avandiaand vaccine partly offset decline zantac oncology emesis zovirax sale zofrangrew cent million drive strong performance cent million asia pacific area grow performance seretide vaccine strong growth number market partly therapeutic area offset low growth cent large market sale relafenfor arthritis fall reflect generic competition australia reflect reduced sale zyban zantac usa pharmaceutical sales geographic area regional analysis region cer major market total growth usa usa usa report cent sale growth year europe business currently represent cent total pharmaceutical france sale sale growth central nervous system product cent drive wellbutrin reflect increase italy prescribe primary care physician psychiatrist paxil germany spain follow launch crformulation april lamictal central indicate epilepsy record sale growth cent eastern europe advairmaintaine strong growth sale million europe drive overall respiratory sale growth cent international adversely affect sale constituent product flovent asia pacific serevent show declinesflonase indicate japan treatment perennial rhinitis grow strongly cent latin america middle east africa sale antiviral therapeutic area grow cent lead canada strong performance trizivir cent partially draw sale constituent product valtrex cent cer represent sale growth constant exchange rate sterling growth calculate sale avandiaincrease cent benefit figure give analysis sale quarter give financial record page sale market europe adjust effect parallel launch avandamet november continue decline trade crossborder import lowprice market zantacsale hold metabolic gastrointestinal category market growth japan reflect strong growth paxiland growth cent antibacterial sale decline augmentin flixotidefloventpartly offset decline old product start experience generic competition second half zantac government price reduction year cardiovascular franchise coreg sale increase million reflect improved market share middle east africa area follow trend market growth seretide avandia vaccine hiv vaccine grow cent respiratory franchise cent canada growth drive seretide paxil avandiaand antiviral partly offset low sale antibacterialsoperate financial review prospect glaxosmithkline consumer healthcare sale cost sale cost sale reduce percentage sale result benefit cer arise merger manufacturing restructuring saving otc medicine movement stock provision favourable regional mix analgesic dermatological selling general administration gastrointestinal sell general administration cost benefit cost saving respiratory tract arise merger integration implementation initiative smoking control produce reduction percentage point natural wellness support relative expense express percentage sale oral care nutritional healthcare research development total consumer healthcare sale research development increase cent reflect increase clinical trial inlicense activity reinvestment growth consumer healthcare sale cent merger synergies pharmaceuticals expenditure represent million otc medicine sale increase cent pharmaceutical sale year cent nutritional healthcare increase cent partly offset decline oral care sale cent trading profit business performance trading profit million otc medicine growth cent strong sale growth seven cent smoking control sale growth drive performance demonstrate improved trading margin point nicodermniquitinnicabate usa nicodermgrew strongly cent compare principally despite competition private label launch competitor cost saving derive merger integration manufacturing patch niquitin lozenge commit launch usa initiatives november clinical study commitcan help smoker try quit analgesic panadolrecorde good profit taxation business performance sale growth cent partly offset decline number brands abreva usa zoviraxin europe analysis discussion profit taxation relate treatment cold sore drive dermatological sale growth business performance cent gastrointestinal sale citrucel rise cent offset decline tumsand tagamet operating incomeexpense oral care royalty income oral care sale grow marginally europe decline highly operate expense competitive market overall oral care sale decline cent principally result reduce aquafresh sale income equity investment increase sensodynesale partially offset disposal nutritional healthcare nutritional healthcare lucozade ribenareporte strong operating incomeexpense include litigation cost costs growth europe drive increase availability promotion associate product liability claim cost respect horlickssale decline primarily international market product withdrawal equity investment writedown adverse stock market condition royalty income product disposal equity trading profit business performance investment sale illustrate glaxosmithkline business performance operating expense million year compare analysis trading profit subsequent discussion million income year year movement exclude merger item integration restructuring cost reflect high provision product liability disposal business management believe exclusion claim low proceed disposal equity nonrecurre item provide well comparison business investment sale performance period present accordingly information provide supplement contain consolidated profit disposal interest associate statement profit loss page prepare disposal interest associate accordance ukgaap group sell million share quest diagnostic inc realise gain million cer share profitslosse joint venture associate sale undertaking cost sale share profit associate arise principally group sell general hold inquest diagnostic inc administration research development trading profit glaxosmithkline operate financial review prospect taxation net interest payable restate interest payable business performance investment income merger restructure disposal subsidiary share interest payable associate net interest payable increase compare largely business performance taxation result high average level net debt drive use cash charge taxation business performance profit fund group share buyback programme benefit million represent effective tax rate cent small number share issue reflect earning share represent increase compare effective rate cent restate implementation profit ordinary activity taxation frs defer tax operating incomeexpense disposal integrate nature group worldwide operation involve interest associate reduce profit significant investment research strategic manufacture million add million profit limited number location consequential crossborder supply take account contribution associate net interest route numerous endmarket give rise complexity payable business performance profit tax million delay negotiation revenue authority profit compare million increase cent individual group company liable tax disagreement revenue authority intragroup merger item restructuring cost disposal business transaction particular price good key item discuss transfer group company different tax jurisdiction produce conflict claim revenue authority merger manufacturing restructuring profit fall tax individual territory resolution glaxosmithkline good progress merger issue continue factoflife glaxosmithkline manufacturing restructuring plan remain track deliver forecast total annual merger manufacturing restructuring usa number year glaxosmithkline saving billion exclude benefit block significant open issue relate transfer pricing issue drug acquisition estimate cost achieve remain affect year present concern number billion billion charge product significant relate success december zantac respect claim internal revenue service irs substantially exceed group estimation cost million incur year respect merger taxation liability irs claim completely manufacture restructure tax relief million quantify continue subject discussion net charge million cost include tax authority competent authority provision severance asset writedown professional fee site closure double tax convention country block drug company inc discussion wide variation view glaxosmithkline acquire block drug january cost tax authority exceptionally incur integrate business million unable reach agreement settle dispute event include redundancie asset writedown site closure tax authority reach agreement matter resolve litigation disposal business glaxosmithkline use good advice determine transfer profit disposal business million reflect pricing methodology seek manage transfer pricing final settlement merger relate product disposal issue satisfactory conclusion basis external disposal healthcare service business professional advice continue believe adequate provision liability likely arise open assessment trading profit statutory group implement new financial reporting standard frs defer tax require defer tax cer account provision basis partial provision sale basis year business performance tax cost sale charge increase million overall tax charge sell general million net defer tax asset december administration reduce million research development merger restructuring trading profit credit taxation merger restructuring item amount million reflect estimate actual tax rate statutory result include merger item integration applicable transaction territory arise restructuring cost disposal subsidiary deliver trading profit million sale millionoperate financial review prospect glaxosmithkline earning legal dispute restate cer glaxosmithkline provide anticipate settlement cost earning associate expense arise asserted claim group basic earning share reasonable estimate likely outcome basic earning ad dispute company director take legal advice establish provision take account insurance adjust earning agreement regard relevant fact adjust earning share circumstance matter accordance accounting adjust earning ad requirement provision unasserted claim weight average number claim reasonable estimate likely share million outcome ultimate liability pende unasserted claim vary amount provide adjusted earning adjust earning share present dependent outcome litigation proceeding order illustrate business performance investigation possible settlement negotiation primary measure management adjust earning increase cent adjust earning share increase cent intangible asset reflect reduction weight average number share intangible asset acquire glaxosmithkline result group share buyback programme interest party cost acquisition capitalise licence cost programme impact group earning compound development amortise estimate actual rate exchange business performance eps increase useful life exceed year estimate useful live cent sterling term compare cent cer review annually impairment review undertake term adverse currency impact eps cent event occur question carry value year reflect significant weakening dollar relative asset brand acquire business capitalise compare cent adverse currency impact independently separable longterm sale difference principally arise different mix value group brand amortise estimate currency profit compare sale useful life exceed year end useful economic life foresee brand take expense taxation product amortise subject annual impairment review future divestment result eps pence compare event cause value intangible asset pence dilute ep pence compare impaired adverse effect future pence merger manufacturing restructuring result group cost low result sterling base growth eps cent significantly high impairment fix asset cer base growth business performance ep despite carry value fix asset subject depreciation overall negative impact currency amortisation review impairment indication value asset impaired dividend impairment determine reference high net board declare fourth interim dividend penny realisable value value use measure reference share make total year penny share discount cash flow future event cause assumption compare dividend penny share impairment review change consequent adverse effect future result group critical accounting policy consolidate financial statement prepare accordance investment share ukgenerally accept accounting principle follow glaxosmithkline invest share employee accounting policy approve board describe note share ownership trust order meet obligation arise financial statement accounting policy management certain company employee share option scheme require estimate assumption affect share hold cost provision recognise shortfall amount asset liability revenue expense report proceed receivable employee exercise financial statement actual amount result differ management believe permanent impairment estimate follow consider critical value relation period time relate share accounting policy adopt option exercise impairment adverse effect result group accounting period sale gross sale reduce discount allowance vary pension postretirement benefit product arrangement buy group arrangement cost provide pension postretirement benefit purchase organisation dependent submission charge profit loss account accordance claim time initial recognition sale ssap period benefit derive provision time sale estimate discount employee service cost assess accordance allowance payable amount subject change dependent advice receive independent actuary basis thing type buy group product assumption select management disclose note sale mix future event cause assumption financial statement employee cost note give discount base change affect future additional disclosure require frs retirement benefit result group selection different assumption affect future result group glaxosmithkline operate financial review prospect financial position resource financial position net debt group net debt december comprise summarise reclassify presentation group balance sheet set cash liquid investment restate borrowing repayable year borrowing repayable year goodwill intangible fix asset net debt tangible fix asset net debt increase million primarily investment use cash fund purchase share company work capital cancellation totalling million special cash debtor creditor contribution million group pension fund provision taxation pension defer taxation group continue account pension arrangement net operating asset accordance ssap transitional provision frs share disclose pension asset liability group dividend payable december net deficit million net debt allow deferred taxation million fourth net asset quarter special cash contribution million reduce funding deficit shareholder fund minority interest company review position annually contribution appropriate pension service cost high financing net asset million take account earning guidance investment glaxosmithkline investment december shareholder fund carry value million million market summary movement equity shareholder fund set value december million million investment include associate joint venture mainly equity share hold derive restate directly group business include connection begin year previously report research collaboration access biotechnology development prior year adjustment potential interest arise business divestment implementation frs share begin year restate december esot hold million profit year glaxosmithkline share carry value million dividend market value million future exercise share share issue exercise share option option share awards valuation shortfall consider share purchase cancel represent permanent diminution value context exchange movement length future period relate share option goodwill write exercise accordingly provision uktax exchange movement unrealise gain equity investment debtor creditor end year net creditor remain line increase prepay pension contribution offset increase accrual equity shareholder fund decrease million salesrelated rebate return december million december decrease arise value share purchase provision cancel exchange movement overseas net asset group carry provision million december exceed retain profit respect estimate future liability million relate pension postretirement commitment contingent liability benefit employee provision tax legal financial commitment summarise note financial dispute indemnify disposal liability cost statement commitment contingent liability manufacture restructuring merger integration extent obligation respect short long term debt set balance sheet date actual constructive obligation note contingent liability note financial exist case merger integration manufacturing statement net debt restructuring majority remain cost expect amount provide pension postretirement benefit recognise end restructure integration plan legal environmental dispute set note financial statement provision liability chargesoperate financial review prospectsglaxosmithkline contractual obligation commitment cash flow follow table set group contractual obligation summary group cash flow set commitment fall payment total yrs yrs yrs total operate cash flow loan dividend associate finance lease obligation net interest minority operating lease preference share dividend commitment tax payment intangible fix asset free cash flow tangible fix asset net capital expenditure commitment net cash operation total dividend share business acquisition intangible fix asset commitment license business disposal agreement principally elbion adolor sale purchase equity investment corporation theravance inc unigene laboratories inc sale purchase interest associate payment future milestone achieve purchase share share option agreement relate compound early use share exercise share option stage development milestone payment continue share issue exercise share option number year compound successfully purchase share cancellation development process generally close product redemption preference share issue marketing approval great possibility success subsidiary payment show represent maximum product divestment pay milestone achieve movement include exchange pension commitment provide note financial increase net debt statement employee cost net cash inflow total operating activity contingent liabilitie million increase million follow table set contingent liability comprise discount bill performance guarantee item arise merger restructuring item million net interest normal course business expect payment minority preference share dividend tax expire payment free cash flow represent cash flow discretionary spending amount million increase total yrs yrs yrs million capital expenditure tangible intangible fix asset guarantee amount million million contingent liability disposal realise million million total total million million realise spend purchase sale investment equity share normal course business group provide indemnification guarantee respect business disposal group purchase share market cancellation legal dispute subsequently arise amount million million relate provision reasonable estimate new buyback programme likely outcome dispute include note share glaxosmithkline plc purchase esot financial statement provision liability charge satisfy future exercise option award employee group policy provide settlement cost share incentive scheme million atotal asserted claim environmental dispute reasonable million million receive employee estimate prior point liability record exercise share option exercise satisfied share previously legal environmental cost discuss risk factor purchase esot yield million million page exercise satisfied issue new share yield million million effect transfer pricing issue taxation inevitable global business glaxosmithkline group future cash flow significant open issue relate transfer pricing number group expect future operate cash flow year basis external professional advice provision sufficient fund operate debt service cost satisfy liability likely arise open assessment normal level capital expenditure meet obligation discuss note financial statement exist licensing agreement meet routine taxation commitment include tax dividend subject risk factor discuss page glaxosmithkline operate financial review prospect subsequent year group expect cash liquidity outflow integrate operation glaxo wellcome group operate globally primarily subsidiary company smithkline beecham unify glaxosmithkline business establish market group trade cash outflow continue implementation nature group business patent protection manufacturing restructuring plan ofthe product group portfolio group product compete largely product efficacy price selling october glaxosmithkline commence new billion margin sufficient cover normal operating cost share buyback programme follow completion group operating subsidiary substantially cash generative billion buyback programme announce exact time future purchase determine operate cash flow fund investment research company dependent market condition factor development new product routine outflow period january march capital expenditure tax dividend repayment mature share purchase cancel cost debt group time time additional demand million finance share purchase acquisition group time time additional demand glaxosmithkline operate low level net debt addition finance acquisition group access tothe strong positive cash flow normal trading activity source liquidity bank financial institution additional liquidity readily available itscommercial addition cash flow operation forsuch needs paperprogramme current backup facility include committed line credit support issuance billion commercial book value net asset decrease million paper programme billion stdecember million december decrease million reflect purchase group uncommitte euro medium term note cancellation share share buyback programme programme billion million issue effect net asset exchange rate movement partly december plan establish similar uncommitted offset retain profit million provide borrowing programme usa dividend treasury operation payment policy objective treasury activity manage posttax net costincome financial operation benefit group group company responsible monitoring manage earning corporate treasury operate profit centre work capital term sale collection supplier payment reflect local commercial practice glaxosmithkline use variety financial instrument include derivative finance operation manage market risk company subsidiarie operation financial instrument comprise cash policy ensure supplier pay time particular liquid resource borrowing spot foreign exchange contract company seek number derivative financial instrument manage settle term payment supplier agree market risk treasury operation derivative instrument term transaction principally comprise forward foreign currency contract interest ensure supplier aware agree term rate currency swap swap borrowing liquid ofpayment asset currency require group purpose abide term payment manage exposure funding risk change foreign policy include arrangement accelerate payment exchange rate interest rate small supplier glaxosmithkline balance use borrowing liquid asset regard cash flow operating activity payment performance thecurrencie earn tax cost intragroup december average number day purchase distribution currency business asset represent trade fix asset creditor company denominate posttax cost borrowing compare wasnil day nil day respect company totheposttax return liquid asset subsidiary aggregate day day liquid asset surplus immediate operating requirement treasury policy group company invest manage centrally corporate treasury requirement group companies glaxosmithkline plc base business report sterling operating finance meet possible central pay dividend sterle profit resource role corporate treasury glaxosmithkline manage external borrowing mainly manage centrally corporate monitor group external internal funding requirement treasury comprise portfolio long mediumterm financial risk support group corporate objective instrument shortterm finance treasury activity govern policy procedure approve board monitor treasury management group glaxosmithkline hold issue derivative financial glaxosmithkline maintain treasury control system procedure instrument trading purpose group treasury policy monitor foreign exchange interest rate liquidity credit specifically prohibit activity transaction financial financial risk instrument undertake manage risk arise underlie business activity speculationoperate financial review prospect glaxosmithkline fund maturity counterparty risk group use limited number interest rate swap group invest centrally manage liquid asset primarily redenominate external borrowing intothe interest rate coupon government bond shortterm corporate debt instrument require group purpose duration swap match minimum shortterm credit rating standard duration theprincipal instrument interest rate derivative poor moodys investor service respectively group instrument account hedge relevant asset manage net borrowing requirement portfolio liability long mediumterm borrowing include bond group manage centrally shortterm cash surplus shortterm finance dollar commercial paper borrowing requirement subsidiary company use forward programme million cent coupon bond contract hedge future repayment originate dollar denominate float rate bond total currency million issue european medium term note programme group raise million float rate debt sensitivity analysis consider sensitivity group net debt private financing arrangement hypothetical change market rate assume variable remain constant base composition net debt group mediumterm borrowing mature date december percentage point basis point private financing mature increase decrease average interest rate result longdate sterling bond mature private finance negligible change group annual interest expense redeem glaxosmithkline time particular event accelerate event equity risk management increase cost funding group group equity investment classify current asset available sale outstanding million flexible auction market prefer group manage disposal meet overall business stock flex amp million auction rate preference requirement arise group regularly monitor value stock arp originally issue million flex equity investment enter hedge selectively amp redeem glaxosmithkline time approval board july remainder flex amp arp redeem glaxosmithkline time financial asset liability glaxosmithkline longterm debt rating standard analysis net debt give note financial poor moodys investor service agency statement net debt analysis financial asset liability shortterm rating paper issue group commercial carrying value fair value reconciliation net debt paper programme respectively give innote financial statement financial instrument relate disclosure discussion derivative foreign exchange risk management financial instrument quantitative disclosure market riskin glaxosmithkline foreign currency transaction exposure arise accordance requirement financial reporting standard normal trade flow respect external intragroup group continue benefit strong positive cash flow trade hedge glaxosmithkline policy minimise group net debt decrease significantly year exposure overseas operating subsidiary transaction risk december group purchase bymatche local currency income local currency cost share market million forthispurpose intragroup trading transaction match centrally intragroup payment term manage reduce financial asset liability december risk exceptional foreign currency cash flow hedge selectively representative treasury policy strategy management corporate treasury glaxosmithkline apply consistently year significant change policy year significant proportion group borrowing include commercial paper programme dollar benefit esot share purchase share purchase cancellation liquidity dollar denominate capital market certain esot market purchase share borrowing swap currency glaxosmithkline plc million share hold require group purpose group seek denominate trust satisfy future exercise option award borrowing currency principal overseas asset group share option award scheme proportion borrowing denominate swap foreign currency share hold trust respect option rule match investment overseas group asset treat scheme require company satisfy exercise hedge relevant net asset market purchase issue new share base composition net debt december share hold trust match option grant cent appreciation sterle major currency diminish dilutive effect new share issue shareholder result reduction group net debt approximately capital earning million cent weaken sterle major currency result increase group net debt annual general meeting shareholder renew approximately million approval glaxosmithkline market purchase share september billion share repurchase interest rate risk management programme announce october complete glaxosmithkline policy interest rate risk management require october glaxosmithkline announce share net borrowing fix rate increase repurchase programme billion exact time ratio forecast net interest payable trading profit future purchase depend market condition factor glaxosmithkline purchase million share cancellation total cost million glaxosmithkline operate financial review prospect outlook risk factor outlook generic drug manufacturer seek market generic version number group important product include pharmaceutical sale growth exist product key driver paxiland wellbutrin prior expiration group patent glaxosmithkline current business performance group plan product future generic product launch new product line extension competitive augmentinwere launch usa years significant impact group sale earning merger manufacturing restructuring saving effort generic manufacturer involve challenge estimate billion group track deliver total validity patent assertion alternative compound annual merger manufacturing restructuring saving infringe group patent group successful reinvestment billion end maintain exclusive right market major saving measure project level product particularly usa group high expenditure forecast glaxo wellcome smithkline margin sale country patent protection beecham immediately prior merger period group revenue margin adversely affect note financial statement legal glaxosmithkline engage legal proceeding validity proceeding discussion patentrelate proceeding infringement group patent relate group involve product particular relate augmentin paxilseroxat wellbutrin discuss risk factor country group operate patent note financial statement legal proceeding protection significantly weak usa european union addition effort control public health result pende matter possible time generic crisis develop country south africa brazil competition paxilin usa unclear consequently recently announce plan substantial reduction glaxosmithkline publish earning guidance remain scope patent protection pharmaceutical product previously state guidance high single digit percentage particular country facilitate competition growth business performance earning share constant market generic manufacturer exchange rate assume generic competition paxilin unable introduce compete product number year usa generic launch paroxetine hydrochloride loss patent protection likely affect adversely imminent glaxosmithkline reassess guidance group operating result group net debt billion low relative pharmaceutical product price subject control pressure market capitalisation position advantage market government intervene directly set opportunity arise build business price addition market major purchaser risk uncertaintie inherent business pharmaceutical product governmental agency affect future performance include expect earning private healthcare provider economic power exert growth discuss risk factor substantial pressure price group predict exist control increase new control introduce risk factor reduce group margin affect adversely ability introduce new product profitably risk uncertaintie relevant group business factor list group think example usa group high margin cause group actual result differ materially expect sale country pricing pressure significantly historical result factor list increase proposal consideration reform adversely affect group medicare federal state programme control cost pharmaceutical adopt medicare programme group operate highly competitive business provide outpatient pharmaceutical coverage pharmaceutical business face competition proprietary beneficiary government enormous purchasing product large international manufacturer producer power programme demand discount generic pharmaceutical significant product innovation technical implicitly create price control prescription drug additionally advance intensification price competition competitor number state propose implement scheme adversely affect group operating result continue control price senior citizen drug programme consolidation pharmaceutical industry adversely affect include importation country bulk purchasing group competitive position continue consolidation drug growth number patient cover group customer increase pricing pressure large manage care institution usa likely particular group face intense competition increase medicare reform increase pricing pressure manufacturer generic pharmaceutical product group product trend adversely affect major market generic product enter market group revenue margin sales usa expiration patent datum exclusivity period group group comply broad range regulatory control product introduction generic product typically lead test approval manufacturing marketing dramatic loss sale reduce group revenue pharmaceutical consumer healthcare product margin proprietary product expiration date country include usa european union patent group major product set regulatory control increasingly demand increase description business patent cost product development time require reach market uncertainty successfully group expect trend continue extend countriesoperate financial review prospectsglaxosmithkline strict regulatory control heighten risk withdrawal group product million regulator approval previously grant reduce billion annual global sale revenue result product recall product liability product paxilseroxatand wellbutrin respect lawsuit addition case group voluntarily group currently defend intellectual property cease marketing product face decline sale base right usa group major concern efficacy safety scientifically product subject problem loss justify absence regulatory action patent protection unexpected effect regulatory proceeding publicity affect doctor patient confidence continue development commercially viable new product pressure compete product new critical group ability replace sale old product effective treatment introduce impact decline expiration exclusive right increase overall group financial result significant sale develop new product costly lengthy uncertain process new product candidate fail stage group conduct substantial portion operation process latestage product candidate fail outside united kingdom fluctuation exchange rate receive regulatory approval new product candidate appear sterling currency especially dollar promise development significant investment fail euro materially affect group financial result reach market limited commercial success group increasingly dependent information technology result efficacy safety concern inability obtain necessary system include internet base system internal regulatory approval difficulty excessive cost manufacture communication communication customer infringement patent intellectual property right supplier significant disruption system computer virus outside incursion group currently defendant number product liability materially adversely affect group operation lawsuit include class action involve substantial claim group control change inflation interest damage relate group pharmaceutical product rate foreign currency exchange rate controls note financial statement legal proceeding economic factor affect business possibility discussion proceeding group currently involve political unrest legal regulatory change nationalisation litigation particularly usa inherently unpredictable jurisdiction group operate factor class action sweep person prescribe materially affect group future financial result group product inflate potential liability force number claim pain suffer punitive damage effective tax rate group earning benefit frequently assert product liability action allow fact portion earning tax favourable represent potentially openende exposure unfavourable rate jurisdiction outside united kingdom resolution similar future proceeding material change tax law application respect group financial result group material matter transfer pricing note financial provision relate legal proceeding reduce statement taxation relate portion group earning earning tax favourable rate increase group effective tax rate adversely affect financial recent loss experience insurance industry result include pharmaceutical product liability exposure increase cost insurance coverage pharmaceutical company new revise accounting standard rule promulgate generally include group order contain insurance cost time time international accounting group adjust coverage profile standardsette board material adverse impact accept great degree uninsured exposure group financial result group respond governmental investigation usa pricing marketing reimbursement prescription drug product investigation result related restitution civil false claim act litigation behalf federal state government proceeding initiate glaxosmithkline behalf consumer private payer unfavourable resolution similar future government investigation material group financial result group material provision relate investigation reduce earning environmental law jurisdiction impose actual potential obligation group remediate contaminate site group identify potentially responsible party comprehensive environmental response compensation liability act number site remediation cost relate group use ownership site note financial statement legal proceeding discussion environmentalrelate proceeding group involve glaxosmithkline operate financial review prospect year accordance ussec disclosure requirement follow respiratory discussion compare result year december successful launch asthma treatment seretideadvair result year december usa number countries europe international helped boost sale growth product exchange combination flixotidefloventand serevent available country worldwide sale seretideadvairexceede billion average sterling exchange rate weak usa million prescription write dollar euro strong yen month follow launch april speed compare aggregate currency movement patient adopt seretideadvairin usa compare net favourable effect sterle successful pharmaceutical product launch result cent respect sale cent seretideadvair wasglaxosmithkline large product europe respect business performance earning share sale million pharmaceutical sale application registration seretidefor treatment total pharmaceutical sale million compare chronic obstructive pulmonary disease copd submit million increase cent like september january fda advisory committee like basis sale product divest recommend approval advairand floventfor treatment regulatory approval merger glaxo wellcome copd associate bronchitis flixotideand sereventa smithkline beecham exclude sale grow cent individual agent approve country million approximately cent treatment copd overall growth come price increase expect sale flixotidefloventand sereventdecline glaxosmithkline exist portfolio sale new product market increase momentum launch major market year seretideadvair sale flixonaseflonase treatment account cent total sale grow cent perennial rhinitis grow strongly million sale establish franchise product old respiratory product ventolinand becotidecontinue amount million represent cent total decline patient convert new product sale growth cent compare year old product actively promote million account antibacterial cent total sale decline seven cent overall sale antibacterial show little growth pharmaceutical sale growth fourth quarter broadspectrum antibiotic augmentinwa high cent million sale usa contribute sell product group portfolio achieve cent million growth cent wholesaler growth worldwide augmentin esextra strength buy pattern distort product sale total report sale launch usa october treatment child growth line underlie demand indicate recurrent persistent middle ear infection submission fda prescription data europe sale improve cent approval augmentin xrextende release submit million international sale improve cent extra data information request fda million overall sale old product zinnatceftin fortumand amoxilcontinue decline sale zinnatceftin pharmaceutical sale therapeutic area grow central eastern europe cent central nervous system major therapeutic area glaxosmithkline portfolio record antiviral sale growth cent seroxatpaxiland wellbutrindrove glaxosmithkline continue expand leadership hivaid sale growth antidepressant sector cent april global market share cent paxilwa approve fda treatment trizivir glaxosmithkline new triple combination medicine generalise anxiety disorder gad december hivaids available tablet key driver growth treatment posttraumatic stress disorder ptsd seroxatpaxilis hivaid franchise launch number key approve country treatment gad market year include europe usa country treatment ptsd wellbutrinsales canada drive sale growth cent result increase awareness physician efficacy favourable sale combivir combination epivirand retrovir effect profile nonanxious depressed patient grow cent major growth market japan asia pacific middle east latin america africa migraine sector successful launch japan imigran tablet treatment previously available sale ziagenincrease cent approval receive injection help imigranimitrexsale grow cent paediatric indication october use ziagenhad lamictalfor treatment epilepsy grow strongly sale approve country worldwide requipfor parkinson disease zybanthe smoking cessation treatment hivaid adult product launch france sale zeffix hepatitis grow market region usa zeffix market epivirhbv approve treatment child year old augustoperate financial review prospectsglaxosmithkline pharmaceutical sale therapeutic area total usa europe international therapeutic area cer cer cer cer major product total growth growth growth growth cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretideadvair seretideadvair flixotideflovent serevent flixonaseflonase ventolin becotide antiviral hiv trizivir combivir epivir retrovir ziagen agenerase herpe valtrex zovirax zeffix antibacterials augmentin zinnatceftin fortum amoxil metabolic gastrointestinal avandia zantac vaccine hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total sale continue business divest product total pharmaceutical sale cer represent sale growth constant exchange rate glaxosmithkline operate financial review prospect performance herpe treatment valtrexand zovirax cns therapeutic area seroxatpaxil launch generalise produce combine sale growth cent usa anxiety disorder april grow strongly wellbutrincontinue valtrex sale helped dtc advertising campaign good growth record product benefit approval usa shorter threeday course therapy grow antidepressant market usa lamictalindicate recurrent genital herpe decline zoviraxin region epilepsy grow cent world result transfer new valtrex antibacterial sector augmentinreflecte gain share product generic competition adult paediatric market growth bolster launch extra strength formulation indicate metabolic gastrointestinal treatment child acute otitis medium middle ear avandia glitazone treatment type diabetes infection key driver growth metabolic gastrointestinal therapy area usa avandiasale benefit increase combination treatment trizivirwa launch market acceptance revolutionary class drug record growth late sale financial year amount cent avandia launch china italy million help produce cent sale growth approve country file marketing approval hivaid sector antiviral antiviral market valtrex japan december herpe show strong performance sale zantaccontinue decline face generic europe competition europe region contribute cent pharmaceutical sale large market france show strong growth good vaccine growth record major market include italy spain infanrix glaxosmithkline combination vaccine diphtheria central eastern europe seretidewa major sale driver tetanus pertussis whoop cough drive total vaccine region usa affect sale sale growth cent strong growth constituent product seretideadvairwa large product priorix tritanrixand typherixmore offset decline europe sale million hepatitis portfolio twinrix havrixand engerixb subsequent year end glaxosmithkline announce discontinuation cns area seroxat couple launch zybanin lymerixin usa result poor demand product market contribute growth launch trizivir help produce cent growth hivaid sector oncology emesis metabolic gastrointestinal zantacsale continue decline continued sale growth zofran management face increase generic competition partially nausea vomiting associate chemotherapy offset performance avandiawith launchesin number radiotherapy cancer treatment benefit oncology emesis market include germany therapy area grow cent overall sale hycamtin approve treatment recurrent ovarian cancer decline antibacterial decline cent reflect generic competition nineper cent principally result adverse wholesaler augmentinand amoxil vaccine show growth buy pattern usa decline hepatitis market germany sale improve european country principally spain italy cardiovascular oncology area growth attributable strong sale coreggrew cent november fda give sale zofranin france germany offset decline approval treatment severe heart failure coregis hycamtinsale european country betablocke agent indicate increase survival mild moderate severe heart failure patient glaxosmithkline international exclusive right market coregin usa cent sale growth international region reflect strong growth major market region therapeutic area sale relafenfor arthritis fall reflect generic competition market growth japan drive number therapeutic usa areas launch tablet form imigranin august seroxatin late key driver switch regional analysis becotideto new product flixotideand zoviraxto newer valtrexcontribute sale growth new usa product lead decline old product group earn cent total pharmaceutical revenue canada significant growth achieve seretideand usa year recording growth cent avandia launch march therapeutic advairseretide launch midapril achieve sale area trizivirfor hiv treatment launch november million launch slow sale growth constituent product flixotidefloventand serevent combine seven cent total sale derive asia pacific sale product amount million area principally australia sale growth cent growth cent meter dose inhaler seretidewas launch market sale zybangrew successful launch late operate financial review prospectsglaxosmithkline latin america report cent sale growth reflect strong trading profit business performance growth mexico cent area predominately benefit illustrate glaxosmithkline business performance seretidesereventflixotidemarket grow analysis trading profit subsequent discussion cent hivaid vaccine market show good return exclude merger item integration restructuring cost antibacterial decline generic competition disposal business management believe exclusion middle east africa area follow trend nonrecurre item provide well comparison business market growth seretide avandiaand hivaid performance period present accordingly information market vaccine area record growth cent provide supplement contain consolidated zofranin oncology area drive growth cent statement profit loss page prepare accordance ukgaap subsaharan south africa key driver growth antiviral vaccine consumer healthcare sale cer sale cer cost sale otc medicine sell general oral care administration nutritional healthcare research total sale continue business development divest product trading profit total consumer healthcare sale acquisition block drug company inc complete cost sale january add million sale purchase add cost sale increase percentage sale loss sensodynetoothpaste brand range denture care brand highmargin product divest december inclusion worldwide significant addition group otc medicine low margin block drug product high stock provision largely usa block drug business integrate partly offset benefit merger manufacturing glaxosmithkline restructure saving result acquisition glaxosmithkline number sell general administration company globally oral care add significant extra scale sell general administration sga cost benefit business particularly north america japan europe merger saving principally general administration expenditure inclusion block drug cost distort year otc medicine year comparison exclude estimate block drug expense report sale otc medicine grow cent growth sga expense cent million primarily result acquisition block drug sga express percentage sale exclude block drug otc medicine decline cent cent lower reflect private label competition smoke control market sluggish growth global otc market research development june glaxosmithkline reach agreement taisho research development expenditure broadly level establish partnership introduce nicotine replacement year saving merger expenditure product japan research development plan increase future merger saving begin reinveste area significant new product introduction otc medicine include niquitin lozenge effective otc product launch trading profit tohelp smoker quit eumovate topical steroid business performance trading profit growth cent glaxosmithkline switch prescription otc major reflect improve trading margin trading margin improve new extension panadolanalgesic fast act formula cent cent result cost saving market actifast slow release product target merger integration partly offset divestment certain high persistent pain introduce scandinavia extend margin product require regulatory authority condition merger oral care acquisition block drug add number brand profit taxation business performance oral care business sensodyne polidentand poligrip exclude block drug oral care sale grow cent analysis discussion profit taxation relate reflect strong growth europe partly offset strong business performance competitive pressure aquafreshin market operating incomeexpense nutritional healthcare royalty income nutritional healthcare business grow seven cent reflect operate expense strong performance lucozadeand horlick income equity investment glaxosmithkline operate financial review prospect operate income significantly low disposal business low sale equity investment low product loss disposal business primarily arise disposal high cost relate product withdrawal sale affymax charge include million writeoff goodwill previously eliminate reserve profit disposal interest associate group sell million share quest diagnostic inc taxation restate restate year realise gain million december share split quest share sale business performance glaxosmithkline hold million share merger restructure disposal subsidiary share profitslosse joint venture associate undertaking share profit associate arise principally group hold inquest diagnostic inc group implement frs defer tax require defer tax account provision basis partial provision basis early year change net interest payable basis account prior year adjustment interest payable comparative information restate necessary investment income business performance taxation share interest payable associate charge taxation business performance profit amount million represent effective tax rate cent tax rate benefit low rate tax applicable net interest payable lower low average level net manufacturing operation singapore puerto rico ireland debt low interest rate merger restructure profit taxation credit taxation merger restructuring item operating incomeexpense disposal amount million reflect estimate actual tax rate interest inanassociate add million profit applicable transaction territory arise taxation compare million reduction onetime profit plan improve overall earning restate restate quality group earning take account contribution earning associate comprise share profit share ofinter basic earning share thegroup net interest payable business performance basic earning ad profit tax million compare million increase cent adjust earning adjust earning share merger item restructuring cost disposal business adjust earning ad key item discuss weighted average number share million merger adjust earning adjust earning share cost arise integration glaxo wellcome glaxosmithkline present order illustrate business smithkline beecham business unify glaxosmithkline performance primary measure management business refer merger integration cost amount discuss early million cost primarily include consultancy fee severance asset writeoff share option retention incentive manufacture restructuring cost million incur implement previously announce glaxo wellcome smithkline beecham plan restructure manufacturing activity million charge respect postmerger restructuring activity cost include consultancy fee severance asset writeoff block drug company inc glaxosmithkline acquire block drug january cost incur acquire integrate business million comprise professional fee severance asset writeoffsoperate financial review prospectsglaxosmithkline select financial datum ukusgaap profit loss account restate restate restate restate amount accordance gaap sale operate profit profit taxation earning basic earning share dilute earning share weight average number share issue basic dilute dividend glaxosmithkline share glaxosmithkline shareholder glaxo wellcome shareholder smithkline beecham shareholder dividend express term glaxosmithkline share amount accordance gaap sale operating profit profitloss tax net incomeloss basic net incomeloss share pence diluted net incomeloss share pence information present gaap net incomeloss net incomeloss share result year end december adjust reverse amortisation expense goodwill indefinitelive intangible asset sfas apply year adjusted net incomeloss adjust basic net incomeloss share pence adjust diluted net incomeloss share pence balance sheet amount accordance gaap total asset net asset equity shareholder fund amount accordance gaap total asset net asset shareholder equity exchange rate guide holder adr follow table set period indicate information exchange rate dollar sterling report federal reserve bank new york noon buying rate average average rate year calculate average noon buying rate day month year feb jan dec nov oct sept high low noon buying rate march frs defer tax implement group ukgaap frs require defer tax account provision basis partial provision basis early year change account prior year adjustment ukgaap purpose comparative information restate necessary change impact usgaap result glaxosmithkline operate financial review prospect result accounting principle review discuss result glaxosmithkline plc prospect year shareholder equity december glaxosmithkline publish expectation future growth prepare accounting principle note earning share ukgaapbasis exclude merger financial statement reconciliation usaccounte principle restructure item outlook result recent financial accounting standard board fasb summary result pronouncement june fasb approve sfas accounting sale obligation associate retirement longlived asset trading profit require fair value obligation associate operating profit retirement longlive asset capitalise profit tax cost implement group effect net incomeloss change january group believe adoption accounting principle standard material impact result cumulative effect change accounting principle january sfas accounting impairment net incomeloss disposal longlive asset adopt group basic net incomeloss share penny sfas develop accounting model longlive asset include discontinued operation dispose sale operating profit low usgaapbasis gaap require longlive asset measure low basis primarily result amortisation impairment carrying fair value cost sell report intangible asset record balance sheet continue discontinue operation adoption sfas gaap operating profit include charge sfas material impact group financial stockbase compensation charge pension post statement retirement benefit partially offset net income april sfas rescission fasbstatement relate defer tax credit amendment fasbstatement technical group adopt sfas january correction issue statement update clarifie implementation sfas result initial impairment simplifie exist accounting standard group million net tax indefinite live intangible asset believe adoption standard material impact group align measurement date result pension plan december impact million sfas accounting cost associate exit disposal credit net tax change reflect cumulative effect activity issue june sfas require company change accounting principle recognise cost associate exit disposal activity effect difference ukgaap lead incur date commitment usgaap profit tax million tax exit disposal plan apply prospectively exit minority interest cumulative effect change disposal activity initiate december group accounting principle net income year million currently assess impact standard profit tax million tax november fasb publish interpretation minority interest net loss million guarantor accounting disclosure requirement guarantee include indirect guarantee indebtedness shareholder equity december fin fin expand account guidance sfass fin provision initial recognition change shareholder equity measurement apply guarantee issue modify beginning year december disclosure requirement net incomeloss effective financial year end december share purchase cancel group believe adoption fin share issue share option material impact result treasury stock dividend january fasb publish interpretation minimum pension liability consideration variable interest entity fin fin primary beneficiary entity consolidate certain entity know variable interest entity measurement end year principle apply group financial statement group believe adoption fin book value glaxosmithkline net asset ukgaap basis material impact result adjust normal ukusgaap difference principal adjustment net asset difference usgaap include goodwill intangible asset glaxos acquisition wellcome glaxo wellcome acquisition smithkline beecham dividend declare propose basis treatment share hold esot treasury stock investment inclusion minimum pension liability net assetsglaxosmithkline financial statement section comprise director statement independent auditor report financial statement financial statement consist principal financial statement support note additional financial data director statement responsibility independent auditor report financial statement consolidate statement profit loss consolidate statement total recognise gain loss consolidate statement cash flow consolidated balance sheet reconciliation movement equity shareholder fund company balance sheet note financial statement presentation financial statement accounting policy new accounting policy requirement exchange rate merger glaxo wellcome smithkline beecham segment information merger item restructuring cost divest business operate incomeexpense operating profit joint venture associate undertaking net interest payable taxation earning share dividend goodwill intangible asset tangible fix asset fix asset investment equity investment stock debtor creditor provision liability charge contingent liability net debt commitment share capital share premium account nonequity minority interest reserve legal proceeding acquisition disposal financial instrument relate disclosure employee cost employee share scheme relate party transaction glaxosmithkline plc investment subsidiary company reconciliation accounting principle principal group company financial record quarterly trend year record glaxosmithkline director statement responsibility director statement responsibility relation internal control tothefinancial statement board audit committee review director assessment risk internal control framework operate glaxosmithkline consider effectiveness responsible ensure maintenance proper accounting system internal control operation inthegroup record disclose reasonable accuracy financial year cover report date approval position group time financial board director statement beprepare comply company act combine code require law prepare financial statement financial period true fair view state board consider glaxosmithkline plc apply principle affair company group end combine code asdescribe corporate governance financial period ofthe profit loss period page comply requirement responsible ensure operation system combine codewiththeexception provision relate internalcontrol take reasonable step safeguard executive director service contract pensionable bonus asset group prevent detect terminationcommitment company position fraud irregularity describe remuneration report financial statement year end december require listing rule financial service authority comprise principal statement support note set auditor haveconsidere director statement infinancial statement page report compliance relation point combine code specify theirreview director confirm suitable accounting policy consistently apply preparation financial statement annual report support reasonable prudent judgement estimate asnecessary applicable accounting standard follow annual report year end december financial statement prepare go comprise report director director remuneration concern basis report financial statement additional information investor approve board director sign responsibility auditor relation financial behalf statement set independent auditor report opposite sir christopher hogg financial statement year end december chairman include annual report publish march hardcopy print form website director responsible maintenance integrity annual report website accordance legislation govern preparation dissemination financial statement access website available outside comparable legislation different director remuneration remuneration report page report set remuneration policy operate glaxosmithkline disclosure director remuneration disclosable information relate director officer interest prepare accordance company act amend director remuneration report regulation complie section combine code go concern basis make enquiry director reasonable expectationthat group company adequate resource continue operational existence foreseeable future forthis reason continue adopt go concern basis inprepare financial statementsglaxosmithkline independent auditor report members glaxosmithkline plc audit consolidated financial statement plan perform audit obtain comprise consolidated statement profit loss information explanation consider necessary consolidated statement total recognise gain loss order provide sufficient evidence reasonable consolidated statement cash flow consolidated balance sheet assurance consolidated financial statement relate note prepare auditable director remuneration report free historical cost convention accounting policy set material misstatement cause fraud statement accounting policy audit irregularity error form opinion evaluate disclosure require schedule company overall adequacy presentation information act contain director remuneration report consolidate financial statement auditable united kingdom opinion respective responsibility director auditor opinion director responsibility prepare annual report financial statement true fair view state director remuneration report consolidate financial affair company group december statement accordance applicable united kingdom law profit cash flow group year accounting standard set statement financial statement properly prepare director responsibilities accordance company act part director remuneration report require responsibility audit consolidated financial statement schedule company act auditable director remuneration report properly prepare accordance company act accordance relevant legal regulatory requirement united kingdom auditing standard issue auditing united states opinion practice board opinion financial statement present fairly report opinion consolidated material respect consolidated financial position group financial statement true fair view december result consolidate financial statement auditable consolidated operation consolidated cash flow director remuneration report properly prepare year period end december accordance company act report conformity accounting principle generally accept opinion report director consistent united kingdom consolidated financial statement company keep proper accounting record receive accounting principle generally accept united kingdom information explanation require audit vary certain significant respect accounting principle information specify law director remuneration generally accept united states application transaction disclose affect determination consolidate net income express sterling year read information contain annual report period end december determination consider implication report aware consolidated shareholder equity express sterle apparent misstatement material inconsistency december extent summarise note consolidated financial statement information consolidated financial statement comprise report director joint statement chairman chief executive officer operate financial review prospect corporate governance pricewaterhousecooper llp statement charter accountant register auditor review corporate governance statement reflect southwark tower company compliance seven provision london england combined code specify review list rule march financial service authority report require consider board statement internal control cover risk control form opinion effectiveness company group corporate governance procedure risk control procedure basis audit opinion conduct audit accordance auditing standard issue united kingdom auditing practice board auditing standard generally accept united states audit include examination test basis evidence relevant amount disclosure financial statement auditable director remuneration report include assessment significant estimate judgement director preparation consolidated financial statement accounting policy appropriate company group circumstance consistently apply adequately disclose glaxosmithkline consolidate statement profit loss year end december merger restructuring business disposal performance subsidiary statutory note turnover cost sale gross profit sell general administrative expenditure research development expenditure trading profit operating incomeexpense operate profit share profitslosse joint venture associate undertaking profit disposal interest associate product divestment merger transaction cost profitloss disposal business profit interest net interest payable profit ordinary activity taxation taxation profit ordinary activity taxation minority interest preference share dividend earning profit attributable shareholder basic earning share adjust earning share dilute earning share profit attributable shareholder dividend retain profit item deal arrive business performance operating profit relate continue activity difference profit ordinary activity taxation retain profit state historical cost equivalent frs defer tax implement group frs require defer tax account provision basis partial provision basis early year change account prior year adjustment comparative information restate necessary consolidated statement total recognise gain loss year end december profit attributable shareholder exchange movement overseas net asset tax exchange movement unrealise gain equity investment total recognise gain loss relate year prior year adjustment implementation frs total recognise gain loss consolidate statement profit lossglaxosmithkline merger merger restructuring restructuring business disposal business disposal performance subsidiary statutory performance subsidiary statutory restate restate restate restate restate restate restate restate glaxosmithkline consolidate statement cash flow year end december reconciliation operating profit operating cash flow note operate profit depreciation impairment asset write amortisation goodwill intangible fix asset loss sale tangible fix asset profit sale equity investment increasedecrease stock increase trade debtor increase trade creditor increase pension provision merger transaction cost pay net cash inflow operating activity cash flow statement net cash inflow operating activity dividend joint venture associate undertaking return investment servicing finance taxation pay capital expenditure financial investment acquisition disposal equity dividend pay net cash inflowoutflow management liquid resource finance management liquid resource finance increasedecrease cash year reconciliation net cash flow movement net debt net debt begin year increasedecrease cash year cash outflowinflow management liquid resource net increase longterm loan net repayment shortterm loan net repayment ofincrease obligation finance lease net noncash fund subsidiary undertaking acquire exchange adjustment noncash movement movement net debt net debt end year consolidated statement cash flowglaxosmithkline analysis cash flow return investment servicing finance interest receive interest pay dividend pay minority shareholder dividend pay preference share capital expenditure financial investment purchase tangible fix asset sale tangible fix asset purchase intangible asset sale intangible asset product divestment purchase share employee share option award proceed share employee share option purchase equity investment sale equity investment acquisition disposalsnote purchase business cash acquire subsidiary disposal business investment joint venture associate undertaking disposal interest associate financing issue share capital redemption preference share issue subsidiary share capital purchase cancellation financing cash flow increase longterm loan repayment longterm loan net repayment shortterm loan net repayment ofincrease obligation finance lease analysis change net debt cash flow acquisition exchange cash bank overdraft debt year commercial paper debt year euro bond mediumterm note private financing management liquid resource liquid investment net debt glaxosmithkline consolidated balance sheet december restate note goodwill intangible asset tangible asset investment fix asset equity investment stock debtor liquid investment cash bank current asset loan overdraft creditor creditor amount year net current asset total asset current liability loan creditor creditor amount year provision liability charge net asset call share capital share premium account reserve profit loss account equity shareholder fund nonequity minority interest equity minority interest capital employ approve board sir christopher hoggchairman march reconciliation movement equity shareholder fund year end december restate note equity shareholder fund begin year previously report prior year adjustment implementation frs equity shareholder fund begin year restate total recognise gain loss year dividend share capital issue share capital purchase cancel exchange movement goodwill write reserve goodwill write equity shareholder fund end year glaxosmithkline company balance sheet december note share subsidiary company cost fix asset amount owe group undertaking taxation current asset taxation dividend payable amount owe group undertaking creditor amount year net current assetsliabilitie net asset call share capital share premium account reserve profit loss account equity shareholder fund approve board sir christopher hoggchairman march glaxosmithkline note financial statement presentation financial statement additional information accordance requirement usgenerally accept accounting principle gaap include description business note financial statement note statement glaxosmithkline major global healthcare group difference reconciliation net income shareholder engage creation discovery development manufacture equity gaap provide principal marketing pharmaceutical product include vaccine financial statement present accordance gaap overthecounter otc medicine healthrelate consumer andin usgaap format product glaxosmithkline principal pharmaceutical product include medicine follow therapeutic area merger glaxowellcome plc smithkline beecham plc central nervous system respiratory antiviral antibacterial glaxosmithkline plc acquire glaxo wellcome plc smithkline metabolic gastrointestinal vaccine oncology emesis beecham plc way scheme arrangement merger cardiovascular arthritis company effective december financial period ukgaap financial statement glaxosmithkline plc financial statement cover financial year prepare merger glaxowellcome plc smithkline january stdecember comparative figure beecham plc comparative figure year financial year january december december include result glaxo january tost december wellcome plc smithkline beecham plc gaap financial statement glaxosmithkline plc composition group prepare acquisition smithkline beecham plc list subsidiary associate undertakings glaxo wellcome plc december accordingly opinion director principally affect profit result smithkline beecham period prior date net asset group give principal group consolidated company note presentation statement profit loss composition financial statement columnar presentation adopt statement consolidated financial statement draw accordance profit loss order illustrate underlie business performance generally accept accounting principle ukgaap primary measure management accounting presentation purpose certain item identify separately exclude financial statement comprise business performance comprise merger integration item include product divestment cost relate previously consolidate statement profit loss announce manufacturing restructuring theeffect consolidated statement total recognise gain loss disposal subsidiary consolidate statement cash flow consolidated balance sheet trading profit reflect sale cost sale comprise cost reconciliation movement equity shareholder fund ofmanufacture external royalty sell general company balance sheet administrative expenditure comprise cost sell note financial statement distribution medical support currently market product cost administration cost research permit section company act development create future product sale profitand loss account company present consolidated statement total recognise gain loss accounting convention include financial statement prepare historical cost convention realise profit attributable shareholder reflect theconsolidated profit loss account accounting standard unrealise gain loss value group overseas financial statement comply applicable accounting net asset relate foreign currency borrowing attributable standard currency movement period reconciliation movement equity shareholder fund accounting principle policy comprise item contribute increase decrease preparation financial statement conformity generally period shareholder fund item include accept accounting principle require management estimate assumption affect report amount total recognise gain loss period asset liability disclosure contingent asset dividend pay propose liability date financial statement report proceed share issue period amount revenue expense report period cost share purchase cancellation actual result differ estimate share buyback programme change goodwill arise acquisition prior financial statement prepare accordance january set directly reserve company accounting policy approve board describe note company implement new financial reporting standard describe innote note financial statement glaxosmithkline accounting policy foreign currency transaction foreign currency transaction group company book consolidation inlocal currency exchange rate ruling date consolidate financial statement include transaction forward rate hedge forward asset liability result cash flow exchangecontract foreign currency asset liability company subsidiary undertaking include employee translate local currency rate exchange ruling share ownership trust esot balance sheet date forward rate exchange difference group share net asset result joint venture areinclude trading profit associate undertaking revenue financial statement undertaking consolidate revenue recognise profit loss account good december service supply external customer order undertaking group material interest receive turnover represent net invoice value account subsidiary group exercise dominant deduction discount give point sale product influence joint venture group exercise joint control despatch available collection customer associate group exercise significant accrual estimate future rebate return value add tax influence esot account subsidiary ground sale taxis exclude revenue group facto control expenditure interest acquire undertaking consolidated expenditure recognise respect good service receive effective date acquisition interest sell consolidated supply accordance contractual term provision upto date disposal obligation exist future liability respect transaction balance subsidiary undertaking past event obligation reliably eliminate profit take sale subsidiary estimate advertising expenditure charge profit loss undertaking sale joint venture associate undertaking account incur shipment cost intercompany transfer product sell customer outside group charge cost sale distribution cost sale customer include sell general administrative expenditure goodwill arise acquisition interestsin subsidiary restructuring cost recognise respect direct undertaking joint venture associate undertaking expenditure business reorganisation plan represent excess purchase consideration sufficiently detail advanced appropriate group share separable net asset acquire capitalise communication affect undertaken asa separate item case subsidiary undertaking balance sheet date cost investment case joint venture associate undertaking goodwill denominate currency research development inwhich acquisition finance case research development expenditure charge profit acquisition prior goodwill write loss account period incur tangible reserve subsequent disposal asset acquisition fix asset research development depreciate related goodwill remove consolidated reserve accordance group policy charge consolidated profit lossaccount group interest joint venture account environmental expenditure thegross equity method group interest associate environmental expenditure relate exist condition result undertaking account equity method past current operation current future benefit discernible charge profit loss defer taxation relief unrealise intragroup profit account group determine liability sitebysite basis account extent consider recoverable record liability time probable asset liability overseas subsidiary associate reasonably estimate liability include group portion undertaking joint venture include related goodwill cost portion potentially responsible translate sterling rate exchange rule balance party cost probable able satisfy sheet date result cash flow overseas subsidiary respective share cleanup obligation recovery associate undertaking joint venture translate reimbursement virtually certain record asset sterling average rate exchange exchange adjustment arise open net asset profit theyear legal dispute retain overseas subsidiary associate undertaking provision anticipate settlement cost legal joint venture translate sterling exchange difference expense associate claim receive legal arise relate foreign currency borrowing take directly dispute group reasonable estimate reserve report statement total recognise likely outcome dispute provision gain andlosse unasserted claim obligation exist dispute possible reasonable estimate cost associate translate sterling asset liability result cash flow claim group party charge overseas subsidiary associate undertaking joint venture profit loss account incur report currency hyperinflationary economy adjustment aremade reflect current price level loss net monetary assetsis charge consolidated profit loss account glaxosmithkline note financial statement account policiescontinue tangible fix asset tangible fix asset state cost provision pension postretirement benefit depreciation impairment cost acquire develop cost provide pension employee postretirement computer software internal use internet site external benefit charge consolidated profit loss account use capitalise tangible fix asset software systematic rational basis base actuarial assumption site support significant business system expenditure period benefit derive employee service lead creation durable asset difference charge contribution pay include asset liability consolidate balance sheet depreciationi calculate write cost tangible fix asset exclude freehold land equal annual instalment employee share plan expect useful life normal expect useful life incentive form share provide employee major category tangible fix asset review annually share option share award scheme respect award scheme certain share option grant company provide finance esot purchase company share open market freehold building year meet company obligation provide share leasehold land short lease term employee exercise option award anyexcess building year purchase price share exercise price option plant machinery year award charge profit loss account fixture equipment year period service respect option award erp system software year grant respect share option grant share option computer software year exercise account share issue exercise price erp system software generally involve significant customisation additional employer cost respect option award prior implementation expect useful economic charge profit loss account period service life seven year maximum year cost run esot charge profit loss computer software account share hold esot account fix asset ondisposal tangible fix asset cost relate investment hold cost provision recognise shortfall accumulate depreciation remove financial proceed receivable employee exercise statement net proceed take deem permanent impairment value consolidate profit loss account goodwill lease goodwill state cost provision amortisation leasing agreement transfer group substantially amortisation calculate write cost equal annual benefit risk ownership asset treat instalment expect useful life useful life finance lease asset purchase outright normally expect exceed year asset include intangible fix asset capital element leasing commitment show obligation finance intangible fix asset lease asset hold finance lease depreciate intangible asset state cost provision amortisation short ofthe lease term useful life asset acquire licence patent knowhow marketing right interest element lease rental charge profit amortise estimate useful life equal instalment lease operating lease annual rental long year item capitalise restrict charge profit straightline basis lease term relate specific compound product develop commercial application estimate useful life impairment fix asset determine amortisation charge review annually carry value fix asset review impairment andtake account estimate time takes bring indication asset impaired compound product market marketable product provision impairment charge profit year anydevelopment cost incur group concern firstyear impairment review conduct areassociate acquire licence patent knowhow acquire goodwill intangible asset certain intangible marketing right write profit loss account consider anindefinite life whenincurre amortise intangible subject annual impairment test impairment determine byreference high net brand value independently fair value realisable value value use measure reference business acquire party brand value discount future cash flow value share hold substantial longterm brand esot review quarterly determine permanent sell separately rest business acquire brand impairment areamortise estimated useful life long year end useful economic life investment joint ventures associates brand foresee investment joint venture associate undertaking prior acquire minor brand similar intangible carry consolidated balance sheet group share eliminate group balance sheet reserve year oftheir net asset date acquisition post acquisition acquisition retain profit loss goodwill arising acquisition net amortisationnote financial statementsglaxosmithkline accounting policiescontinue debt instrument debt instrument state net proceed stock adjustedto amortise issue cost debt evenly term stocksare include financial statement low cost debt include manufacturing overhead appropriate net realisable value cost generally determine new accounting policy future requirement basis group implement financial reporting standard taxation defer tax require defer tax account group account taxation defer accelerate provision basis partial provision basis reason timing difference originate comparative information restate necessary reverse balance sheet date defer tax asset effect increase business performance tax recognise extent consider recoverable charge million million overall tax charge future taxable profit defer tax retain earning million million net defer tax asset overseas subsidiary provide bind december reduce million commitment distribute past earning future periods june council european union adopt defer tax measure average tax rate expect regulation require list company member state apply period time difference expect prepare consolidated financial statement accordance reverse defer tax liability asset discount international accounting standard group initiate project plan implement conversion current asset investment ukgaap international financial reporting standard ifrss current asset investment state low cost net annual report prepare ifrss realisable value year end december financial result announcement prepare accordance ifrss case security acquire significant premium quarter discount maturity value intend hold redemption cost adjust amortise premium discount life exchange rate tomaturity security float rate bond state cost interest income take profit loss account group use average exchange rate prevail receivable basis period translate result cash flow overseas group subsidiary joint venture associate undertaking sterling equity investment include current asset regard period end rate translate net asset asavailable sale undertaking thecurrencie influence translation relevant exchange rate derivative financial instrument group hold issue derivative financial instrument trading purpose average rate derivative financial instrument manage exposure market risk treasury operation principal derivative euro instrument currency swap forward exchange contract yen interest rate swap derivative contract treat period end rate inception economic hedge underlie financial instrument matching accounting treatment cash flow euro derivative contract high correlation specific yen financial instrument hedge inception hedge period derivative instrument long merger glaxo wellcome smithkline beecham designate hedge restate market value future combination glaxo wellcome plc smithkline beecham plc change value take directly profit loss account treat merger december gaap currency swap forward exchange contract fix merger accounting share issue glaxosmithkline plc value relate asset liability contract currency acquire glaxo wellcome smithkline beecham account contract rate accrue profit loss account par share premium arise share acquire life contract gain loss foreign exchange glaxosmithkline glaxo wellcome smithkline beecham contracts designate hedge forecast foreign exchange similarly account nominal value share issue transaction defer include measurement inthe consolidated financial statement glaxosmithkline relate foreign currency transaction period occur result netasset glaxo wellcome smithkline beecham gain loss balance sheet hedge accrue combine book amount subject alignment take directly reserve forward premiumdiscount adjustment recognise interest life contract inview proximity merger date financial year end interest differential interest swap agreement recognise date relative insignificance business activity profit loss account adjustment ofinter expense december december accounting life agreement date merger practical purpose take stdecember profit financial year glaxo wellcome plc smithkline beecham plc wasdeeme relate period prior merger date glaxosmithkline note financial statement segment information analysis turnover profit taxation total asset net asset tangible fix asset business geographical sector areset belowthe business sector consist pharmaceutical prescription pharmaceutical vaccine consumer healthcare oralcare otc medicine nutritional healthcare thegeographical sector reflect group significant regional market consistent group regional market management reportingstructure business sector datum include allocation corporate cost sector sale business sector group activity organise global basis geographical sector figure influence location group operate resource particular manufacturing research variation time intragroup trading funding arrangement restate restate turnover business sector pharmaceutical consumer healthcare external turnover profit tax business sector pharmaceutical consumer healthcare operate profit share profitslosse joint venture associate undertaking profit disposal interest associate profit disposal business product divestment merger transaction cost net interest payable profit taxation profit taxation taxation minority interest preference share dividend earning total asset business sector pharmaceutical consumer healthcare total asset net asset business sector pharmaceutical consumer healthcare net asset note financial statementsglaxosmithkline segment informationcontinue restate restate turnover location subsidiary undertaking usa europe international gross turnover usa europe international intersegment turnover usa europe international external turnover turnover location customer usa europe international external turnover profit tax location subsidiary undertaking usa europe international operating profit share profitslosse joint venture associate undertaking profit disposal interest associate profit disposal business product divestment merger transaction cost net interest payable profit taxation profit taxation taxation minority interest preference share dividend earning total asset location subsidiary undertaking usa europe international total operating asset cash bank liquid investment total asset net asset location subsidiary undertaking usa europe international net operating asset net debt net asset glaxosmithkline note financial statement segment informationcontinue plant land equipment computer asset building vehicle software construction total total tangible fix asset location subsidiary undertaking usa europe international total segment information give separately respect include group europe market region consider group home segment purpose segmental reporting restate turnover location customer gross turnover intersegment turnover turnover location subsidiary operating profit total asset net operating asset merger item restructuring cost divest business manufacture restructuring cost incur glaxosmithkline implementation previously announce plan restructure manufacturing activity cost incur glaxo wellcome smithkline beecham merger integration cost relate integration glaxo wellcomeand smithkline beecham unify glaxosmithkline business cost include consultancy fee respect integration planning severance cost asset writeoff cost relate early vest lapse performance condition share option share incentive award cost programme encourage staff convert glaxo wellcome smithkline beecham share option glaxosmithkline share option integration cost incur relate integration block drug business cost include professional fee severance cost asset writeoff product divestment income arise relate finalisation disposal famvir kytrilandother product require order obtain regulatory approval merger merger transaction cost incur order effect themerg cost comprise fee expense incur prepare implement scheme arrangement merger disposal business relate finalisation disposal clinical laboratory healthcare service disposal business primarily arise sale affymax include million write goodwill previously eliminate group reserve disposal business relate disposal healthcare service restructuring cost incur healthcare service disposal share associate relate restructuring cost incur quest diagnostic restruc disposal merger ture block drug subsidiary total manufacturing restructuring merger integration cost block drug integration cost effect operate profit product divestment profit disposal business effect profit tax effect taxation operate item effect taxation nonoperate item effect taxation effect earning note financial statementsglaxosmithkline merger item restructuring cost divest business continue restruc disposal total merger ture block drug subsidiary restate manufacturing restructuring merger integration cost block drug integration cost effect operate profit loss disposal business effect profit tax effect taxation operate item effect taxation nonoperate item effect taxation effect earning restruc disposal total merger ture associate subsidiary restate manufacturing restructuring merger integration cost effect operate profit share associate product divestment merger transaction cost loss disposal business effect profit tax effect taxation operate item effect taxation nonoperate item effect taxation effect earning operating incomeexpense royalty income operate expense income equity investment disposal royalty income principally core recur income form royalty outlicense intellectual property operating expense comprise nonrecurre cost relate product liability claim cost respect product withdrawal income equity investment disposal arise equity investment sale equity investment writedown adverse market condition product property disposal glaxosmithkline note financial statement operating profit follow item charge operating profit employee cost note advertising distribution cost depreciation tangible fix asset own asset lease asset amortisation goodwill amortisation intangible fix asset exchange loss foreign currency depositsloans operate lease rental plant machinery land building audit fee fee auditor work auditor ukfirm auditor overseas firm analysis fee auditor work nonstatutory assurance service tax advisory service merger glaxo wellcome smithkline beecham service include audit fee fee relate company audit glaxosmithkline plc include fee auditor work amount million millionpaid auditor management consulting practice sell joint venture associate undertaking associate undertaking share profit quest diagnostic inc share loss associate undertaking amortisation goodwill share lossesprofit joint venture share turnover joint venture sale joint venture associate undertaking net interest payable interest payable bank loan overdraft loan respect finance lease share interest payable associate investment income interest income realise gain provision market value adjustment note financial statement glaxosmithkline taxation restate restate taxation charge base profit period corporation tax statutory rate double taxation relief overseas taxation defer taxation share taxation charge associate reconciliation current taxation rate group profit restate restate ukstatutory rate taxation overseas taxis average group tax rate effect special tax status manufacturing location share option deduction usa merger restructuring cost credit previously recognise permanent difference capital allowance excess depreciation intragroup profit reverse time difference tax loss time difference prior year item current tax rate ordinary activity capital allowance excess depreciation intragroup profit reverse time difference tax loss time difference share associate taxation prior year item tax rate ordinary activity group operate country tax rate differ ukrate standard rate tax group estimate aggregate local standard tax rate weight proportion accounting profit profit arise manufacturing operation singapore puerto rico ireland tax reduce rate effect reduction taxation charge increase earning share integrate nature group worldwide operation involve significant investment research strategic manufacture limited number location consequential crossborder supply route numerous endmarket give rise complexity delay negotiation revenue authority profit individual group company liable tax disagreement revenue authority intragroup transaction particular price good transfer group company different tax jurisdiction produce conflict claim revenue authority profit fall tax individual territory resolution issue continue factoflife glaxosmithkline usa number years glaxosmithkline significant open issue relate transfer pricing issue affect year present concern number product significant relate success zantac respect claim internal revenue service irs substantially exceed group estimation taxation liability irs claim completely quantify continue subject discussion tax authority competent authority provision double tax convention country discussion wide variation view tax authority exceptionally unable reach agreement settle dispute event tax authority reach agreement matter resolve litigation glaxosmithkline use good advice determine transfer pricing methodology seek manage transfer pricing issue satisfactory conclusion basis external professional advice continue believe adequate provision liability likely arise open assessment glaxosmithkline note financial statement taxation continue show financial statement provision taxation arise distribution profit retain overseas subsidiary associate undertaking ground remittance profit retain december require way incremental tax arise december group corporate tax loss approximately million capital loss estimate excess billion recognise defer tax asset insufficient evidence loss current defer defer tax creditor tax debtor tax provision tax balance january previously report prior year adjustment january restate exchange adjustment charge profit loss account cash pay movement december restate defer taxation assetliability accelerate capital allowance stock valuation adjustment intragroup profit product business disposal pension postretirement benefit tax loss legal dispute manufacture restructure net timing difference category provide defer taxation stock valuation adjustment intragroup profit time difference arecurrent defer taxation movement arise origination reversal timing difference group implement new financial reporting standard frs defer tax require defer tax account provision basis partial provision basis year business performance tax charge increase million total tax charge million net defer tax asset december reduced millionnote financial statement glaxosmithkline earning share restate restate basic earning share adjustment merger item restructuring cost disposal subsidiary merger integration transaction cost product divestment restructuring cost block drug integration cost disposal business associate adjust earning share dilute earning share basic adjust earning share calculate divide profit attributable shareholder weight average number ofshare issue period number calculate basic diluted earning share reconciledbelow illustrate business performance primary performance measure management adjust earning adjust earning share present exclude merger item integration restructuring cost disposal business management believe exclusion nonrecurre item provide well comparison business performance period present accordingly information provide supplement contain consolidated statement profit loss page prepare accordance ukgaap basic diluted earning share include nonrecurre item net profit period attributable shareholder earning basic diluted adjustment merger item restructuring cost disposal subsidiary adjust earning weight average number share issue million million million basic adjust dilution share option dilute share hold employee share ownership trust esot exclude trustee waive right dividend share hold esot glaxosmithkline note financial statement dividend glaxosmithkline plc interim second interim interim fourth interim glaxo wellcome plc interim second interim final smithkline beecham plc interim second interim interim fourth interim dividend share glaxosmithkline plc interim second interim interim fourth interim glaxo wellcome plc glaxo wellcome share interim second interim final equivalent dividend glaxosmithkline share dividend glaxo wellcome share smithkline beecham plc smithkline beecham share interim second interim interim fourth interim smithkline beecham plc equivalent dividend glaxosmithkline share interim second interim interim fourth interim note financial statement glaxosmithkline goodwill total cost january exchange adjustment addition note cost december amortisation january exchange adjustment provision year amortisation december net book value january net book value december licence intangible asset patent etc brand total cost january exchange adjustment addition acquisition business asset write cost december amortisation january exchange adjustment provision year asset write amortisation december impairment january exchange adjustment impairment loss impairment december net book value january net book value december licence patent acquire year relate acquisition compound right research base agreement note brand largely comprise portfolio sterling product panadol solpadeineand hedex block drug product sensodyne polidentand poligrip consider indefinite life give strength durability brand level marketing support accordingly amortise thevaluation sterling brand review annually year cash flow forecast basis original independent assessment acquire posttax discount rate cent valuation block drug brand review annually year cash flow forecast posttax discount rate cent glaxosmithkline note financial statement plant land equipment computer asset tangible fix asset building vehicle software construction total cost january exchange adjustment addition acquisition disposal reclassification cost december depreciation january exchange adjustment provision year disposal reclassification depreciation december impairment january exchange impairment loss disposal reclassification impairment december net book value january net book value december net book value december group land building comprise freehold property million january million property lease year million january million property lease year million stjanuary million include plant equipment vehicle december lease asset cost million january million accumulate depreciation million january million net book value million january million impairment loss principally relate reduction forecast cash flow result decision close manufacturing facility andhasbeen measure reference value use typically discount rate cent joint associate equity fix asset investment venture undertaking investment share total january exchange adjustment addition charge year impairment transfer disposal retain profit year goodwill amortisation december investments joint venture comprise million share gross asset million million share gross liability million principal associate undertaking quest diagnostic inc clinical laboratory business list new york stock exchange investment book value december million million market value million millionat december group own percent quest cent hold reduce cent february follow quest acquisition unilab corporation book value include goodwill amortise year amortisation charge million goodwill december amount million million goodwill million relate continue group interest clinical laboratory asset attribute quest remain eliminate group reserve equity investment comprise list investment million million unlisted investment million million market value list investment million million investment share consist share hold employee share ownership trust note market value share december million million valuation shortfall consider represent permanent diminution value context length future period relate share option exercise accordingly provision madenote financial statement glaxosmithkline equity investment total january exchange adjustment additions transfer fix asset investment impairment disposal december equity investment include list investment million million themarket value list investment million million stock raw material consumable work progress finish good debtor restate amount year trade debtor debtor prepay pension contribution prepayment accrue income amount year debtor prepayment accrue income defer taxation note debtor include trading balance nil million joint venture associate undertaking creditor amount year trade creditor taxation note social security creditor accrual defer income dividend payable amount year creditor accrual defer income accrual include obligation wage salarie million million glaxosmithkline note financial statement provision pension legal postretirement manufacturing merger defer liability charge benefit restructure integration dispute taxation provision total january previously report prior year adjustment note january restate exchange adjustment charge year apply reclassification movement december december group special cash contribution total million german pension scheme contribution relate german pension scheme include amount apply provision contribution relate pension scheme increase prepayment show debtor note group recognise cost respect plan manufacture restructuring initiate follow merger glaxo wellcome smithkline beecham acquisition block drug plan largely complete cost recognise provision principally respect identify severance site announce manufacturing activity cease expect incur mainly cost asset writedown recognise impairment fix asset group recognise cost respect plan integration glaxo wellcome smithkline beecham business additional cost incur implementation integration follow merger continue cost recognise provision respect identify severance expect incur respect programme encourage staff convert glaxo wellcome smithkline beecham share option glaxosmithkline share option employee exercise option provision legal dispute matter include amount relate antitrust product liability contract termination selfinsurance environmental cleanup property rental company director take legal advice establish provision take account insurance agreement regard relevant fact circumstance matter accordance accounting requirement provision unasserted claim ultimate liability matter vary amount provide dependent outcome litigation proceeding investigation possible settlement negotiation glaxosmithkline involve number legal dispute include notification possible claim early stage matter reliable estimate outcome accordingly provision record matter unasserted claim nature group business number matter subject negotiation litigation year large individual amount provide expect settle year discussion litigation issue refer legal proceeding note contingent liability contingent liability comprise guarantee discount bill item arise normal course business amount december million millionnote financial statement glaxosmithkline net debt liquid investment cash bank loan overdraft year bank loan overdraft commercial paper eurobond mediumterm note obligation finance lease loan loan year bank loan eurobond mediumterm note private financing loan stock obligation finance lease loan net debt balance sheet date group liquid investment aggregate market value million million loan overdraft year commercial paper comprise billion programme million issue december december million back committed facility day duration million renewable annually liquid investment million weight average interest rate commercial paper borrowing december cent loan year million cent coupon bond usdollar denominated float rate bond total million issue european medium term note programme group raise million float rate debt private financing arrangement redeem group time particular event accelerate event increase cost funding group loan year repayable period follow year year year year year loan repayable year carry interest effective rate cent cent repayment date range glaxosmithkline note financial statement net debt continue secure loan loan amount million million secure charge fix current asset finance lease obligation rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total finance lease obligation financial instrument information give note commitment capital commitment contract provide financial statement intangible fix asset tangible fix asset number commitment licensing agreement principally elbion adolor corporation theravance inc unigene laboratories inc payment future milestone achieve agreement relate compound early stage development milestone payment continue number year compound successfully development process generally close product marketing approval great possibility success group commitment million relate payment licence alliance principally exelixis inc commitment operating lease pay rental year operating lease land building expire year year year operating lease plant equipment vehicle expire year year year commitment operating lease pay rental future year note financial statement glaxosmithkline share share capital share premium account redeemable preference share ordinary share ccm number number share capital authorise december december share capital issue fully pay january share capital redeem par share capital issue share option scheme share capital purchase cancel december share capital issue share option scheme share capital purchase cancel december number number share issuable outstanding option note december december number unissue share option december december redeemable preference share redeem company august nominal redeemable preference share convert ordinary share penny result authorise share capital december billion ordinary share pence october glaxosmithkline commence new billion share buyback programme follow completion billion buyback programme announce total millionwa spend million relate new buyback programme exact time future purchase determine group dependent market condition factor period january march share purchase cancel cost million detail substantial shareholding refer substantial shareholding nonequity minority interest smithkline beecham holdings corporation sbh corp subsidiary incorporate delaware usa issue million flexible auction market prefer stock flex amp comprise share issue series dividend half share fix issuance seven year period dividend half fix year period end vary predominately prevail interest rate set seven week auction share trade sbh corp issue million auction rate preference stock arp comprise share issue series dividend vary condition similar flex amp describe arp flex amp constitute preference share represent nonequity minority interest smithkline beecham plc certain circumstance guarantee payment dividend declare preference share smithkline beecham plc agree sbh corp certain circumstance provide support sbh corp relation principal guarantee support limit circumstance holder preference share favourable position holder preference share smithkline beecham plc preference share represent longterm nonequity minority interest group balance sheet accordance frs capital instrument uitf obligation capital instrument glaxosmithkline note financial statement profit loss account total reserve reserve restate restate december goodwill write exchange movement tax exchange movement share issue profit attributable shareholder dividend revaluation goodwill exchange december goodwill write exchange movement share purchase cancellation profit attributable shareholder dividend revaluation goodwill exchange december exchange movement uktax exchange movement share purchase cancellation profit attributable shareholder dividend unrealise gain equity investment december goodwill arise acquisition january write reserve amount million include goodwill million previously hold goodwill reserve offset reserve goodwill write relate primarily disposal affymax group hold quest diagnostic inc goodwill denominate local currency subject revaluation amount million december goodwill acquisition january capitalise accordance accounting policy set note exchange movement take reserve include loss million loss million loss million foreign currency loan deposit gain million loss million gain million retranslation net asset nil loss million loss million goodwill eliminate reserve tax exchange movement year million nil million credit relate taxable element foreign currency loan deposit take reserve exchange adjustment debit reserve cumulatively million reserve include merger reserve create merger glaxo wellcome smithkline beecham amounting million december million million reserve include capital redemption reserve create result share buyback programme amount million december million nil total reserve amount million december million million million million nil relate company million million million relate joint venture associate undertakings profit glaxosmithkline plc year million million december december nil dividend million million december december nil give retain profit million million december december nil cost share purchase cancellation million million december december nil unrealise profit capital reduction subsidiary million nil december december nil profit loss account reserve december stand million million nilnote financial statementsglaxosmithkline legal proceeding fda approve pentech anda glaxosmithkline believe pentech capsule group involve legal administrative substitutable paxiltablet proceeding principally product liability intellectual property antitrust governmental investigation relate private october glaxosmithkline file action synthon litigation significant matter describe pharmaceutical district court middle district north carolina infringement group patent intellectual property paroxetine hydrochloride paroxetine mesylate synthon usa number distributor generic drug file file application paper nda fda application fda market generic version paroxetine mesylate different salt form paroxetine paxilseroxatparoxetine hydrochloride prior expiration market form paxil fda approve group patent paroxetine hydrochloride synthon application glaxosmithkline believe synthon hemihydrate distributor looking bring market compound substitutable paxil briefing anhydrate version paroxetine hydrochloride summary judgement motion file party case paroxetine mesylate case complex group complete motion remain pende trial date believe generic anhydrate version infringe set hatchwaxman stay fda approval synthon contain andor convert hemihydrate form application expire april andor infringe group patent response group file action distributor infringement follow expiration datum exclusivity period europe group patent market authorisation issue synthon bvgenthon october regulatory authority denmark paroxetine july glaxosmithkline file action apotex mesylate different salt form paroxetine district court northern district illinois infringement market form seroxatpaxil marketing authorisation group patent paroxetine hydrochloride hemihydrate grant european country national apotex file abbreviate new drug application anda approval approval mutual recognition process fda seek approval introduce generic form paxil base original danish approval generic product contain follow trial february judge rule paroxetine mesylate launch denmark germany glaxosmithkline patent valid infringe apotexs netherlands austria ireland sweden italy product glaxosmithkline appeal rule non product austria denmark withdraw follow infringement court appeal federal circuit award patent interim injunction group initiate cafc hears appeal usdistrict court litigation challenge approval danish medicine agency intellectual property matter ground authorisation grant june glaxosmithkline file action geneva abridge procedure paroxetine mesylate pharmaceutical subsidiary novartis pharmaceutical essentially similar seroxat marketing authorisation district court eastern district pennsylvania issue european country product contain infringement group patent paroxetine hydrochloride paroxetine hydrochloride anhydrate variant group follow notice genevas anda filing case product generic product contain anhydrate consolidated similar infringement action market germany austria denmark netherlands spain generic company subsequently file andas additional sweden finland glaxosmithkline believe marketing infringement action bring base patent issue paroxetine hydrochloride anhydrate product paroxetine subsequent original filing apotex northern mesylate product party european country infringe district illinois group file action apotex patent litigate position action european relate new patent eastern district pennsylvania country outside usa june european patent december judge grant deny office opposition division reject opposition file synthon summary judgement motion file apotex result group european patent cover crystal form issue validity infringement new patent paroxetine mesylate synthon product decision trial glaxosmithkline petitioned district appeal contrast follow action initiate court permit interim appeal cafc expire synthon court revoke correspond patent relate hatchwaxman stay fda approval apotex anda expire paroxetine mesylate december appeal september court appeal expect commence february dutch court revoke correspond dutch february cafc hear apotexs appeal decision patent decision appeal district court district columbia deny apotexs request fda require delist certain response challenge basf group patent group patent paxilfrom orange book cafc paroxetine hydrochloride anhydrate high court rule matter addition apotex apply july judge decide patent partly valid court litigation eastern district pennsylvania partly invalid claim hold valid assert apotex order glaxosmithkline delist certain patent neolab waymade healthcare interim injunction prevent sale version product grant march glaxosmithkline file action pentech november decision grant injunction affirm pharmaceutical district court northern district appeal early february trial relate allege illinois infringement group patent paroxetine infringement allege invalidity place june hydrochloride pentech file anda capsule version paxil assert compound presentation infringe group patent patent invalid glaxosmithkline note financial statement legal proceeding continue month hatchwaxman stay final fda approval expire april final fda approval hold view geneva pharmaceutical commence action right day marketing exclusivity hold district court eastern district virginia andrx patent recently issue glaxosmithkline cover clavulanic acid key ingredient augmentinand timentin geneva ask group file action infringement patent court declare new patent expire cefuroxime axetil active ingredient group ceftinanti invalid august geneva extend complaint cover infective product ranbaxy pharmaceutical district additional patent expire september court new jersey preliminary injunction grant teva pharmaceutical file similar action challenge favour group cafc subsequently vacate recently issue patent patent expire december injunction remand case district court cover augmentin december ranbaxy pharmaceutical trial merit ranbaxy launch generic version file action challenge patent expire march trial schedule begin july ranbaxy teva action consolidated patent group claim infringement expire geneva case december march hearing group seek monetary damage base tevas motion summary judgement trial judge hold ranbaxys sale group file similar action apotex group patent expire invalid second distributor generic pharmaceutical product consolidate trial judge rule district court northern district illinois preliminary patent expire invalid fda grant injunction grant favour group june apotex approval company lek pharmaceutical subsequently obtain fda approval generic product generic product market usa trial apotex conclude january group continue believe patent valid appeal date report decision announce district court decision cafc hearing appeal august group commence action district hear march date report court district new jersey reddycheminor cafc rule appeal reddys laboratory allege infringement patent august group commence proceeding ondansetron active ingredient zofrantablet fda approval geneva pharmaceuticals parent novartis biochemie anda file reddy stay early january gmbh biochemie spa international trade resolution patent infringement litigation march commission colorado state court alleging group file similar action teva allege manufacture sale usa genevas genericaugmentin invalidity noninfringement method use patent product production strain steal early compound patent expire district court glaxosmithkline constitute misappropriation group trade district delaware trial date november secret unfair competition proceeding seek prevent set teva case ondansetron case involve importation sale usa generic augmentin orally disintegrate zofran tablet commence february contain clavulanate steal glaxosmithkline kali laboratorie district court production strain colorado action seek damage district new jersey similar state court action initiate teva lek august group commence action district ranbaxy court district new jersey teva allege distributor generic pharmaceutical product file infringement group compound patent lamotrigine andas sustain release bupropion hydrochloride tablet active ingredient lamictaloral tablet patent expire july wellbutrin srand zyban usa accompanied case defendant file anda fda certification invalidity group patent group certification invalidity group patent fda approval bring suit patent infringement filing anda stay early january resolution party group file suit andrx pharmaceutical patent infringement litigation case early stage file anda district court southern district october pfizer inc file action bayer florida february district court judge grant andrxs glaxosmithkline district court district summary judgement motion rule product delaware allege manufacture sale levitra infringe group patent group appeal decision vardenafil infringe patent newly issue pfizer cafc oral argument appeal hold ask bayer glaxosmithkline permanently enjoin december date report cafc case early stage rule appeal action file watson pharmaceutical district court southern district january cipla neolab file action high ohio eon labs manufacture district court court seek revocation group patent relate southern district new york impax laboratorie district asthma treatment seretideadvair patent set expire court northern district california excel include supplementary protection certificate protection pharmaceutical district court district new relate combination active ingredient salmeterol jersey district court eastern district virginia fluticasone propionate separate patent exist watson case settle judge grant summary challenge provide patent protection judgement noninfringement impax excel case late seretide patent example appeal cafc summary judgement relate diskusdevice cfcfree mdi device deny eon eons motion reconsideration judge expire respectively confirm denial summary judgement trial date challenge challenge group patent set eon case point eon distributor relate seretideadvairin usa countries tentative fda approval generic version productnote financial statementsglaxosmithkline legal proceeding continue follow report yale haemorrhagic stroke project find suggestion association use february group receive paragraph notification phenylpropanolamine ppa decongestant haemorrhagic noninfringement patent relate film coat forimitrex stroke group manufacturer voluntarily sumatriptan connection anda filing ranbaxy withdraw consumer healthcare product ppa active respect imitrex paragraph notification extend ingredient ppa product withdrawal group basic patent product expire name defendant numerous personal injury class action lawsuit file state federal court allege personal injury february fda website post receipt agency increase risk injury use product contain ppa anda filing respect valtrex date report unfair deceptive business practice plaintiff seek remedy group receive notice paragraph notification include compensatory punitive damage refund invalidity andor noninfringement respect product federal case consolidate multidistrict litigation group patent active ingredient valtrex proceed district court district washington valaciclovir expire judge responsible proceeding initially deny class certification strike class allegation federal personal product liability injury consumer refund class action grant plaintiff leave fda aware report cardiac valvular file renew motion certify consumer refund class problem individual fenfluramine dexfenfluramine consist person possess ppacontaining product combination phentermine prescribe time fda advisory november subsequently regimen weight reduction request voluntary judge deny renew motion lawsuit early withdrawal fenfluramine dexfenfluramine market stage final determination report cardiac valvular problem subsequent lawsuit file state court permit proceed withdrawal product market spawn numerous class action class certification deny california state product liability lawsuit file manufacturer court appeal motion class certification distributor fenfluramine dexfenfluramine phentermine pende pennsylvania state court number manufacturer phentermine group august bayer withdraw baycolcerivastatin sodium defendant thousand lawsuit state federal worldwide light report adverse event include death district court usa file class involve rhabdomyolosis glaxosmithkline participate action lawsuit seek relief include combination marketing baycol usa pursuant copromotion compensatory punitive damage medical monitoring agreement bayer license holder refund purchase drug judicial panel manufacturer product follow withdrawal bayer multidistrict litigation issue order consolidate transferring glaxosmithkline name defendant thousand federal action district court eastern district lawsuit file state federal court usa behalf pennsylvania court approve global settlement propose individual putative class baycoluser defendant wyeth sell fenfluramine dexfenfluramine number suit allege plaintiff suffer personal settlement subsequently confirm circuit court injury include rhabdomyolosis use baycol appeal include phentermine defendant claim person take baycol injure include group individual plaintiff elect opt risk future injury suffer economic damage class settlement pursue claim individually wyeth purchasing baycol plaintiff seek remedy include continue settle individual state court case trial compensatory punitive statutory damage creation group continue dismiss lawsuit settle fund medical monitoring glaxosmithkline bayer wyeth corporation principal subsidiary bayer sign glaxosmithkline receive purport class action lawsuit file allocation agreement bayer corporation agree state federal court usa allege paroxetine pay cent settlement compensatory damage active ingredient paxil addictive cause dependency judgement party retain responsibility withdrawal reaction plaintiff seek remedy include attorney fee punitive damage federal case compensatory punitive statutory damage cost consolidated multidistrict litigation proceed fund medical monitoring january federal district district court district minnesota lawsuit court judge california deny class action certification early stage determination permit counsel plaintiff file motion lawsuit group party certification remain lawsuit early permit proceed class action stage determination glaxosmithkline number pharmaceutical lawsuit pende state federal court company name defendant number permit proceed class action purport class action numerous individual personal injury decade litigation lawsuit state federal district court usa allege manufacturer prozac sustain serotonin reuptake thimerosal preservative vaccine cause inhibitor ssri products paxil homicidal suicidal neurodevelopmental disorder injurie plaintiff seek behaviour exhibit user product group remedy include compensatory punitive statutory damage receive claim lawsuit respect paxil cost fund medical monitoring research purport class action lawsuit early stage determination purport class action permit proceed class action glaxosmithkline note financial statement legal proceeding continue antitrust november federal trade commission ftc staff follow voluntary withdrawal lotronex usa advise group staff conduct nonpublic november number lawsuit file investigation determine group violate group state federal district court include individual section federal trade commission act monopolize personal injury action purport class action assert attempt monopolize market paroxetine product liability consumer fraud claim plaintiff seek remedy hydrochloride prevent generic competition paxil include compensatory punitive statutory damage request group submit certain information connection number claim settle remain action investigation group cooperate staff early stage tentative trial date investigation case set early follow public reference ftc investigation paxil government investigation purport consumer class action file district glaxosmithkline receive subpoenas attorney court eastern district pennsylvania behalf putative office boston massachusetts request production class indirect purchaser include consumer party document period present relate payer plaintiff claim group monopolise repackage relabelle private label arrangement market paxilby bring allegedly sham patent litigation glaxosmithkline discuss thirdparty customer allegedly abuse regulatory procedure list period issue price charge patent fda orange book treble damage seek party glaxosmithkline product count allege overcharge flow conduct case medicaid good price purpose group receive letter early stage determination center medicare medicaid services cms state permit proceed class action cmss position certain price pharmaceutical business smithkline include medicaid good price request beecham glaxo wellcome group party number glaxosmithkline retroactively adjust good price report antitrust suit certain certify class action quarter prior july include price group institute nation retail pharmacy consumer involve discussion attorney office resolve state allege conspiracy restraint trade issue challenge pricing practice group significant glaxosmithkline respond subpoenas number pharmaceutical company wholesaler office inspector general department health sue similar litigation action human services department justice state action bring state court texas california connection allegation consolidate pretrial purpose district court pharmaceutical company include glaxosmithkline northern district illinois federal class action component violate federal fraud abuse law federal false include pharmacy represent approximately twothird claim act respect texas california comparable total retail sale volume settle glaxo wellcome state law result way certain drug price smithkline beecham time group way medicare medicaid programmes reimburse enter settlement satisfactory term group drug nevada montana state attorney general engage conspiracy admission file civil lawsuit state court glaxosmithkline wrongdoing include final agreement drug company action claim behalf august district court district state payer behalf instate patient massachusetts rule group patent nabumetone relafen consumer damage restitution base defendant invalid anticipatory art unenforceable ground price undefined set pharmaceutical product inequitable conduct group file appeal decision quarter county suffolk new york november august cafc issue decision file action federal court assert claim affirm district court judgement invalidity decline glaxosmithkline relate report average rule judgement inequitable conduct follow wholesale price certain drug cover states medicaid district court decision antitrust claim allege competitive injury program new york state attorney general file similar overcharge file teva generic manufacturer complaint new york state court addition private payer class nabumetone purport class direct purchaser action lawsuit file glaxosmithkline payer individual group purport direct purchaser federal district state court number federal case plaintiff claim base allegation fraudulent consolidated multidistrict litigation proceed procurement patent wrongful listing patent fda district court district massachusetts orange book prosecution sham patent infringement civil suit file state attorney general class action plaintiff litigation case originally file district remove federal court remove case court district massachusetts eastern district include nevada montana case consolidate pennsylvania pende district massachusetts district massachusetts proceeding step early stage determination take consolidate remove case nevada putative class action permit proceed montana private class action plaintiff class action originally file state court seeking case remand respective state court action early stagesnote financial statementsglaxosmithkline legal proceeding continue proceeding seek require operator hazardous waste facility transporter waste site generator district court eastern district virginia hazardous waste dispose site clean site find patent cover augmentin invalid group reimburse government cleanup cost instance file appeal decision pende glaxosmithkline involve allege generator hazardous cafc immediately follow adverse trial court decision waste site glaxosmithkline purport antitrust class action file behalf consumer involve current operator facility party payer federal court superfund provide defendant jointly severally transfer consolidated district court liable cleanup cost proceeding frequently resolve eastern district virginia plaintiffs allege group basis nature quantity waste dispose knowingly obtain invalid patent engage site generator glaxosmithkline proportionate liability anticompetitive conduct prevent entry generic product cleanup cost substantially determined violation monopolization section antitrust law site refer plaintiff seek declaratory injunctive relief treble damage allege overcharge glaxosmithkline potential liability vary greatly site site determination putative class action cost investigation study remediation site early stage permit proceed class action time substantial glaxosmithkline routinely accrue separately group prosecute patent infringement suit amount related share liability matter company file anda seek permission sell generic bupropion wellbutrin srzyban tax matter case summary judgement enter pende tax matter describe note group follow adverse ruling patent litigation purport class action behalf purchaser party payer file district court eastern district pennsylvania allege group engage anticompetitive conduct include prosecution sham patent infringement litigation prevent entry generic product plaintiff seek declaratory injunctive relief treble damage allege overcharge commercial matter otsuka pharmaceutical ltd initiate arbitration proceeding december concern group unilateral withdrawal grepafloxacin raxarvaxar october safety reason otsuka allege product withdrawal simultaneous public announcement constitute material breach license supply agreement group believe underlie product withdrawal consistent term agreement valid defence exist claim arbitration panel select meet hear determine liability schedule december smithkline beecham clinical laboratory indemnitie connection sale smithkline beecham clinical laboratory sbcl quest diagnostics inc group agree indemnify quest diagnostic aftertax basis respect certain liability arise conduct sbcl business prior closing include governmental private claim arise government investigation sbcls billing marketing practice environmental matter glaxosmithkline notify potential responsibility relate past operation past waste disposal practice certain site primarily usa matter subject litigation include proceeding initiate federal state government waste disposal site remediation cost tort action bring private party glaxosmithkline advise responsible party approximately site appear national priority list create comprehensive environmental response compensation liability act superfund glaxosmithkline note financial statement acquisition disposal detail acquisition disposal subsidiary associate undertaking joint venture give book fair value net asset goodwill cost value adjustment acquire capitalise acquisition acquisition iterfi sterilyo human kft iterfi sterilyo group acquire iterfisterilyo group initial cash consideration million payment payable maximum million depend financial performance acquire company net asset iterfisterilyo incorporate financial statement provisional fair value human kft group acquire vaccine relate asset human kft manufacturing business locate hungary cash consideration million disposal clinical laboratory cash refund million receive respect indemnify liability arise clinical laboratory disposal occur refund result successful case court appeal clinical iterfi human laboratory sterilyo kft total cash flow cash consideration pay cash acquire net cash payment acquisition net cash proceed disposal book fair value net asset goodwill cost value adjustment acquire capitalise acquisition acquisition block drug shionogi joint venture block drug company inc january group acquire block drug cash consideration million represent fair value asset acquire shionogi joint venture group establish joint venture shionogi develop commercialise number compound contribute party group acquire cent equity share capital cash consideration million commit contribution certain development milestone achievednote financial statementsglaxosmithkline acquisition disposal continue disposal quest diagnostic inc group disposed million share investment quest diagnostic inc cash proceed million reduce group hold december cent recognise charge goodwill previously write reserve million profit million recognise affymax group complete sale affymax business affymax inc new hold company million nonvoting preference share affymax inc represent value million million recognise charge goodwill previously write reserve million loss million disposal cost million incur completing sale tagamet february group sell tagamet japan sumitomo pharmaceutical ltd cash consideration million recognise charge goodwill previously write reserve million loss million recognise quest diagnostic affymax tagamet block drug shionogi total cash flow cash consideration pay cash acquire net cash payment acquisition net cash proceed disposal book fair value net asset goodwill cost value adjustment acquire capitalise acquisition acquisition glaxosmithkline pharmaceuticals acquisition minority interest glaxosmithkline pharmaceuticals group acquire cent glaxosmithkline pharmaceutical polfa poznan poland cash consideration million goodwill million capitalise amortise line initial acquisition disposal affymetrix inc group sell million share affymetrix inc cash proceed million realise profit million clinical laboratory final cash settlement million million pay october complete sale clinical laboratory clinical glaxosmithkline laboratory affymetrix pharmaceutical total cash flow cash consideration pay cash acquire net cash payment acquisition net cash proceed disposal glaxosmithkline note financial statement financial instrument relate disclosure fair value financial asset liability table present carry amount policy gaap fair value group financial asset discussion group objective policy liability december december management offinancial instrument associate risk debtor creditor year exclude include treasury policy operate financial review prospect fair value financial asset liability include atthe instrument exchange investment current transaction willing party force group hold number equity investment frequently liquidationsale follow method assumption entity group enter research collaboration estimate thefair value group seek realise value investment equity investment market value base quote market inpart research collaboration help create price case list investment market value certain investment regard available sale reference quote price similar company recent account foras current asset investment purpose finance information case material unlisted ofusgaap current asset investment classify investment available sale cash bank approximate carry glaxosmithkline hedge equity value liquid investment base quote market price similar holding large equity investment quest diagnostic inc company recent financing information case series variable sale forward contract contract marketable security approximate carry equity collar structure series inthe case time deposit short maturity million quest share mature shortterm loan overdraft approximate carry short maturity instrument group liquid investment represent fund surplus mediumterm loan market value base quote market immediate operating requirement account price case eurobond fix rate current asset investment purpose usgaap borrowing approximate carry case investment classify available sale proceed offloate rate bank loan loan sale investment classify available saleunder gaap forward exchange contract base market price year end stdecember weremillion exchange rate balance sheet date proceed include rollover liquid fund shortterm deposit currency swap base market valuation balance gross gain loss reflect consolidated profit sheetdate loss account respect investment classify available sale equity collar fair value determine base option gaap million andmillionrespectively pricing model interest rate instrument base market valuation foreign exchange risk management balance sheet date group enter forward foreign exchange contract debtor creditor approximate carry inorder swap liquid asset borrowing currency provision approximate carry require group purpose december group auction rate preference stock approximate carry outstanding contract sell purchase foreign currency case float rate instrument total notional principal million flexible auction market prefer stock base market million majority contract period valuation balance sheet date month end year group number currency swap fair value investment share inplace respect mediumterm debt instrument group december investments share million million fair value borrowing denominate swap foreign currency million million difference match investment overseas group asset treat carry fair value represent unrealised ahedge relevant net asset exchange gain loss million valuation shortfall consider loss record reserve represent permanent diminution value context length future period relate share option interest rate risk management exercise accordingly provision manage fixedfloate interest rate profile debt group investment exclude financial instrument disclosure interest rate swap outstanding commercial bank fair value market value base quote market price december share represent purchase employee share ownership concentration credit risk credit exposure trust satisfy future exercise option award financialinstrument employee incentive scheme purchase match group believe expose major concentration option predetermine exercise price gain loss credit risk group expose creditrelate loss recognise measured exercise price event nonperformance counterpartie financial market value instrument expect counterpartie fail meet obligation group apply boardapprove limit credit exposure counterparty employ strict minimum credit worthiness criterion choice counterpartynote financial statementsglaxosmithkline financial instrument relate disclosure continue classification fair value financial asset liability follow table set classification financial asset liability provide reconciliation group net debt note shortterm debtor creditor exclude financial asset liability provision include contractual obligation settle cash carry fair carry fair value value net debt liquid investment cash bank current asset financial instrument sterling note bond dollar note bond private financing note bond swap dollar currency swap interest rate swap note bond swap yen currency swap mediumterm borrowing shortterm loan overdraft total borrowing interest rate swap total net debt fix asset equity investment current asset equity investment debtor year creditor year provision foreign exchange derivative equity collar auction rate preference stock flexible auction market prefer stock total nonequity minority interest total financial asset liability total financial asset total financial liability appropriate currency interest rate swap present alongside underlie principal instrument carrying amount instrument adjust effect currency interest rate swap acting hedge difference carry fair value equity fix current asset liquid investment represent gross unrealised gain million million respectively glaxosmithkline note financial statement financial instrument relate disclosure continue currency interest rate risk profile financial liability financial liability take account currency interest rate swap analyse total financial liability comprise total borrowing million million creditor year million million provision million million nonequity minority interest preference share million million exclude foreign exchange derivative nil million creditor year exclude benchmark rate determine interest payment float rate financial liability table libor fix rate noninterest bearing weight weight average average weight december interest year float average rate rate rate year total currency fix maturity dollar sterle euro japanese yen currency fix rate noninterest bearing weight weight average average weight december interest year float average rate rate rate year total currency fix maturity dollar sterle euro japanese yen currency currency interest rate risk profile financial asset total financial asset comprise fix asset equity investment million million current asset equity investment million million liquid investment million million cash bank million million debtor year million million exclude foreign exchange derivative million nil benchmark rate determine interest receipt float rate asset table libor december fix float noninterest rate rate bear total currency dollar sterle euro japanese yen currency december fix float noninterest rate rate bear total currency dollar sterle euro japanese yen currency note financial statementsglaxosmithkline financial instrument relate disclosure continue currency exposure net monetary assetsliabilitie group currency exposure rise net currency gain loss recognise profit loss account arise principally company sterle functional currency monetary asset liability denominate overseas functional currency andborrowing designate hedge overseas net asset exclude table stdecember functional currency group operation net monetary assetsliabilitie sterle euro yen total hold nonfunctional currency sterle dollar euro japanese yen stdecember functional currency group operation net monetary assetsliabilitie sterle euro yen total hold nonfunctional currency sterle dollar euro japanese yen nonequity finance minority total total debt lease interest maturity financial liability year demand year year year gain loss net hedge unrecognise gain loss begin year gain loss arise previous year recognise year gain loss arise beginning year unrecognised end year unrecognised gain loss arise year total unrecognised gain loss end year expect recognise year expect recognise year total unrecognised gain loss end year unrecognised gain loss represent difference carry fair value currency swap interest rate swap equity collar foreign exchange derivative commit facility group commit facility commercial paper programme million million day duration renewable annually december undrawn commit facility total million glaxosmithkline note financial statement employee cost wage salary social security cost pension postretirement cost cost sharebase incentive plan severance cost arise integration restructuring activity pension postretirement cost arise integration group provide benefit employee commensurate local practice individual country include market healthcare insurance subsidise car scheme personal life assurance information director remuneration give remuneration report page average number person employ group include director year number number number manufacturing sell general administration research development average number group employee exclude temporary contract staff number group employee end financial year give financial record pension postretirement cost pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme postemployment cost analyse fund define benefithybrid scheme unfunded define benefit scheme define contribution scheme unfunded postretirement healthcare scheme postemployment cost pension postretirement cost arise integration include ukpension cost exceptional charge million relate pension augmentation redundancy arise manufacturing restructuring plan pension group undertaking operate pension arrangement cover group material obligation provide pension retire employee thesearrangement develop accordance local practice country concern pension benefit provide state scheme define contribution scheme retirement benefit determine value fund arise contribution pay respect employee define benefit scheme retirement benefit base employee pensionable remuneration length ofservice define benefit scheme include define contribution section aredescribe hybrid scheme table majority case contribution define benefit scheme determine accordance advice independent professionally qualified actuary formal independent actuarial valuation group main plan undertake regularly normally year theasset fund scheme generally hold separately administer trust insure pension cost accounting purpose assess accordance independent actuarial advice generally project unit method spread surplus deficit average expect remain service live respective membership certain country pension benefit provide unfunded basis scheme administer trustee company whereasset hold specific purpose matching liability unfunded scheme provision include provision pension postretirement benefit charge profit respect benefit aggregate ofthe increase year intheassesse liability member service net movement provision set pension inpayment liability generally assess annually accordance advice independent actuariesnote financial statementsglaxosmithkline employee cost continue pension arrangement glaxo wellcome company smithkline beecham company continue operate separately instance include usa pension arrangement merge follow information deal set arrangement accordingly market value asset group fund define benefit pension fund date late actuarial valuation date billion actuarial value asset sufficient cover approximately cent benefit accrue member allow future salary andpension increase define benefit pension scheme account approximately cent group plan asset valuation project benefit term define benefit pension scheme account approximately cent group plan asset valuation project benefit term december group special funding contribution german pension scheme totalling million company review pension position annually contribution appropriate pension cost expect high new actuarial valuation ukand scheme available define benefit pension scheme operate benefit glaxo wellcome employee smithkline beecham employee remain separate scheme close new entrant subsequent employee entitle join define contribution scheme relevant assumption calculate pension cost glaxo wellcome smithkline beecham define benefit scheme accounting purpose follow rate increase future earning discount rate expect longterm rate return investment expect pension increase equity dividend growth regular cost glaxo wellcome pension arrangement million million credit financial statement allowance spread surplus disclose level percentage salary expect future working lifetime exist member year recent triennial actuarial valuation glaxo wellcome scheme funding purpose carry stmarch date asset scheme represent cent actuarial value benefit accrue member allow future salary pension increase trustee pension scheme agree company request grant benefit improvement include cent enhancement entitlement beneficiary allowance improvement funding level fall cent follow valuation normal company contribution scheme remain suspend formal valuation thetotal market value asset hold scheme march million regular cost smithkline beecham scheme million increase accounting cost million allowance spread deficit expect future working lifetime current employee scheme year late valuation carry december date actuarial value scheme asset represent cent actuarial value accrue service liability base assumption total market value asset hold scheme december million usa usa glaxo wellcome smithkline beecham define benefit hybrid scheme merge relevant assumption calculate pension cost accounting purpose follow rate increase future earning discount rate expect longterm rate return investment cash balance creditconversion rate equity dividend growth regular cost scheme million increase accounting cost million allowance spread deficit expect future working lifetime current employee scheme late valuation carry january date actuarial value scheme asset represent cent actuarial value theaccrue service liability total market value asset hold scheme january million glaxosmithkline note financial statement employee cost continue frs disclosure group continue account pension arrangement accordance ssap accounting pension cost transitional provision frs retirement benefit certain disclosure require basis valuation methodology adopt frs define benefit scheme fair value pension scheme asset december compare future pension liability calculate project unit method apply follow assumption usa rest world rate increase future earning discount rate expect pension increase cash balance creditconversion rate inflation rate expect longterm rate return asset fair value asset liability define benefit scheme aggregate datum define benefit scheme group follow usa rest world group average december expect rate fair expect rate fair expect rate fair fair return value return value return value value equitie property bond asset fair value asset present value scheme liability value scheme surplus defer tax liability value scheme deficit defer tax asset group total asset ukand scheme include special contribution pay december allocate equity bond usa rest world group average december expect rate fair expect rate fair expect rate fair fair return value return value return value value equitie property bond asset fair value asset present value scheme liability value scheme surplus defer tax liability value scheme deficit defer tax asset group total note financial statementsglaxosmithkline employee cost continue define benefit scheme define contribution section account balance total million december million define benefit section scheme close new member project unit method value pension scheme liability current service cost increase member scheme approach retirement deficit frs reflect different basis value asset liability compare ssap include immediate impact fair value asset december group operate number unfunded postretirement healthcare scheme principal usa liability frs scheme assess assumption pension scheme assumption future medical inflation cent reduce cent year cent basis liability usscheme assess million million reduce million million taking account defer tax define benefit pension postretirement benefit scheme account frs follow amount record profit loss account statement total recognise gain loss year end december postretirement pension benefit usa rest world group group amount charge operating profit current service cost past service cost curtailmentssettlement amount creditedcharge net interest expect return pension scheme asset interest scheme liability amount record statement total recognise gain loss actual return expect return pension scheme asset experience gainslosse arise scheme liability change assumption relate present value scheme liability movement deficit year deficit scheme january exchange adjustment charge operating profit employer contribution finance incomeexpense actuarial loss recognise statement total recognise gain loss deficit scheme december history experience gain loss difference expect actual return scheme asset percentage scheme asset december experience gainslosse scheme liability percentage present value scheme liability december total recognise statement total recognise gain loss percentage present value scheme liability december glaxosmithkline note financial statement employee cost continue frs valuation basis apply financial statement instead ssap valuation basis effect profit loss account reserve take account defer tax follow restate profit loss account reserve balance sheet pension liability frs pension liability ssap balance sheet postretirement healthcare scheme frs postretirement healthcare scheme provision balance sheet profit loss account reserve include pension postretirement healthcare liability employee share scheme company operate share option scheme option grant employee acquire share adss glaxosmithkline plc grant price share award scheme award grant employee acquire share adss glaxosmithkline plc cost subject tothe achievement performance target detail give relate scheme operate glaxosmithkline separately glaxo wellcome smithkline beecham date merger scheme glaxosmithkline merger glaxo wellcome option outstanding date merger convert glaxosmithkline option smithkline beecham share option wasconverte glaxosmithkline share option smithkline beecham ad option convert glaxosmithkline ad option correspond adjustment grant price glaxosmithkline share option scheme company operate share option scheme savingsrelate share option scheme grant share option scheme normally exercisable year date grant grant savingsrelate share option scheme normally exercisable year save option share option scheme normally grant market price ruling date grant accordance practice majority option savingsrelate share option scheme grant price cent market price ruling date grant option outstanding share option share option savingsrelate scheme share scheme adss share option scheme december weight weight weight number exercise number exercise number exercise price price price december convert option convert option option exercise option cancel december option grant option exercise option cancel december option grant option exercise option cancel december range exercise price order encourage employee convert option exclude savingsrelate share option hold glaxo wellcome smithkline beecham share adss glaxosmithkline share adss programme establish additional cash benefit cent exercise price original option provide employee voluntarily leave group year date merger exercise option early month expiry date original option year date merger cash benefit pay option expire unexercised market price exercise price date expirynote financial statementsglaxosmithkline employee share scheme continue option outstanding share option share option savingsrelate scheme share scheme adss share option scheme december weight late weight late weight late number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total option exercisable option share grant option share adss grant savingsrelate share option grant change effective exercise price outstanding option year option grant december rdmarch option exercisable share option share option savingsrelate scheme share scheme adss share option scheme weight weight weight number exercise number exercise number exercise price price price december december december glaxosmithkline share award scheme group operate performance share plan award grant director senior staff cost percentage award vest base performance group year measurement period performance condition consist part apply cent award condition compare glaxosmithkline total shareholder return tsr period tsr company ukftse index period second performance condition compare glaxosmithkline earning share growth increase ukretail price index year performance period share adss number share adss issuable number number december convert glaxo wellcome award convert smithkline beecham awards awards exercise december award grant award exercise award cancel december award grant award exercise award cancel december award relate share nil relate adss exercisable december glaxosmithkline note financial statement employee share scheme continue smithkline beecham share option scheme date merger smithkline beecham share option exercisable share adss weight weight exercise exercise number share adss issuable outstanding option number price number price december option grant option exercise option cancel convert glaxosmithkline option december smithkline beecham midterm incentive plan smithkline beecham adopt midterm incentive plan mtip participation mtip grant annually senior staff smithkline beecham designate target number share participant base job grade follow threeyear measurement period committee review smithkline beecham total shareholder return relative company comprise ftse index final award proportion target number share cent depend performance measurement period end december cent cent respectively target number share award receipt award defer case share remain mtip result merger outstanding award payable cent target number share end threeyear cycle share adss number share issuable midterm incentive plan number number december award grant award exercise award cancel convert glaxosmithkline awards december glaxo wellcome share option scheme date merger glaxo wellcome option share option grant savingsrelate share option grant exercisable performance condition applicable lapsed savingsrelate share option scheme share option scheme total weighted weight weight exercise exercise exercise number share issuable outstanding option number price number price number price december option grant option exercise option cancel convert glaxosmithkline option december glaxo wellcome share award scheme glaxo wellcome operate long term incentive plan annual incentive plan long term incentive plan grant award share director senior staff nominal cost percentage award vest base performance glaxo wellcome threeyear period annual incentive plan performance bonus consist basic award ofshare matching award threeyear retention period result merger awards long term incentive plan payable retention period annual incentive plan lapse number share issuable share award scheme number december award grant award exercise award cancel convert glaxosmithkline awards december note financial statementsglaxosmithkline employee share schemescontinue employee share ownership trust group sponsor employee share ownership trust acquire hold share glaxosmithkline plc satisfy award employee incentive plan option grant employee share option scheme trustee employee share ownership trust purchase share onthe open market finance provide group way loan contribution expect cost obligation deliver share scheme normally spread period service respect award option grant accelerated charge respect outstanding cost provide share award option exercisable solely result merger share hold share award scheme number share nominal value cost provision market value share hold share option scheme number share nominal value cost provision market value trust acquire hold share meet notional dividend reinveste deferred award smithkline beecham midterm incentive plan trustee waive right dividend share hold employee share ownership trust option pricing purpose value option arrive stockbase compensation adjustment reconciliation accounting principle note blackschole option pricing model assumption model follow riskfree interest rate dividend yield volatility expect life option grant share option scheme year year saving relate share option scheme year year related party transaction glaxosmithkline hold cent interest quest diagnostic inc hold reduce cent february follow quest acquisition unilab corporation december glaxosmithkline quest amend term global trial agreement longterm contractual relationship quest primary provider clinical laboratory testing support group clinical trial testing requirement worldwide february ingram member cet purchase portion land residential property own group adjacent ingrams residence total sale price base independent valuation land group subsequently determine retention residential property long serve business need list property sale independent valuation property june value property offer sale estate agent ingram high offer property purchase group total consideration glaxosmithkline plc investment subsidiary company glaxosmithkline plc initiate internal reorganisation result company acquire direct investment subsidiary company previously hold indirect investment glaxosmithkline note financial statement reconciliation usaccounte principle summary material difference gaap financial statement analyse reconciliation present capitalise interest note represent financial information gaap group capitalise interest usgaap require generally accept accounting principle usgaap require interest incur cost construct fix apply instead ukgaap asset capitalise amortise life asset significant difference gaap computer software ukgaap combination glaxo wellcome plc gaap group capitalise cost incur acquire smithkline beecham plc account merger develop computer software internal use pool interest usgaap transaction software support significant business system account purchase business combination glaxo expenditure lead creation durable asset gaap wellcome acquire smithkline beecham group apply sop accounting cost computer software develop obtain internal use glaxosmithkline plc form effect scheme restrict category cost capitalise arrangement merger glaxo wellcome plc smithkline beecham plc effective thdecember glaxosmithkline plc goodwill intangible fix asset acquire issue share capital glaxo wellcome plc ukgaap goodwill arise acquisition smithkline beecham plc exchange share account purchase method eliminate glaxosmithkline plcupon completion merger shareholder fund additionally ukgaap require shareholder glaxo wellcome hold approximately cent subsequent disposal closure business goodwill shareholder smithkline beecham hold previously take directly shareholder fund charge approximately cent issue share capital income beginning group change glaxosmithkline plc accounting policy forgoodwill intangible asset gaap respect acquisition ukgaap combination glaxo wellcome smithkline beecham goodwill arise acquisition capitalise account merger ukgaap financial amortise period exceed year statement glaxosmithkline ukgaap represent combine financial statement glaxo wellcome smithkline gaap goodwill arise acquisition prior beecham historical basis june capitalise amortise period exceed year july fasb issue sfas gaap business combination qualify goodwill intangible asset sfas require pool interest account glaxo wellcome goodwill long amortise estimate useful life determine accounting acquirer purchase acquisition group instead identify value reporting unit date thdecember gaap financial purpose assess annually potential impairment statement glaxosmithkline prior merger goodwill allocate reporting unit additionally group glaxo wellcome reassesse useful live exist recognise intangible asset view proximity merger date financial year end intangible asset deem indefinite life long date relative insignificance business activity amortise instead test annually potential december december accounting impairment separate intangible asset finite life continue date acquisition practical purpose take amortise useful life stdecember group adopt sfas january reconciliation consolidated income statement implementation sfas result impairment consolidate statement comprehensive income change group goodwill initial impairment million shareholder equity year end december million net tax indefinitelive asset show correspondingly reflect purchase method accounting cumulative effect accounting change theacquisition smithkline beecham glaxo wellcome ukgaap cost incur integrate income statement present gaap format restructure wellcome smithkline beecham block drug certain exceptional item ukgaap product business follow acquisition divestment merger integration cost addition writeoff respectively charge profit loss account post inprocess research development classify acquisition usgaap certain cost consider operate profit allocation purchase consideration affect consolidated balance sheet consolidate statement cash goodwill arise acquisition flow usgaap usgaapformat present ukgaap certain intangible asset relate specific financial statement reflect purchase method compound product purchase party accounting combination glaxo wellcome smithkline develop commercial application capitalise beecham material adjustment usgaap payment compound product require usgaap apply instead ukgaap development receive regulatory theperiod present summary purchase accounting approval charge directly profit loss time adjustment usgaap adjustment provide receive regulatory approval reconciliation profit attributable shareholder equity shareholder fund usgaapnote financial statementsglaxosmithkline reconciliation accounting principle continue result merger certain group option vest immediately require acceleration compensation expense merger transaction cost stockbase compensation expense relate glaxo wellcome incur total mergerrelate transaction cost accelerate vest million disclosure million exclude integration restructuring cost require sfas include note gaap merger transaction cost expense incur usgaap direct acquisition cost additionally group entitle receive tax deduction acquire company include portion purchase treat compensation tax rule employee consideration stock option exercise usemployee year ukgaap treat reduction tax restructuring cost expense usgaap portion requirement record provision restructuring cost credit equity different certain aspect usgaap gaap accordingly adjustment eliminate employee share ownership trust esot ukgaapprovision restructuring cost notmeet gaap share group stock hold esot gaaprequirement arerecorde cost provision represent difference cost option exercise price account marketable security fix asset investment project loss exercise marketable security consist primarily equity security option cover share record profit certain liquid investment ukgaap security loss account life theoption gaap share state low cost net realisable value group stock purchase esot account gaap security available sale statement shareholder equity cost gainsorlosse arise subsequent financial accounting standard sfas accounting issuance share employee satisfy share option certain investment debt equity security carry record adjustment toshareholder equity fair value unrealise gain loss net tax report separate component shareholder equity derivative instrument statement financial accounting standard accounting pension postretirement benefits derivative instrument hedge activity sfas key difference ssap usgaap relation amend sfas sfas interpret define benefit pension plan derivative implementation group adopt group ukgaap effect variation cost effect january sfas establish accounting accumulate successive valuation amortise reporting standard derivative instrument include certain aggregate basis gaap amortisation derivative instrument embed contract collectively transition asset cost past service benefit refer derivative hedge activity improvement separately track experience gainslosse gaap derivative instrument hedging deal aggregate basis amortise recognise balance sheet matching principle outside cent corridor match gain loss hedge contract foreign currency transaction profit relate gaap allow measurement plan asset liability sfas require entity recognise derivative base result late actuarial valuation usgaap assets liability consolidate balance sheet measure require measurement plan asset liability instrument fair value change fair value date financial statement month period record current earning hedge account prior date obtain group designate derivative pension adjustment include impact change qualify hedge instrument sfas sfas prescribe minimum pension liability include accumulate requirement designation documentation hedge comprehensive income relationship ongoing assessment effectiveness order qualify hedge accounting group decide align measurement date pension plan december certain group evaluate contract embed derivative group plan measurement date pension asset consider embed derivative bifurcate liability september separate host contract accordance sfas requirement embed derivative exist clearly impact reflect cumulative effect account closely relate host contract account change million credit net tax income separately host contract derivative disclosure require sfas include note gain loss relate fair value adjustment derivative instrument classify consolidated statement stockbase compensation income cash flow accordance nature gaap share option account equity derivative exercise value issuance price usgaap group apply sfas accounting stockbase compensation fair value book value derivative instrument respect relate accounting interpretation accounting option plan financial asset liability december require option fair value grant date disclose classification fair value financial asset include profit loss vest period option liability table note glaxosmithkline note financial statement reconciliation accounting principle continue comprehensive income statement requirement sfas report comprehensive income valuation derivative instrument provide comprehensive income statement meet ukgaap fair value derivative instrument sensitive movement statement total recognise gain loss page underlie market rate variable group monitor statement comprehensive income usgaap fair value derivative instrument periodic basis derivative year period end december present include interest rate swap cross currency swap value page usgaap statement include standard valuation model counterparty valuation net impact gain loss equity liquid investment party valuation standard valuation model group translation adjustment consider relevant discount rate market yield curve valuation date forward currency exchange rate counterparty recent financial accounting standard board fasb risk significant rate variable obtain market pronouncement source valuation base remain term maturity june fasb approve sfas accounting instrument foreign exchange contract value obligation associate retirement longlive asset forward rate observe quote price relevant market require fair value obligation associate possible group assume party longterm contract retirement longlive asset capitalise economically viable reserve right exercise early cost require implement group termination right economically beneficial right exist effect january group believe contract adoption standard material impact result dividend gaap dividend propose provide year january sfas accounting impairment respect recommend board ofdirector disposal longlived asset adopt group approval shareholders usgaap suchdividends sfas develop accounting model longlive asset provide declare board ofdirector include discontinue operation dispose sale require longlive asset measure lower defer taxation carry fair value cost sell report gaap group implement frs continue discontinue operation adoption sfas defer tax require defer tax account material impact group financial provision basis similar requirement usgaap statement partial provision basis early year consequence profit attributable shareholder equity april sfas rescission fasbstatement shareholder fund ukgaap defer tax amendment fasbstatement technical adjustment usgaap prior period restate correction issue statement update clarifie impact net loss shareholder equity simplifie exist accounting standard group gaap previously report adoption frs believe adoption standard material impact eliminate difference defer tax previously result exist ukgaap usgaap result sfas accounting cost associate exit disposal adjustment primarily relate defer tax effect activity issue june sfas require company usgaap adjustment recognise cost associate exit disposal activity incur date commitment exceptional item exit disposal plan apply prospectively exit item classify exceptional gaap meet disposal activity initiate december group definition extraordinary gaap currently assess impact standard classify operating expense november fasb publish interpretation consolidate statement cash flow guarantor accounting disclosure requirement usgaap cash flow statement report change cash guarantee include indirect guarantee indebtedness cash equivalent include shortterm highly liquid othersfin fin expand accounting guidance investment original maturity month sfass fin provision initial recognition onlythree category cash flow report operating measurement apply guarantee issue modify activity include tax interest investing activity include december disclosure requirement effective capital expenditure acquisition disposal financial year end december group cashflow available sale current asset investment believe adoption fin material andfinance activity include dividend pay statement impact result ofcash flow present january fasb publish interpretation consolidation variable interest entity fin fin cash cash equivalent primary beneficiary entity consolidate certain gaap cash balance include cash bank entity know variable interest entity measurement cash balance usgaap cash cash equivalent principle apply group financial statement include cash bank certain liquid investment original group believe adoption fin maturity month material impact resultsnote financial statementsglaxosmithkline reconciliation accounting principle continue consolidated balance sheet underus gaap asset current asset cash cash equivalent marketable security account note receivable inventory prepaid expense defer income taxis total current asset goodwill intangible asset property plant equipment investment affiliate asset defer income taxis total asset liability shareholder equity current liability cash overdraft account payable shortterm borrowing capital lease obligation income taxis dividend payable deferred income taxis accrue liability total current liability longterm borrowing capital lease obligation liability defer income taxis total liability minority interest contingent liability commitment note shareholder equity common stock share par value share authorise share issue redeemable preference share share par value share authorise nil nil share outstanding additional paidin capital retain deficit cumulative comprehensive loss treasury stock total shareholder equity total liability shareholder equity certain item year end december reclassify comparative purpose glaxosmithkline note financial statement reconciliation accounting principle continue glaxo glaxo smithkline gaap smithkline gaap adjustment gaap reconciliation consolidated income statement revenue cost sale gross profit sell general administrative expenditure research development expenditure trading profit operating incomeexpense amortisation impairment goodwill intangible asset writeoff inprocess acquire product divestment merger transaction cost operate profit share profitslosse joint venture associate undertaking profitloss disposal interest associate disposal business profit interest net interest expense profit ordinary activity taxation taxation profit ordinary activity taxation minority interest preference share dividend net incomeloss cumulative effect change accounting principle cumulative effect change accounting principle net incomeloss basic diluted net incomeloss share cumulative effect change accounting principle gaap pence cumulative effect change accounting principle share usgaappence basic diluted net incomeloss share cumulative effect change accounting principle usgaap pence basic diluted net incomeloss ad cumulative effect change accounting principle gaap cumulative effect change accounting principle ad usgaap basic diluted net incomeloss ad cumulative effect change accounting principle usgaap consolidated statement comprehensive income change shareholder equity usgaap shareholders equity beginning year net incomeloss exchange movement overseas net asset unrealise lossgain equity investment net tax unrealised gainloss liquid investment net tax unrealise gain derivative minimum pension liability cumulative effect change accounting principle comprehensive lossincome dividend share purchase cancel share issue employee share ownership plan share issue purchase smithkline beecham shareholders equity end year certain item year end december reclassify comparative purposesnote financial statementsglaxosmithkline smithkline glaxo glaxo beecham smithkline gaap glaxo smithkline preacquisition gaap glaxo gaap adjustment smithkline gaap gaap adjustment smithkline restate restate usgaap restate restate restate usgaap glaxosmithkline note financial statement reconciliation accounting principle continue consolidated statement cash flow usgaap cash flow operating activity net incomeloss adjustment reconcile net income net cash provide operating activity depreciation amortisation intangible asset writeoff inprocess acquire impairment goodwill tangible intangible fix asset gainloss sale fix asset productive asset defer taxis stock compensation tax benefit exercise stock option income associate loss sale associate investment derivative change operate asset liability net acquisition increasedecrease inventory increase trade debtor increase trade creditor increasedecrease pension provision net cash provide operating activity cash flow invest activity acquisition fix asset acquisition intangible asset acquisition smithkline beecham cash receive acquisition acquisition new business net cash acquire proceed disposition fix asset business proceed sale intangible fix asset increasedecrease equity investment net cash inprovide investing activity cash flow financing activity increasedecrease liquid investment proceed additional borrowing reduction debt purchase treasury stock dividend pay net repayment shortterm loan net repayment ofincrease cash overdraft redemption preference share issue subsidiary ordinary share purchase cancellation issue share capital net cash financing activity net increasedecrease cash cash equivalent exchange rate movement cash cash equivalent begin year cash cash equivalent end year supplemental cash flow information cash pay year interest income taxis noncash investing financing activity purchase acquisition date december group acquire outstanding share smithkline beecham exchange share ofglaxosmithkline conjunction acquisition liability assume follow fair value asset acquire fair value share issue fair value liability assume note financial statementsglaxosmithkline reconciliation accounting principle continue follow summary material adjustment profit shareholder fund require gaap apply instead gaap adjustment reflect income statement balance sheet present accordance usgaap restate restate profit profit attributable shareholder gaap smithkline beecham preacquisition profit attributable shareholder gaap merger alignment adjustment usgaap adjustment writeoff smithkline beecham inprocess acquire capitalise interest computer software purchase intangible reversalamortisation goodwill amortisation impairment intangible asset recognition cost sale fair value stepup inventory disposal purchase investment product divestment loss disposal subsidiary pension postretirement benefit stockbase compensation provision esot share derivative instrument restructure tax benefit exercise stock option merger transaction cost defer taxation impairment equity investment net incomeloss gaap cumulative effect change accounting principle cumulative effect change accounting principle net incomeloss cumulative effect change accounting principle restate equity shareholder fund equity shareholder fund gaap usgaapadjustment tangible fix asset investment product right capitalise interest computer software goodwill intangible asset unrealise gain marketable security pension postretirement benefit employee share ownership trust restructuring cost derivative instrument dividend defer taxation shareholder equity gaap certain item year end december reclassify comparative purpose frs defer tax implement group ukgaap frs require defer tax account provision basis partial provision basis early year change account prior year adjustment ukgaap purpose comparative adjustment arrive usgaap restate necessary change impact usgaap results glaxosmithkline note financial statement reconciliation accounting principle continue cthe market value investment include book value smithkline beecham net asset gaap increase acquisition smithkline beecham investment relate increase fair market value gaap financial statement glaxosmithkline prior nonmarketable security december include merger glaxo wellcome gaap account inthis increase equity investment equity acquirer acquisition smithkline beecham account investment measure fair value excess purchase method date merger fair value underlie tangible asset liability thdecember recognise goodwill investment goodwill long amortise review annually impairment purchase accounting adjustment order determine proper allocation purchase price dthe fair value attribute pension obligation reflect related acquire asset smithkline beecham recognition previously unrecognise actuarial gainslosse gaap purchase accounting cost acquisition calculate prior service cost transition amount amount recognise market value share issue fair value vest werebase actuarial assessment acquisitiondate option exchange direct external acquisition cost ethe fair value attribute intangible asset relate allocate fair value net asset acquire result primarily management estimate value product fair value exercise increase value smithkline beecham right inclusive respective patent trade mark inventory tangible fix asset investment pension obligation onexisting product assemble workforce thefair recognise fair market value attribute value product right determine base intangible asset mainly product right inclusive patent discount net future cash flow analysis smithkline beecham trade mark assemble workforce inprocess research approve product portfolio include exist approve development appropriate defer taxation effect product pharmaceutical therapeutic area difference cost acquisition fair value consumer healthcare product portfolio supplemental asset liability smithkline beecham products development process build exist record asgoodwill allocate inprocess research chemical entity exist area andwhich development require gaap expense subject separate food drug administration approval immediately thefirst report period business include management base estimate combination glaxosmithkline period end weight average useful life product right future stdecember fair value adjustment record period substantial majority estimate net inventory expense additional future cash flow value expect realise fair value amortisation depreciation berecorde respect assemble workforce reclassify togoodwill fair value adjustment tangible intangible asset sfas review annually impairment result goodwill period respective economic useful life total consideration allocate smithkline beecham inprocess research development project iprd adjustment asset liability smithkline beecham wasestimate current estimate status reflect fair value allocation excess purchase prospect portfolio iprd include consideration fair value net asset acquire base identify project advance stage development onmanagement good estimate fair value summarise management believe reasonable estimate project thetable opposite discuss cash flow prepare include basic athe total assume purchase consideration calculate discovery portfolio gene patent report iprd bymultiplye number glaxosmithkline share issue value intend reflect present value tosmithkline beecham shareholder outstanding development activity way value allocate smithkline beecham share average fair value glaxo iprd determine utilise risk adjusted income approach wellcome security average fair value glaxo wellcome include earning discount appropriate cost security calculate period day prior capital investment estimate future cash flow relate subsequent theannouncement merger individual iprd project base exist estimate january total assume purchase consideration revenue contribution margin project include fair value smithkline beecham vest gadditional liability relate restructuring cost directly link option exchange vested option glaxosmithkline plan place date acquisition total number smithkline beecham vest option liability reflect cost close certain smithkline beecham multiply bythe respective fair value ordinary manufacturing site redundancy cost liability share adr plan determine thjanuary relate additional defer tax liability previously bthe increase fair value inventory fix asset recognise determined base difference carry hdeferre taxis compute excess fair value value market value asset increase book value goodwill inprocess research inventory expense inventory sell development applicable weighted average statutory increase infix asset allocate respective category tax rate depreciate remain useful life asset goodwill represent remainder unallocated purchase consideration include value originally allocate workforce goodwill long amortise sfas review annually impairmentnote financial statementsglaxosmithkline reconciliation accounting principle continue purchase accounting adjustment total assume purchase consideration outstanding share cost fee transaction book value smithkline beecham net asset gaap goodwill excess fair value inventory excess fair value tangible fix asset excess fair value investment excess fair value pension asset fair value attribute intangible asset fair value attribute workforce consider goodwill fair value attribute inprocess project additional liability assume defer tax liability relate purchase price adjustment goodwill glaxosmithkline note financial statement reconciliation accounting principle continue follow table present detail group total purchase identifiable intangible asset subject amortisation accumulate december gross amortisation impairment net product right brand total follow launch usa generic augmentinproduct carry value product right relate augmentinha review impairment million record carry value certain product right review impairment million record fair value determine discount cash flow model discuss note legal proceeding number distributor generic drug file application market generic version paxilin usa prior expiration group patent carrying value paxilproduct right usgaap billion december group continue position review accumulate december gross amortisation impairment net product right brand total estimate future amortisation expense year purchase identifiable intangible asset subject amortisation december follow year total carrying identifiable intangible asset subject amortisation brand follow initial implementation sfas carry value brand determined indefinite life review impairment million million net tax recognise record cumulative effect change accounting principle addition million charge recognise result change market condition management forecast certain brand intangible follow table present change goodwill allocate group reportable segment carry value assemble workforce december net tax reclassify opening balance goodwill accordance sfas acquire impairment exchange pharmaceutical consumer healthcare total group account goodwill identifiable intangible asset indefinite live sfas year end december impact report usgaap result follow net income usgaap amortisation net tax goodwill brand adjust net income usgaap adjust basic net income share penny adjust diluted net income share pence note financial statementsglaxosmithkline reconciliation accounting principle continue earning share gaap weight average number share issue million million million basic adjustment share option dilute share hold employee share ownership trust exclude share issue taxation restate restate total tax expense gaap current tax expense defer tax expense total tax expense gaap current tax expense defer tax expense total tax expense defer taxation usgaap classification glaxosmithkline defer taxation liability asset gaap follow liability stock valuation adjustment current defer taxation liability accelerate capital allowance product right time difference total defer taxation liability asset intragroup profit time difference current defer taxation asset asset disposal pension postretirement benefit tax loss manufacture restructure legal dispute time difference total defer taxation asset net defer taxation gaap difference effective taxation rate effective taxation rate primarily relate fair value adjustment goodwill intangible relate acquisition wellcome smithkline beecham glaxosmithkline note financial statement reconciliation accounting principle continue segment information usgaap gaap segment information present note include result operation information historical combine glaxo wellcome smithkline beecham basis gaap segment information result operation reflect merge operation glaxosmithkline relate glaxo wellcome period practical purpose regard prior acquisition smithkline beecham glaxo wellcome operate segment pharmaceutical segment information respect asset relate glaxo wellcome smithkline beecham consolidated basis december acquisition smithkline beecham glaxo wellcome occur december restate restate turnover location customer usa europe international external turnover turnover business sector pharmaceutical consumer healthcare external turnover operate profitloss business sector pharmaceutical consumer healthcare operate profitloss turnover location subsidiary undertaking usa europe international gross turnover usa europe international intersegment turnover usa europe international external turnover profit tax location subsidiary undertaking usa europe international operate profitloss share profit joint venture associate undertaking profitloss disposal business andor interest associate net interest expense profitloss taxation profitloss taxation taxation minority interest preference share dividend net incomeloss cumulative effect change accounting principle cumulative effect change accounting principle net incomeloss note financial statementsglaxosmithkline reconciliation accounting principle continue total asset business sector pharmaceutical consumer healthcare total asset total asset location subsidiary undertaking usa europe international total operating asset cash cash equivalent marketable security total asset total liability business sector pharmaceutical consumer healthcare total liability total liability location subsidiary undertaking usa europe international total liability plant land equipment computer asset building vehicle software construction total total tangible fix asset location subsidiary undertaking usa europe international total segment information give separately respect include group europe market region consider group home segment purpose segmental reporting turnover location customer gross turnover intersegment turnover turnover location subsidiary operating profit total asset glaxosmithkline note financial statement reconciliation accounting principle continue pension usgaap sfas disclosure year end december provide relation employee glaxosmithkline income statement disclosure provide relation employee glaxo wellcome group decide align measurement date pension plan certain group pension plan measurement date pension asset liability september group elect change measurement date plan september december result include net loss million credit income million net tax treat cumulative effect change accounting principle average number person employ group include director year number number number manufacturing sell general administration research development pension postretirement cost pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme postemployment cost analyse fund define benefithybrid scheme unfunded define benefit scheme define contribution scheme unfunded postretirement healthcare scheme postemployment cost disclosure include additional information require sfas pension cost major overseas define benefit pension plan restate follow table accordance gaap pension cost million million million respect minor retirement plan recalculate accordance requirement sfas exclude net periodic pension costincome major retirement plan comprise service cost interest cost expect return plan asset amortisation prior service cost amortisation transition obligation recognise net actuarial gain net periodic pension costincome gaap termination benefit curtailment cost adjustment change accounting principle major assumption compute pension costincome rates future pay increase discount rate expect longterm rate return plan asset aggregate average international plan assumption vary significantly assumptionsnotes financial statementsglaxosmithkline reconciliation accounting principle continue change benefit obligation benefit obligation begin year adjustment change accounting principle amendment service cost interest cost plan participant contribution actuarial loss benefit pay acquisition termination benefit curtailment cost exchange benefit obligation end year benefit obligation end year pension plan accumulate benefit obligation excess plan asset change plan asset fair value plan asset begin year adjustment change accounting principle actual return plan asset employer contribution plan participant contribution benefit pay acquisition termination benefit curtailment cost exchange fair value plan asset end year fair value plan asset end year pension plan accumulate benefit obligation excess plan asset plan asset consist primarily investment overseas equity fix interest security security link retail price index property december equity include million glaxosmithkline share million share market value million million fund status fund status unrecognise net actuarial loss unrecognise prior service cost unrecognised transition obligation net recognise amount recognise statement financial position consist prepay benefit cost accrue pension liability additional require liability intangible asset accumulate comprehensive income net recognise glaxosmithkline note financial statement reconciliation accounting principle continue postretirement healthcare usgaap disclosure provide relation employee glaxosmithkline income statement disclosure provide relation employee glaxo wellcome net healthcare cost service cost interest cost amortisation prior service cost net healthcare cost major assumption calculate net healthcare cost rate future healthcare inflation discount rate rate future healthcare inflation reflect fact benefit certain group participant cap change benefit obligation benefit obligation begin year adjustment change accounting principle amendment service cost interest cost plan participant contribution actuarial loss benefit pay acquisition curtailment exchange benefit obligation end year change plan asset fair value plan asset begin year employer plan participant contribution benefit pay fair value plan asset end year fund status fund status unrecognise net actuarial loss unrecognise prior service cost accrue postretirement healthcare cost decrease increase impact cent variation rate future healthcare inflation effect total service interest cost effect provision postretirement benefit note financial statementsglaxosmithkline principal group company follow represent principal subsidiary associated undertakings glaxosmithkline group stdecember detail give principal country operation location headquarters business segment business activity equity share capital undertaking wholly own group percentage interest show company incorporate principal country operation state europe location subsidiary undertaking segment activity england brentford glaxosmithkline service unlimite plc phch glaxosmithkline services plc brentford smithkline beecham plc phch greenford glaxo group ltd brentford smithkline beecham research ltd brentford smithkline beecham investments ltd phch brentford glaxosmithkline research development ltd brentford glaxosmithkline export ltd brentford glaxosmithkline ukltd greenford wellcome foundation ltd brentford wellcome limited phch brentford smithkline beecham swg ltd brentford glaxo operation ltd brentford glaxo wellcome international footnote phch brentford glaxo wellcome investment footnote phch stockley park glaxo wellcome ltd brentford staffordmiller ltd austria vienna glaxosmithkline pharma gmbh belgium genval glaxosmithkline glaxosmithkline belgium rixensart glaxosmithkline biological rixensart glaxosmithkline biological manufacture guernsey peter port insurance ltd phch denmark ballerup glaxosmithkline consumer healthcare smithkline beecham brndby glaxosmithkline pharma finland espoo glaxosmithkline france marly roi glaxosmithkline sante grand publique sas marly roi glaxo wellcome production sas germany buehl glaxosmithkline consumer healthcare gmbh munich smithkline beecham gmbh greece athens glaxosmithkline aebe glaxo wellcome aebe hungary budapest glaxosmithkline kft phch italy verona glaxosmithkline spa milan glaxosmithkline consumer healthcare spa luxembourg mamer glaxosmithkline international luxembourg phch mamer glaxosmithkline luxembourg phch glaxosmithkline note financial statement principal group company continue europe location subsidiary undertaking segment activity netherlands zeist glaxosmithkline zeist glaxosmithkline consumer healthcare norway oslo glaxosmithkline poland poznan glaxosmithkline pharmaceuticals warsaw glaxosmithkline consumer healthcare zoo portugal lisbon glaxosmithklineprodutos farmaceutico lda instituto lusofarmaco lda republic carrigaline smithkline beecham cork ltd footnote ireland carrigaline smithkline beecham manufacturingltd footnote spain madrid glaxo wellcome madrid smithkline beecham sweden mlndal glaxosmithkline switzerland muenchenbuchsee glaxosmithkline investments switzerland gmbh phch muenchenbuchsee glaxosmithkline international switzerland gmbh phch muenchenbuchsee glaxo wellcome international footnote phch muenchenbuchsee glaxosmithkline agformerly glaxo wellcome zug adechsa gmbh turkey istanbul glaxosmithkline ilaclari sanayi ticaret glaxo wellcome isas usa usa philadelphia smithkline beecham corporation phch pittsburgh glaxosmithkline consumer healthcare jersey city block drug company inc wilmington glaxosmithkline financial inc phch wilmington smithkline beecham holdings corporation phch wilmington glaxosmithkline holdings americas inc phch americas bermuda hamilton glaxosmithkline insurance ltd phch canada mississauga glaxosmithkline inc phch asia pacific australia boronia glaxo wellcome australia ltd dandenong smithkline beecham australia pty ltd phch china hong kong glaxosmithkline limit glaxo wellcome china ltd tianjin sinoamerican tianjin smith kline french laboratories ltd india mumbai glaxosmithkline pharmaceuticals ltd footnote nabha glaxosmithkline consumer healthcare ltd smithkline beecham consumer healthcare ltd footnote malaysia selangor glaxosmithkline pharmaceutical sdn bhd darul ehsan new zealand auckland glaxosmithkline limited pakistan karachi glaxo wellcome pakistan ltd philippines manila glaxo wellcome philippines inc singapore singapore glaxo wellcome manufacturing pte ltd singapore glaxosmithkline pte ltd glaxo wellcome asia pacific pte ltd south korea seoul glaxosmithkline korea taiwan taipei glaxo wellcome taiwan ltd pnote financial statementsglaxosmithkline principal group company continue japan location subsidiary undertaking segment activity japan tokyo glaxosmithkline kobe block drug company japan inc latin america argentina buenos aires glaxosmithkline argentina phch brazil rio janeiro glaxosmithkline brasil lda smithkline beecham brasil lda phch colombia bogota glaxosmithkline colombia phch mexico mexico city glaxosmithkline mexico sade phch glaxo wellcome mexico puerto rico san juan glaxosmithkline puerto rico inc hato rey pharmco puerto rico inc venezuela caracas glaxosmithkline venezuela glaxo wellcome middle east africa egypt cairo glaxo wellcome egypt sae south africa midrand glaxosmithkline south africa pty glaxo wellcome south africa pty ltd johannesburg smithkline beecham consumer healthcare pty ltd usa location associated undertaking usa teterboro quest diagnostics inc footnote iii new jersey footnote exempt provision section company amendmentact ireland consolidated subsidiary undertaking accordance section company act ground significant influence iii hold reduce cent february follow quest acquisition unilab corporation incorporate netherlands incorporate republic ireland directly hold wholly own subsidiary glaxosmithkline plc business segment phpharmaceutical chconsumer healthcare business activity ddevelopment eexporte ffinance hholde company iinsurance mmarketing pproduction rresearch sservice detail group subsidiary associate undertaking attach company annual return file registrar ofcompanie glaxosmithkline financial record quarterly trend unaudite analysis provide quarter group result sterle financial year analysis comprise statutory result business performance result pharmaceutical sale therapeutic area profit loss account statutory month cer cer sales pharmaceutical consumer healthcare total sale cost sale sell general administrative expenditure research development expenditure operating cost trading profit pharmaceutical consumer healthcare total trading profit operating incomeexpense operate profit share profitslosse joint venture associate undertaking disposal business product divestment profit interest net interest payable profit ordinary activity taxation taxation profit ordinary activity taxation minority interest preference share dividend earning profit attributable shareholder basic earning share profit loss account business performance sale pharmaceutical consumer healthcare total sale cost sale sell general administrative expenditure research development expenditure operating cost trading profit pharmaceutical consumer healthcare total trading profit operating incomeexpense operate profit share profitslosse joint venture associate undertaking profit interest net interest payable profit ordinary activity taxation taxation profit ordinary activity taxation minority interest preference share dividend adjust earning profit attributable shareholder adjust earning share financial recordglaxosmithkline month month cer cer cer cer cer glaxosmithkline financial record pharmaceutical sale total group cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory seretideadvair flixotideflovent serevent seretideadvair flixotideflovent serevent flixonaseflonase ventolin becotide antiviral hiv combivir trizivir epivir retrovir ziagen agenerase herpe valtrex zovirax zeffix antibacterials augmentin zinnatceftin fortum amoxil metabolic gastrointestinal avandia zantac vaccine hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total pharmaceutical sale financial recordglaxosmithkline pharmaceutical sale usa cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory seretideadvair flixotideflovent serevent seretideadvair flixotideflovent serevent flixonaseflonase ventolin becotide antiviral hiv combivir trizivir epivir retrovir ziagen agenerase herpe valtrex zovirax zeffix antibacterials augmentin zinnatceftin fortum amoxil metabolic gastrointestinal avandia zantac vaccine hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total pharmaceutical sale glaxosmithkline financial record pharmaceutical sale europe cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory seretideadvair flixotideflovent serevent seretideadvair flixotideflovent serevent flixonaseflonase ventolin becotide antiviral hiv combivir trizivir epivir retrovir ziagen agenerase herpe valtrex zovirax zeffix antibacterials augmentin zinnatceftin fortum amoxil metabolic gastrointestinal avandia zantac vaccine hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total pharmaceutical sale financial recordglaxosmithkline pharmaceutical sale international cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory seretideadvair flixotideflovent serevent seretideadvair flixotideflovent serevent flixonaseflonase ventolin becotide antiviral hiv combivir trizivir epivir retrovir ziagen agenerase herpe valtrex zovirax zeffix antibacterials augmentin zinnatceftin fortum amoxil metabolic gastrointestinal avandia zantac vaccine hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total pharmaceutical sale glaxosmithkline financial record year record record financial performance provide analysed accordance current reporting practice sale business segment pharmaceutical consumer healthcare retain business healthcare service pharmaceutical sale therapeutic area central nervous system respiratory antibacterial antiviral metabolic gastrointestinal vaccine oncology emesis cardiovascular arthritis continue business divest product pharmaceutical sale geographic area usa europe international asia pacific japan latin america middle east africa canada international consumer healthcare sale otc medicine oral care nutritional healthcare continue business divest product financial recordglaxosmithkline restate restate restate restate statutory result sale profit taxation earning profit attributable shareholder dividend retain profit return capital employ cent return capital employ calculate statutory profit taxation percentage average capital employ year merger restructure disposal subsidiary manufacture restructuring merger cost product divestment item lossprofit taxation lossprofit attributable shareholder business performance result retain business sale expenditure cent sale trading profit cent sale net interest payable profit taxation adjust earning profit attributable shareholder business performance primary performance measure management present exclude merger item integration restructuring cost disposal business management believe exclusion nonrecurre item provide well comparison business performance period present accordingly information provide supplement include consolidated statement profit loss page prepare accordance ukgaap statutory result include nonrecurre item share statistic earning share dividend glaxosmithkline share glaxosmithkline shareholder glaxo wellcome shareholder smithkline beecham shareholder dividend glaxosmithkline ad glaxosmithkline shareholder glaxo wellcome shareholder smithkline beecham shareholder dividend express term glaxosmithkline sharead merger glaxo wellcome smithkline beecham thdecember shareholders adr holder receive share glaxosmithkline follow ratio glaxo wellcome share glaxosmithkline share smithkline beecham share glaxosmithkline share glaxo wellcome ad glaxosmithkline ad smithkline beecham ad glaxosmithkline adss glaxosmithkline ad represent glaxosmithkline share glaxosmithkline financial record restate restate restate restate net asset fix asset asset liability net operating asset net debt capital employ share capital share premium reserve equity shareholder fund minority interest capital expenditure tangible fix asset number employees usa europe international asia pacific japan latin america middle east africa canada total international manufacturing sell administration research development number employee number permanent employ staff end financial period exclude employee employ manage glaxosmithkline contract basisglaxosmithkline investor information section discuss shareholder return return shareholder form dividend share price movement provide information shareholder shareholder return shareholder information share capital taxation information shareholder glaxosmithkline shareholder return merger glaxo wellcome smithkline beecham dividend merger implement way scheme arrangement glaxosmithkline pay dividend quarterly present expect effective december new hold level dividend quarter company glaxosmithkline plc acquire glaxo wellcome high dividend fourth quarter quarter dividend smithkline beecham accordance agree merger announce time quarterly result announcement term shareholder glaxo wellcome smithkline beecham board declare dividend follows receive exchange exist share share glaxosmithkline follow dividend share pence pence glaxo wellcome ordinary share glaxosmithkline interim pay july ordinary share second interim pay october smithkline beecham ordinary share interim pay january glaxosmithkline ordinary share fourth interim payable april total case share hold american depositary share adss holder glaxo wellcome adrs holders smithkline beecham adrs receive dividend adss guide holder adr table set dividend glaxo wellcome ad glaxosmithkline ad pay ad dollar year dividend smithkline beecham ad glaxosmithkline adss adjust tax credit withholding tax applicable glaxosmithkline share commence trading london stock translate dollar applicable exchange rate exchange glaxosmithkline adss commenced trading april claim refund tax credit dividend new york stock exchange december tax authority negligible benefit shareholders taxation year gsk general information concern tax effect share ownership set taxation information shareholder share price gsk january dividend pay glaxo wellcome smithkline beecham adr high year holder express dividend glaxosmithkline ad low year december dividend calendar december fourth quarter decreaseincrease exdividend date february record date february table set middle market closing price derive payable april london stock exchange daily official list quarter company share price decline cent exdividend date price january record date december compare decrease ftse payable july index cent year year merger share price decline cent second quarter january line similar decrease exdividend date july ftse index period record date august payable october market capitalisation market capitalisation glaxosmithkline december quarter billion date glaxosmithkline large company market capitalisation ftse index exdividend date october record date october payable january smithkline beecham plc float rate unsecured loan stock loan stock list exchange holder require smithkline beecham plc redeem loan stock par loan stock hold business day march june september december holder wish redeem loan stock complete notice loan stock certificate return registrar arrive day relevant redemption dateglaxosmithkline shareholder information ordinary share annual general meeting company share list london stock exchange queen elizabeth conference centre broad sanctuary westminster registrar london swp company share register administer lloyds tsb registrar provide follow service annual general meeting company principal forum communication private shareholder addition formal glaxosmithkline investment plan resolution meeting presentation plan enable shareholder reinvest quarterly dividend chief executive officer performance business andor monthly investment company ordinary future development opportunity question share special deal arrangement board chairman board committee glaxosmithkline individual saving account question matter relate committee glaxosmithkline individual saving account isa investor hold share company nominee service taxefficient way invest company ordinary share arrange nominee service appoint glaxosmithkline corporate sponsor nominee corporate representative proxy respect shareholde corporate sponsor nominee provide facility order attend vote meeting shareholder hold share need share adr holder wish attend meeting obtain proxy certificate shareholder detail hold main bank new york enable attend share register remain confidential meeting vote business transact adr holder shareview service instruct bank new york share shareview portfolio service provide shareholder represent adrs vote complete information investment company shareholder return voting card provide bank new york register service wwwshareviewcouk accordance instruction give share deal facility financial reporting natw stockbroker limit offer sharedealing service financial reporting calendar behalf company shareholder wish buy sell company share announcement quarter result april announcement quarter result july share price information announcement quarter result october share price information available company website wwwgskcom information available ceefax teletext preliminary announcement annual result february cityline call publication annual reportreview march call charge minute plus vat time result announcement american depositary share result announcement issue london stock exchange lse available lse news service company share list new york stock exchange time shortly issue medium form american depositary share adss available website file usa evidence american depositary receipt adr security exchange commission new york stock represent ordinary share exchange adr programme administrator financial report adr programme administer bank new york company publish annual report investor provide follow service need detail report annual review global buydirect available date publication glaxosmithkline global buydirect direct ad purchasesale dividend website reinvestment plan adr holder annual review send shareholder date publication shareholder elect receive report publication write company registrar alternatively shareholder year glaxosmithkline produce separate report elect receive notification email publication financial cover group contribution society corporate report register wwwshareviewcouk social responsibility report cover issue copy previous financial report available company primary interest stakeholder include contribution website print copy obtain registrar society business ethic integrity access medicine customer response center usa community investment environment health safety report available secretariat company head office website wwwgskcom glaxosmithkline share capital nature trading market glaxo wellcome penny share ordinary share company list london fiscal period december high low stock exchange december share list new york stock exchange inthe form american depositary share adss date follow table set period indicate high dollar ad low middle market closing quotation pence share fiscal period december high low london stock exchange derive daily official list high low report sale price dollar adss new york stock exchange derive new york stock exchange composite tape information relate share ad price glaxo wellcome smithkline beecham prior date smithkline beecham pence share merger give fiscal period december high low glaxosmithkline penny share fiscal period december high low quarter end march february dollar ad january december fiscal period december high low november october september quarter end december quarter end september quarter end june quarter end march quarter end december quarter end september quarter end june quarter end march december dollar ad fiscal period december high low quarter end march february january december november october september quarter end december quarter end september quarter end june quarter end march quarter end december quarter end september quarter end june quarter end march december march share capitalglaxosmithkline analysis shareholding number total total number analysis shareholding december account account share share hold share total hold nominee company investment trust company insurance company individual corporate body bny nominee limit total bank new york hold hold bny nominees limited represent company adr programme ad represent ordinary share nominal value march number holder record share usa holdings share thenumberof register holder adr holding adr certain share adrs hold broker nominee result number holder record register holder usa representative number beneficial holder orofthe residence beneficial holder control company far know company directly indirectly own control corporation government thecompany know arrangement operation result change control company substantial shareholding march company receive notification follow interest cent share bnynominee limited hold share represent cent share hold behalf holder american depositary receipt evidence american depositary share legal general investment management limited hold share represent cent barclays plc hold share represent cent far know company person owner cent share company director officer interest director officer company define thecompanie act share option company give remuneration report page exchange control limitation affect securityholder currently law decree regulation restrict import export capital affect remittance dividend orother payment holder companys share nonresident limitation relate nonresident english law company memorandum article association right tobe holder tovote respect company share glaxosmithkline taxation information shareholder information shareholder shareholder summary principal tax consequence holder follow summary certain united kingdom taxation share adr citizen resident united united states federal income tax consideration kingdom united states set relevant usholder share adr summary complete analysis possible tax consequence apply shareholder hold share adr capital purchase ownership security asset citizen resident united states domestic corporation subject united states federal shareholder subject special rule income taxation net income basis respect share doubt taxation position consult adrs resident united kingdom uktax professional advisor purpose hold share purpose trade new ukus income tax convention sign profession vocation carry united kingdom july date set ratification branch agency statement united kingdom united states tax law practice set base taxation dividend law practice force date report gross dividend receive include amount respect associate tax credit withholding tax treat holder adrs generally treat owner foreign source dividend income tax purpose underlie share purpose current united eligible dividend receive deduction allow statesunite kingdom double taxation convention relate corporation dividend adr payable dollars income gain income tax convention estate gift taxis dividend share payable pound sterling dividend estate gift tax convention purpose pay pound sterling include income internal revenue code amend code dollar calculate reference exchange rate follow analysis deal dividend pay day dividend receive holder holder qualify april advance corporation tax act abolish benefit current income tax convention dividend pay date united states united kingdom eligible subject generally applicable limitation receive special shareholder foreign tax credit equal oneninth cash dividend receive share long taxation dividend election include income additional notional april rate tax credit reduce dividend equal tax credit holder ninth result compensate reduction rate tax tax position determine effective use dividend income increase tax bear special foreign tax credit tax liability resident individual shareholder tax credit long repayable shareholder tax liability april rate tax credit reduce associate tax credit ninth act abolish consequently claim refund tax credit dividend pay date taxation capital gain negligible benefit shareholder shareholder liable tax gain disposal share adrs entitle taxation capital gain indexation relief taper relief sale indexation relief generally holder subject capital gain tax calculate market value share march subject tax capital gain realise sale cost subsequent purchase date disposal share adr purchase indexation relief individual shareholder cease april taper relief available individual shareholder estate gift taxis hold deem hold share year estate gift tax convention shareholder sell generally subject inheritance tax inheritance tax stamp duty individual shareholder liable inheritance tax stamp duty case sdrt subject transfer share adrs tax charge certain exemption payable issue transfer share value shareholder estate reduce adr custodian depository rate cent result transfer way gift disposal price issue consideration provide market value exceptionally gift disposal transfer sale value transfer subject inheritance tax estate gift tax consideration estate gift tax convention generally provide sdrt payable transfer adr tax pay united states credit tax payable stamp duty payable transfer adr provide united kingdom instrument transfer execute remain time outside stamp duty transfer adr stamp duty payable rate cent consideration stamp duty case stamp duty reserve tax transfer sale underlie share result sdrt subject certain exemption payable liability stamp duty case sdrt rate purchase share rate cent purchase price cent minimum charge stamp minimum charge stamp duty liability duty liability arise arisesglaxosmithkline cross reference form table provide cross reference information include annual report requirement form item item identity director senior management advisor financial information consolidate statement financial information offer statistic expect timetable financial statement item key information legal proceeding select financial datum significant change risk factor offer list information company share price history history development company markets business overview additional information product memorandum articles association footnote competition material contract regulation exchange control marketing distribution taxation manufacture supply document display research development intellectual property quantitative qualitative disclosure market risk information technology treasury policy environment health safety note financial instrument relate disclosure access medicine develop world description security equity security global community partnership default dividend arrearage delinquencie organisational structure property plant equipment material modification right security holder environmental responsibility use proceed note segment information control procedure note tangible fix asset reserve operate financial review prospect financial statement operating result financial statement director statement responsibility independent auditor report accounting principle consolidate statement profit loss liquidity capital resource consolidate statement total recognise gain loss research development patent license etc consolidated statement cash flow trend information consolidate balance sheet director senior management employee reconciliation movement equityshareholder fund director senior management company balance sheet compensation notesto financial statement remuneration report exhibit board practice corporate governance employee footnote glaxosmithkline people information responsive item incorporate reference note employee cost memorandum articles association glaxosmithkline financial record page group annual report form share ownership year end december glaxosmithkline people note employee share scheme share option incentive plan director interest major shareholder relate party transaction major shareholder relate party transaction glaxosmithkline glossary term term annual report equivalent brief description accelerate capital allowance tax allowance excess depreciation arise purchase fix asset delay charge payment tax equivalent tax depreciation advance corporation tax act advance payment tax dividend pay direct equivalent american depositary receipt adr receipt evidencing title ad glaxosmithkline adr represent ordinary share american depositary share adss ordinary share register new york stock exchange calledup share capital ordinary share issue fully pay cer growth growth constant exchange rate combine code guideline require listing rule financial service authority address principal aspect corporate governance company glaxosmithkline plc creditor account payable currency swap exchange currency couple subsequent reexchange currency agree exchange rate date debtor account receivable define benefit plan pension plan specific employee benefit call final salary scheme define contribution plan pension plan specific contribution level pension dependent growth pension fund derivative financial instrument financial instrument derive value price rate underlie item dilute earning share diluted income share dividend cover profit attributable shareholdersnet income divide dividend payable shareholder earning share basic income share employee share ownership trust trust establish group satisfy share base employee incentive plan equity shareholder fund aggregation share reserve own shareholder equivalent shareholder equity finance lease capital lease free cash flow cash resource available payment dividend shareholder acquisition freehold ownership absolute right perpetuity gearing ratio net debt percentage shareholder fund net debt minority interest group glaxosmithkline plc subsidiary undertaking hedging reduction risk normally relation foreign currency interest rate movement bymake offset commitment intangible fix asset asset physical substance brand licence patent knowhow marketing right purchase outside party interest cover number time profit interest exceed net interest payable interest payable interest expense interest receivable interest income nonequity minority interest preference share issue subsidiary outside party preference share share issue vary dividend rate treat outside interest profit income profit loss account reserve retain earning profit attributable shareholder net income share capital ordinary share capital stock common stock issue fully pay share option stock option share premium account additional paidup capital paidin surplus distributable share issue share outstanding statement total recognise gain loss statement comprehensive income stock inventory subsidiary undertaking affiliate glaxosmithkline hold majority shareholding andor exercise control tangible fix asset property plant equipment turnover revenueglaxosmithkline index corporate executive team forwardlooke statement access healthcare accountability audit internal control corporate governance accounting policy corporate social responsibility committee gearing accounting standard critical accounting policy global community partnership acquisition disposal cross reference form global supply network adr programme administrator glossary term inside cover go concern basis american depositary share derivative financial instrument goodwill animal research annual general meeting dermatological governmental investigation antitrust description business group company dialogue shareholder antibacterial directtoconsumer advertising antiviral director senior management healthcare service associate hedge audit committee director history development company auditor independent interest hiv aids interest contract balance sheet remuneration report impairment asset block drug responsibility share option independent auditor board executive share ownership guideline information technology board committee term condition inlicense business community diversity intangible asset business performance divest business divest product intellectual property business segment dividend interest cover interest rate risk management internal control capital employ earning share investment capital expenditure cardiovascular employee investor information cash flow cost diversity joint ventures cautionary statement involvement associate centralnervoussystemcns number performance reward centres excellence drug discovery cedd share schemes development lease chairman chief executive employee share ownership trust esot legal proceeding officer statement liquid investment charitable donation environment health safety chlorofluorocarbon cfc loan overdraft combine code equity risk management lymphatic filariasis commitment exchange control community investment exchange rate competition malaria consumer healthcare external supplier manufacture supply business sectorsegment manufacturing restructuring fair value competition market capitalisation manufacturing supply marketing distribution finanial result committee marketing distribution maturity counterparty risk financial asset liability product memorandum articles association financial instrument sale merger accounting adjustment financial period research development metabolic gastrointestinal financial position regulation financial record trade mark year record constant exchange rate cer quarterly trend net debt financial reporting calendar net interest payable contact detail inside cover financial reporting standard frs contaminate land new product contingent liability financial statement nomination committee control company financial summary nonexecutive director corporate administration financial trend ratio noon buying rate transaction committee fix asset investment nutritional healthcare foreign exchange risk management glaxosmithkline index oncology emesis sale vaccine consumer healthcare operate financial review prospect pharmaceutical oral care world economy operating incomeexpense clinical laboratory world market segment information outlook overthecounter otc medicine select financial datum senior management compensation interest share buyback patent share capital payment policy share premium pension postretirement share price benefit share purchase share statistic pharmaceutical shareholder information approval submission shareholder return business sector shareholder fund competition shareholding analysis manufacture supply statement total marketing distribution recognise gain loss product sale taxation research development taxation information shareholder tax rate regulation trade mark patent trade mark treasury operation pipeline treasury policy presentation financial statement tuberculosis price control profit loss account segment property plant equipment gaap reconciliation accounting provision liability charge principle consolidate balance sheet consolidated income statement reconciliation equity movement comprehensive income equity shareholder fund change shareholder equity registrar consolidated statement cash flow regulation earning sharead remuneration committee material difference remuneration report gaap report director postretirement benefit research collaboration purchase accounting research development result usaccounte principle account policy segment information animal research select financial data consumer healthcare taxation disease develop world expenditure pharmaceutical pipeline respiratory return capital employ revenue accounting policy risk factor risk oversight compliance council rocc contact detail internet information investor company available glaxosmithkline corporate website wwwgskcom head office register office glaxosmithkline plc great west road brentford middlesex tel united kingdom united states america investor relation investor relation great west road franklin plaza brentford box middlesex philadelphia tel fax tel toll free tel outside usa registrar fax lloyds tsb registrar causeway adr programme administrator worthe bank new york west sussex shareholder relation wwwshareviewcouk box church street station general enquiry annual report orderline new york corporate nominee service wwwadrbnycom tel inside tel toll free tel outside tel outside usa shareholder investment plan customer response center dividend reinvestment enquiry tel toll free tel inside tel outside monthly saving plan enquiry tel inside tel outside isa enquiry tel inside tel outside glaxo wellcome smithkline beecham corporate pep share centre limited oxford house oxford road aylesbury buck tel corporate share deal facility natw stockbroker corporate employee service mansell street london tel inside tel outside email contactcesnatwestcom quote gsk shareholder service print ives westerham press paper production document pulp harvest sustainable forest sawmill residue forest thinning elemental chlorinefree